id	sid	tid	token	lemma	pos
dpc-4503	1	1	dermatology	dermatology	NOUN
dpc-4503	1	2	:	:	PUNCT
dpc-4503	1	3	practical	practical	ADJ
dpc-4503	1	4	and	and	CCONJ
dpc-4503	1	5	conceptual	conceptual	ADJ
dpc-4503	1	6	original	original	ADJ
dpc-4503	1	7	article	article	NOUN
dpc-4503	1	8	|	|	ADV
dpc-4503	1	9	dermatol	dermatol	ADJ
dpc-4503	1	10	pract	pract	NOUN
dpc-4503	1	11	concept	concept	NOUN
dpc-4503	1	12	.	.	PUNCT
dpc-4503	2	1	2024;14(4):e2024250	2024;14(4):e2024250	NUM
dpc-4503	2	2	1	1	NUM
dpc-4503	2	3	anti	anti	ADJ
dpc-4503	2	4	-	-	ADJ
dpc-4503	2	5	il-17/23	il-17/23	ADJ
dpc-4503	2	6	drugs	drug	NOUN
dpc-4503	2	7	for	for	ADP
dpc-4503	2	8	the	the	DET
dpc-4503	2	9	treatment	treatment	NOUN
dpc-4503	2	10	of	of	ADP
dpc-4503	2	11	moderate	moderate	ADJ
dpc-4503	2	12	-	-	PUNCT
dpc-4503	2	13	to	to	ADP
dpc-4503	2	14	-	-	PUNCT
dpc-4503	2	15	severe	severe	ADJ
dpc-4503	2	16	hidradenitis	hidradenitis	NOUN
dpc-4503	2	17	suppurativa	suppurativa	NOUN
dpc-4503	2	18	in	in	ADP
dpc-4503	2	19	patients	patient	NOUN
dpc-4503	2	20	with	with	ADP
dpc-4503	2	21	concomitant	concomitant	ADJ
dpc-4503	2	22	psoriasis	psoriasis	NOUN
dpc-4503	2	23	:	:	PUNCT
dpc-4503	2	24	a	a	DET
dpc-4503	2	25	multicenter	multicenter	ADJ
dpc-4503	2	26	retrospective	retrospective	ADJ
dpc-4503	2	27	study	study	NOUN
dpc-4503	2	28	luigi	luigi	PROPN
dpc-4503	2	29	gargiulo1,2	gargiulo1,2	PROPN
dpc-4503	2	30	,	,	PUNCT
dpc-4503	2	31	luciano	luciano	PROPN
dpc-4503	2	32	ibba1,2	ibba1,2	PROPN
dpc-4503	2	33	,	,	PUNCT
dpc-4503	2	34	alessandra	alessandra	PROPN
dpc-4503	2	35	narcisi1	narcisi1	PROPN
dpc-4503	2	36	,	,	PUNCT
dpc-4503	2	37	silvia	silvia	PROPN
dpc-4503	2	38	giordano3	giordano3	PROPN
dpc-4503	2	39	,	,	PUNCT
dpc-4503	2	40	carlo	carlo	PROPN
dpc-4503	2	41	a.	a.	PROPN
dpc-4503	2	42	maronese4,5	maronese4,5	PROPN
dpc-4503	2	43	,	,	PUNCT
dpc-4503	2	44	fabrizio	fabrizio	PROPN
dpc-4503	2	45	martora6	martora6	PROPN
dpc-4503	2	46	,	,	PUNCT
dpc-4503	2	47	federica	federica	PROPN
dpc-4503	2	48	repetto3	repetto3	PROPN
dpc-4503	2	49	,	,	PUNCT
dpc-4503	2	50	giovanni	giovanni	PROPN
dpc-4503	2	51	paolino7	paolino7	PROPN
dpc-4503	2	52	,	,	PUNCT
dpc-4503	2	53	anna	anna	PROPN
dpc-4503	2	54	balato8	balato8	PROPN
dpc-4503	2	55	,	,	PUNCT
dpc-4503	2	56	martina	martina	PROPN
dpc-4503	2	57	burlando9	burlando9	PROPN
dpc-4503	2	58	,	,	PUNCT
dpc-4503	2	59	paolo	paolo	PROPN
dpc-4503	2	60	dapavo3	dapavo3	PROPN
dpc-4503	2	61	,	,	PUNCT
dpc-4503	2	62	valentina	valentina	PROPN
dpc-4503	2	63	dini10	dini10	PROPN
dpc-4503	2	64	,	,	PUNCT
dpc-4503	2	65	claudio	claudio	NOUN
dpc-4503	2	66	guarneri11	guarneri11	NOUN
dpc-4503	2	67	,	,	PUNCT
dpc-4503	2	68	angelo	angelo	PROPN
dpc-4503	2	69	v.	v.	PROPN
dpc-4503	2	70	marzano4,5	marzano4,5	PROPN
dpc-4503	2	71	,	,	PUNCT
dpc-4503	2	72	matteo	matteo	PROPN
dpc-4503	2	73	megna6	megna6	PROPN
dpc-4503	2	74	,	,	PUNCT
dpc-4503	2	75	santo	santo	PROPN
dpc-4503	2	76	r.	r.	PROPN
dpc-4503	2	77	mercuri7	mercuri7	PROPN
dpc-4503	2	78	,	,	PUNCT
dpc-4503	2	79	antonio	antonio	PROPN
dpc-4503	2	80	costanzo1,2	costanzo1,2	PROPN
dpc-4503	2	81	,	,	PUNCT
dpc-4503	2	82	mario	mario	PROPN
dpc-4503	2	83	valenti1,2	valenti1,2	PROPN
dpc-4503	2	84	1	1	NUM
dpc-4503	2	85	dermatology	dermatology	NOUN
dpc-4503	2	86	unit	unit	NOUN
dpc-4503	2	87	,	,	PUNCT
dpc-4503	2	88	irccs	ircc	VERB
dpc-4503	2	89	humanitas	humanitas	NOUN
dpc-4503	2	90	research	research	NOUN
dpc-4503	2	91	hospital	hospital	NOUN
dpc-4503	2	92	,	,	PUNCT
dpc-4503	2	93	rozzano	rozzano	PROPN
dpc-4503	2	94	,	,	PUNCT
dpc-4503	2	95	milan	milan	PROPN
dpc-4503	2	96	,	,	PUNCT
dpc-4503	2	97	italy	italy	PROPN
dpc-4503	2	98	2	2	NUM
dpc-4503	2	99	department	department	NOUN
dpc-4503	2	100	of	of	ADP
dpc-4503	2	101	biomedical	biomedical	ADJ
dpc-4503	2	102	sciences	sciences	PROPN
dpc-4503	2	103	,	,	PUNCT
dpc-4503	2	104	humanitas	humanita	NOUN
dpc-4503	2	105	university	university	NOUN
dpc-4503	2	106	,	,	PUNCT
dpc-4503	2	107	pieve	pieve	PROPN
dpc-4503	2	108	emanuele	emanuele	PROPN
dpc-4503	2	109	,	,	PUNCT
dpc-4503	2	110	milan	milan	PROPN
dpc-4503	2	111	,	,	PUNCT
dpc-4503	2	112	italy	italy	PROPN
dpc-4503	2	113	3	3	NUM
dpc-4503	2	114	department	department	PROPN
dpc-4503	2	115	of	of	ADP
dpc-4503	2	116	biomedical	biomedical	ADJ
dpc-4503	2	117	science	science	NOUN
dpc-4503	2	118	and	and	CCONJ
dpc-4503	2	119	human	human	ADJ
dpc-4503	2	120	oncology	oncology	NOUN
dpc-4503	2	121	,	,	PUNCT
dpc-4503	2	122	second	second	ADJ
dpc-4503	2	123	dermatologic	dermatologic	ADJ
dpc-4503	2	124	clinic	clinic	NOUN
dpc-4503	2	125	,	,	PUNCT
dpc-4503	2	126	university	university	PROPN
dpc-4503	2	127	of	of	ADP
dpc-4503	2	128	turin	turin	PROPN
dpc-4503	2	129	,	,	PUNCT
dpc-4503	2	130	turin	turin	PROPN
dpc-4503	2	131	,	,	PUNCT
dpc-4503	2	132	italy	italy	PROPN
dpc-4503	2	133	4	4	NUM
dpc-4503	2	134	dermatology	dermatology	NOUN
dpc-4503	2	135	unit	unit	NOUN
dpc-4503	2	136	,	,	PUNCT
dpc-4503	2	137	fondazione	fondazione	PROPN
dpc-4503	2	138	irccs	irccs	NOUN
dpc-4503	2	139	ca	can	AUX
dpc-4503	2	140	’	'	PUNCT
dpc-4503	2	141	granda	granda	PROPN
dpc-4503	2	142	ospedale	ospedale	PROPN
dpc-4503	2	143	maggiore	maggiore	PROPN
dpc-4503	2	144	policlinico	policlinico	PROPN
dpc-4503	2	145	,	,	PUNCT
dpc-4503	2	146	milan	milan	PROPN
dpc-4503	2	147	,	,	PUNCT
dpc-4503	2	148	italy	italy	PROPN
dpc-4503	2	149	5	5	NUM
dpc-4503	2	150	department	department	PROPN
dpc-4503	2	151	of	of	ADP
dpc-4503	2	152	pathophysiology	pathophysiology	NOUN
dpc-4503	2	153	and	and	CCONJ
dpc-4503	2	154	transplantation	transplantation	NOUN
dpc-4503	2	155	,	,	PUNCT
dpc-4503	2	156	università	università	PROPN
dpc-4503	2	157	degli	degli	PROPN
dpc-4503	2	158	studi	studi	PROPN
dpc-4503	2	159	di	di	X
dpc-4503	2	160	milano	milano	PROPN
dpc-4503	2	161	,	,	PUNCT
dpc-4503	2	162	milan	milan	PROPN
dpc-4503	2	163	,	,	PUNCT
dpc-4503	2	164	italy	italy	PROPN
dpc-4503	2	165	6	6	NUM
dpc-4503	2	166	section	section	NOUN
dpc-4503	2	167	of	of	ADP
dpc-4503	2	168	dermatology	dermatology	NOUN
dpc-4503	2	169	,	,	PUNCT
dpc-4503	2	170	department	department	NOUN
dpc-4503	2	171	of	of	ADP
dpc-4503	2	172	clinical	clinical	ADJ
dpc-4503	2	173	medicine	medicine	NOUN
dpc-4503	2	174	and	and	CCONJ
dpc-4503	2	175	surgery	surgery	NOUN
dpc-4503	2	176	,	,	PUNCT
dpc-4503	2	177	university	university	NOUN
dpc-4503	2	178	of	of	ADP
dpc-4503	2	179	naples	naples	PROPN
dpc-4503	2	180	federico	federico	PROPN
dpc-4503	2	181	ii	ii	PROPN
dpc-4503	2	182	,	,	PUNCT
dpc-4503	2	183	naples	naples	PROPN
dpc-4503	2	184	,	,	PUNCT
dpc-4503	2	185	italy	italy	PROPN
dpc-4503	2	186	7	7	NUM
dpc-4503	2	187	unit	unit	NOUN
dpc-4503	2	188	of	of	ADP
dpc-4503	2	189	dermatology	dermatology	NOUN
dpc-4503	2	190	,	,	PUNCT
dpc-4503	2	191	irccs	ircc	VERB
dpc-4503	2	192	ospedale	ospedale	PROPN
dpc-4503	2	193	san	san	PROPN
dpc-4503	2	194	raffaele	raffaele	PROPN
dpc-4503	2	195	,	,	PUNCT
dpc-4503	2	196	milan	milan	PROPN
dpc-4503	2	197	,	,	PUNCT
dpc-4503	2	198	italy	italy	PROPN
dpc-4503	2	199	.	.	PUNCT
dpc-4503	3	1	vita	vita	PROPN
dpc-4503	3	2	-	-	PUNCT
dpc-4503	3	3	salute	salute	NOUN
dpc-4503	3	4	university	university	NOUN
dpc-4503	3	5	,	,	PUNCT
dpc-4503	3	6	milan	milan	PROPN
dpc-4503	3	7	,	,	PUNCT
dpc-4503	3	8	italy	italy	PROPN
dpc-4503	3	9	8	8	NUM
dpc-4503	3	10	dermatology	dermatology	NOUN
dpc-4503	3	11	unit	unit	NOUN
dpc-4503	3	12	,	,	PUNCT
dpc-4503	3	13	university	university	PROPN
dpc-4503	3	14	of	of	ADP
dpc-4503	3	15	campania	campania	PROPN
dpc-4503	3	16	l.	l.	PROPN
dpc-4503	3	17	vanvitelli	vanvitelli	PROPN
dpc-4503	3	18	,	,	PUNCT
dpc-4503	3	19	naples	naples	PROPN
dpc-4503	3	20	,	,	PUNCT
dpc-4503	3	21	italy	italy	PROPN
dpc-4503	3	22	9	9	NUM
dpc-4503	3	23	department	department	NOUN
dpc-4503	3	24	of	of	ADP
dpc-4503	3	25	dermatology	dermatology	NOUN
dpc-4503	3	26	,	,	PUNCT
dpc-4503	3	27	dipartimento	dipartimento	ADP
dpc-4503	3	28	di	di	PROPN
dpc-4503	3	29	scienze	scienze	PROPN
dpc-4503	3	30	della	della	PROPN
dpc-4503	3	31	salute	salute	NOUN
dpc-4503	3	32	(	(	PUNCT
dpc-4503	3	33	dissal	dissal	NOUN
dpc-4503	3	34	)	)	PUNCT
dpc-4503	3	35	,	,	PUNCT
dpc-4503	3	36	university	university	NOUN
dpc-4503	3	37	of	of	ADP
dpc-4503	3	38	genoa	genoa	PROPN
dpc-4503	3	39	,	,	PUNCT
dpc-4503	3	40	irccs	ircc	VERB
dpc-4503	3	41	ospedale	ospedale	PROPN
dpc-4503	3	42	policlinico	policlinico	PROPN
dpc-4503	3	43	san	san	PROPN
dpc-4503	3	44	martino	martino	PROPN
dpc-4503	3	45	,	,	PUNCT
dpc-4503	3	46	genoa	genoa	PROPN
dpc-4503	3	47	,	,	PUNCT
dpc-4503	3	48	italy	italy	PROPN
dpc-4503	3	49	10	10	NUM
dpc-4503	3	50	dermatology	dermatology	NOUN
dpc-4503	3	51	unit	unit	NOUN
dpc-4503	3	52	,	,	PUNCT
dpc-4503	3	53	department	department	NOUN
dpc-4503	3	54	of	of	ADP
dpc-4503	3	55	clinical	clinical	ADJ
dpc-4503	3	56	and	and	CCONJ
dpc-4503	3	57	experimental	experimental	ADJ
dpc-4503	3	58	medicine	medicine	NOUN
dpc-4503	3	59	ospedale	ospedale	PROPN
dpc-4503	3	60	santa	santa	PROPN
dpc-4503	3	61	chiara	chiara	PROPN
dpc-4503	3	62	,	,	PUNCT
dpc-4503	3	63	pisa	pisa	PROPN
dpc-4503	3	64	,	,	PUNCT
dpc-4503	3	65	italy	italy	PROPN
dpc-4503	3	66	11	11	NUM
dpc-4503	3	67	department	department	PROPN
dpc-4503	3	68	of	of	ADP
dpc-4503	3	69	biomedical	biomedical	ADJ
dpc-4503	3	70	and	and	CCONJ
dpc-4503	3	71	dental	dental	ADJ
dpc-4503	3	72	sciences	science	NOUN
dpc-4503	3	73	and	and	CCONJ
dpc-4503	3	74	morphofunctional	morphofunctional	ADJ
dpc-4503	3	75	imaging	imaging	NOUN
dpc-4503	3	76	,	,	PUNCT
dpc-4503	3	77	unit	unit	NOUN
dpc-4503	3	78	of	of	ADP
dpc-4503	3	79	dermatology	dermatology	NOUN
dpc-4503	3	80	,	,	PUNCT
dpc-4503	3	81	university	university	PROPN
dpc-4503	3	82	of	of	ADP
dpc-4503	3	83	messina	messina	PROPN
dpc-4503	3	84	,	,	PUNCT
dpc-4503	3	85	aou	aou	PROPN
dpc-4503	3	86	policlinico	policlinico	PROPN
dpc-4503	3	87	g.	g.	PROPN
dpc-4503	3	88	martino	martino	PROPN
dpc-4503	3	89	,	,	PUNCT
dpc-4503	3	90	messina	messina	PROPN
dpc-4503	3	91	,	,	PUNCT
dpc-4503	3	92	italy	italy	PROPN
dpc-4503	3	93	key	key	ADJ
dpc-4503	3	94	words	word	NOUN
dpc-4503	3	95	:	:	PUNCT
dpc-4503	3	96	il-17	il-17	NUM
dpc-4503	3	97	,	,	PUNCT
dpc-4503	3	98	il-23	il-23	NOUN
dpc-4503	3	99	,	,	PUNCT
dpc-4503	3	100	hs	hs	INTJ
dpc-4503	3	101	,	,	PUNCT
dpc-4503	3	102	psoriasis	psoriasis	NOUN
dpc-4503	3	103	citation	citation	NOUN
dpc-4503	3	104	:	:	PUNCT
dpc-4503	3	105	gargiulo	gargiulo	PROPN
dpc-4503	3	106	l	l	NOUN
dpc-4503	3	107	,	,	PUNCT
dpc-4503	3	108	ibba	ibba	ADJ
dpc-4503	3	109	l	l	NOUN
dpc-4503	3	110	,	,	PUNCT
dpc-4503	3	111	narcisi	narcisi	ADV
dpc-4503	3	112	a	a	PRON
dpc-4503	3	113	,	,	PUNCT
dpc-4503	3	114	et	et	PROPN
dpc-4503	3	115	al	al	PROPN
dpc-4503	3	116	.	.	PUNCT
dpc-4503	4	1	anti	anti	ADJ
dpc-4503	4	2	-	-	ADJ
dpc-4503	4	3	il-17/23	il-17/23	ADJ
dpc-4503	4	4	drugs	drug	NOUN
dpc-4503	4	5	for	for	ADP
dpc-4503	4	6	the	the	DET
dpc-4503	4	7	treatment	treatment	NOUN
dpc-4503	4	8	of	of	ADP
dpc-4503	4	9	moderate	moderate	ADJ
dpc-4503	4	10	-	-	PUNCT
dpc-4503	4	11	to	to	ADP
dpc-4503	4	12	-	-	PUNCT
dpc-4503	4	13	severe	severe	ADJ
dpc-4503	4	14	hidradenitis	hidradenitis	NOUN
dpc-4503	4	15	suppurativa	suppurativa	NOUN
dpc-4503	4	16	in	in	ADP
dpc-4503	4	17	patients	patient	NOUN
dpc-4503	4	18	with	with	ADP
dpc-4503	4	19	concomitant	concomitant	ADJ
dpc-4503	4	20	psoriasis	psoriasis	NOUN
dpc-4503	4	21	:	:	PUNCT
dpc-4503	4	22	a	a	DET
dpc-4503	4	23	multicenter	multicenter	ADJ
dpc-4503	4	24	retrospective	retrospective	ADJ
dpc-4503	4	25	study	study	NOUN
dpc-4503	4	26	.	.	PUNCT
dpc-4503	5	1	dermatol	dermatol	NOUN
dpc-4503	5	2	pract	pract	PROPN
dpc-4503	5	3	concept	concept	NOUN
dpc-4503	5	4	.	.	PUNCT
dpc-4503	6	1	2024;14(4):e2024250	2024;14(4):e2024250	NUM
dpc-4503	6	2	.	.	PUNCT
dpc-4503	7	1	doi	doi	PROPN
dpc-4503	7	2	:	:	PUNCT
dpc-4503	7	3	https://doi	https://doi	PROPN
dpc-4503	7	4	.org/10.5826	.org/10.5826	PROPN
dpc-4503	7	5	/	/	SYM
dpc-4503	7	6	dpc.1404a250	dpc.1404a250	NUM
dpc-4503	7	7	accepted	accept	VERB
dpc-4503	7	8	:	:	PUNCT
dpc-4503	7	9	june	june	PROPN
dpc-4503	7	10	24	24	NUM
dpc-4503	7	11	,	,	PUNCT
dpc-4503	7	12	2024	2024	NUM
dpc-4503	7	13	;	;	PUNCT
dpc-4503	7	14	published	publish	VERB
dpc-4503	7	15	:	:	PUNCT
dpc-4503	8	1	october	october	PROPN
dpc-4503	8	2	2024	2024	NUM
dpc-4503	8	3	copyright	copyright	NOUN
dpc-4503	8	4	:	:	PUNCT
dpc-4503	8	5	©	©	PROPN
dpc-4503	8	6	2024	2024	NUM
dpc-4503	8	7	gargiulo	gargiulo	NOUN
dpc-4503	8	8	et	et	PROPN
dpc-4503	8	9	al	al	PROPN
dpc-4503	8	10	.	.	PUNCT
dpc-4503	9	1	this	this	PRON
dpc-4503	9	2	is	be	AUX
dpc-4503	9	3	an	an	DET
dpc-4503	9	4	open	open	ADJ
dpc-4503	9	5	-	-	PUNCT
dpc-4503	9	6	access	access	NOUN
dpc-4503	9	7	article	article	NOUN
dpc-4503	9	8	distributed	distribute	VERB
dpc-4503	9	9	under	under	ADP
dpc-4503	9	10	the	the	DET
dpc-4503	9	11	terms	term	NOUN
dpc-4503	9	12	of	of	ADP
dpc-4503	9	13	the	the	DET
dpc-4503	9	14	creative	creative	ADJ
dpc-4503	9	15	commons	common	NOUN
dpc-4503	9	16	attributionnoncommercial	attributionnoncommercial	ADJ
dpc-4503	9	17	license	license	NOUN
dpc-4503	9	18	(	(	PUNCT
dpc-4503	9	19	by	by	ADP
dpc-4503	9	20	-	-	PUNCT
dpc-4503	9	21	nc-4.0	nc-4.0	NOUN
dpc-4503	9	22	)	)	PUNCT
dpc-4503	9	23	,	,	PUNCT
dpc-4503	9	24	https://creativecommons.org/licenses/by-nc/4.0/	https://creativecommons.org/licenses/by-nc/4.0/	PROPN
dpc-4503	9	25	,	,	PUNCT
dpc-4503	9	26	which	which	PRON
dpc-4503	9	27	permits	permit	VERB
dpc-4503	9	28	unrestricted	unrestricted	ADJ
dpc-4503	9	29	noncommercial	noncommercial	ADJ
dpc-4503	9	30	use	use	NOUN
dpc-4503	9	31	,	,	PUNCT
dpc-4503	9	32	distribution	distribution	NOUN
dpc-4503	9	33	,	,	PUNCT
dpc-4503	9	34	and	and	CCONJ
dpc-4503	9	35	reproduction	reproduction	NOUN
dpc-4503	9	36	in	in	ADP
dpc-4503	9	37	any	any	DET
dpc-4503	9	38	medium	medium	NOUN
dpc-4503	9	39	,	,	PUNCT
dpc-4503	9	40	provided	provide	VERB
dpc-4503	9	41	the	the	DET
dpc-4503	9	42	original	original	ADJ
dpc-4503	9	43	authors	author	NOUN
dpc-4503	9	44	and	and	CCONJ
dpc-4503	9	45	source	source	NOUN
dpc-4503	9	46	are	be	AUX
dpc-4503	9	47	credited	credit	VERB
dpc-4503	9	48	.	.	PUNCT
dpc-4503	10	1	funding	funding	NOUN
dpc-4503	10	2	:	:	PUNCT
dpc-4503	10	3	none	none	NOUN
dpc-4503	10	4	.	.	PUNCT
dpc-4503	11	1	competing	compete	VERB
dpc-4503	11	2	interests	interest	NOUN
dpc-4503	11	3	:	:	PUNCT
dpc-4503	11	4	l.	l.	PROPN
dpc-4503	11	5	gargiulo	gargiulo	PROPN
dpc-4503	11	6	has	have	AUX
dpc-4503	11	7	been	be	AUX
dpc-4503	11	8	a	a	DET
dpc-4503	11	9	consultant	consultant	NOUN
dpc-4503	11	10	for	for	ADP
dpc-4503	11	11	almirall	almirall	ADJ
dpc-4503	11	12	,	,	PUNCT
dpc-4503	11	13	pfizer	pfizer	NOUN
dpc-4503	11	14	,	,	PUNCT
dpc-4503	11	15	and	and	CCONJ
dpc-4503	11	16	ucb	ucb	PROPN
dpc-4503	11	17	pharma	pharma	PROPN
dpc-4503	11	18	.	.	PUNCT
dpc-4503	12	1	l.	l.	PROPN
dpc-4503	12	2	ibba	ibba	PROPN
dpc-4503	12	3	has	have	AUX
dpc-4503	12	4	been	be	AUX
dpc-4503	12	5	a	a	DET
dpc-4503	12	6	consultant	consultant	NOUN
dpc-4503	12	7	for	for	ADP
dpc-4503	12	8	almirall	almirall	NOUN
dpc-4503	12	9	.	.	PUNCT
dpc-4503	13	1	a.	a.	PROPN
dpc-4503	13	2	narcisi	narcisi	PROPN
dpc-4503	13	3	has	have	AUX
dpc-4503	13	4	served	serve	VERB
dpc-4503	13	5	on	on	ADP
dpc-4503	13	6	advisory	advisory	ADJ
dpc-4503	13	7	boards	board	NOUN
dpc-4503	13	8	,	,	PUNCT
dpc-4503	13	9	received	receive	VERB
dpc-4503	13	10	honoraria	honorarium	NOUN
dpc-4503	13	11	for	for	ADP
dpc-4503	13	12	lectures	lecture	NOUN
dpc-4503	13	13	and	and	CCONJ
dpc-4503	13	14	research	research	NOUN
dpc-4503	13	15	grants	grant	NOUN
dpc-4503	13	16	from	from	ADP
dpc-4503	13	17	almirall	almirall	ADJ
dpc-4503	13	18	,	,	PUNCT
dpc-4503	13	19	abbvie	abbvie	PROPN
dpc-4503	13	20	,	,	PUNCT
dpc-4503	13	21	leo	leo	PROPN
dpc-4503	13	22	pharma	pharma	PROPN
dpc-4503	13	23	,	,	PUNCT
dpc-4503	13	24	celgene	celgene	NOUN
dpc-4503	13	25	,	,	PUNCT
dpc-4503	13	26	eli	eli	PROPN
dpc-4503	13	27	lilly	lilly	PROPN
dpc-4503	13	28	,	,	PUNCT
dpc-4503	13	29	janssen	janssen	PROPN
dpc-4503	13	30	,	,	PUNCT
dpc-4503	13	31	novartis	novartis	PROPN
dpc-4503	13	32	,	,	PUNCT
dpc-4503	13	33	sanofi‐genzyme	sanofi‐genzyme	PROPN
dpc-4503	13	34	,	,	PUNCT
dpc-4503	13	35	amgen	amgen	PROPN
dpc-4503	13	36	,	,	PUNCT
dpc-4503	13	37	and	and	CCONJ
dpc-4503	13	38	boehringer	boehringer	PROPN
dpc-4503	13	39	ingelheim	ingelheim	PROPN
dpc-4503	13	40	.	.	PUNCT
dpc-4503	14	1	a.	a.	PROPN
dpc-4503	14	2	balato	balato	PROPN
dpc-4503	14	3	has	have	AUX
dpc-4503	14	4	received	receive	VERB
dpc-4503	14	5	honoraria	honorarium	NOUN
dpc-4503	14	6	for	for	ADP
dpc-4503	14	7	participation	participation	NOUN
dpc-4503	14	8	in	in	ADP
dpc-4503	14	9	advisory	advisory	ADJ
dpc-4503	14	10	boards	board	NOUN
dpc-4503	14	11	,	,	PUNCT
dpc-4503	14	12	meetings	meeting	NOUN
dpc-4503	14	13	,	,	PUNCT
dpc-4503	14	14	or	or	CCONJ
dpc-4503	14	15	as	as	ADP
dpc-4503	14	16	speaker	speaker	NOUN
dpc-4503	14	17	for	for	ADP
dpc-4503	14	18	abbvie	abbvie	PROPN
dpc-4503	14	19	,	,	PUNCT
dpc-4503	14	20	celgene	celgene	NOUN
dpc-4503	14	21	,	,	PUNCT
dpc-4503	14	22	janssen	janssen	NOUN
dpc-4503	14	23	-	-	PUNCT
dpc-4503	14	24	cilag	cilag	PROPN
dpc-4503	14	25	,	,	PUNCT
dpc-4503	14	26	eli	eli	PROPN
dpc-4503	14	27	lilly	lilly	PROPN
dpc-4503	14	28	,	,	PUNCT
dpc-4503	14	29	novartis	novartis	PROPN
dpc-4503	14	30	pharma	pharma	PROPN
dpc-4503	14	31	,	,	PUNCT
dpc-4503	14	32	pfizer	pfizer	NOUN
dpc-4503	14	33	,	,	PUNCT
dpc-4503	14	34	sanofi	sanofi	PROPN
dpc-4503	14	35	-	-	PUNCT
dpc-4503	14	36	genzyme	genzyme	PROPN
dpc-4503	14	37	,	,	PUNCT
dpc-4503	14	38	and	and	CCONJ
dpc-4503	14	39	ucb	ucb	PROPN
dpc-4503	14	40	pharma	pharma	PROPN
dpc-4503	14	41	.	.	PUNCT
dpc-4503	15	1	m.	m.	NOUN
dpc-4503	15	2	burlando	burlando	PROPN
dpc-4503	15	3	has	have	AUX
dpc-4503	15	4	acted	act	VERB
dpc-4503	15	5	as	as	ADP
dpc-4503	15	6	a	a	DET
dpc-4503	15	7	speaker	speaker	NOUN
dpc-4503	15	8	and	and	CCONJ
dpc-4503	15	9	consultant	consultant	NOUN
dpc-4503	15	10	for	for	ADP
dpc-4503	15	11	abbvie	abbvie	PROPN
dpc-4503	15	12	,	,	PUNCT
dpc-4503	15	13	janssen	janssen	PROPN
dpc-4503	15	14	,	,	PUNCT
dpc-4503	15	15	amgen	amgen	PROPN
dpc-4503	15	16	,	,	PUNCT
dpc-4503	15	17	novartis	novartis	PROPN
dpc-4503	15	18	,	,	PUNCT
dpc-4503	15	19	eli	eli	PROPN
dpc-4503	15	20	lilly	lilly	PROPN
dpc-4503	15	21	,	,	PUNCT
dpc-4503	15	22	and	and	CCONJ
dpc-4503	15	23	ucb	ucb	PROPN
dpc-4503	15	24	pharma	pharma	PROPN
dpc-4503	15	25	.	.	PUNCT
dpc-4503	16	1	p.	p.	NOUN
dpc-4503	16	2	dapavo	dapavo	PROPN
dpc-4503	16	3	has	have	AUX
dpc-4503	16	4	been	be	AUX
dpc-4503	16	5	a	a	DET
dpc-4503	16	6	speaker	speaker	NOUN
dpc-4503	16	7	for	for	ADP
dpc-4503	16	8	novartis	novartis	PROPN
dpc-4503	16	9	,	,	PUNCT
dpc-4503	16	10	abbvie	abbvie	PROPN
dpc-4503	16	11	,	,	PUNCT
dpc-4503	16	12	sanofi	sanofi	PROPN
dpc-4503	16	13	,	,	PUNCT
dpc-4503	16	14	ucb	ucb	PROPN
dpc-4503	16	15	,	,	PUNCT
dpc-4503	16	16	janssen	janssen	PROPN
dpc-4503	16	17	,	,	PUNCT
dpc-4503	16	18	lilly	lilly	PROPN
dpc-4503	16	19	,	,	PUNCT
dpc-4503	16	20	and	and	CCONJ
dpc-4503	16	21	leopharma	leopharma	PROPN
dpc-4503	16	22	.	.	PUNCT
dpc-4503	17	1	c.	c.	PROPN
dpc-4503	17	2	guarneri	guarneri	PROPN
dpc-4503	17	3	has	have	AUX
dpc-4503	17	4	been	be	AUX
dpc-4503	17	5	a	a	DET
dpc-4503	17	6	scientific	scientific	ADJ
dpc-4503	17	7	consultant	consultant	NOUN
dpc-4503	17	8	/	/	SYM
dpc-4503	17	9	speaker/	speaker/	PROPN
dpc-4503	17	10	clinical	clinical	ADJ
dpc-4503	17	11	study	study	NOUN
dpc-4503	17	12	investigator	investigator	NOUN
dpc-4503	17	13	for	for	ADP
dpc-4503	17	14	abbvie	abbvie	PROPN
dpc-4503	17	15	,	,	PUNCT
dpc-4503	17	16	celgene	celgene	NOUN
dpc-4503	17	17	,	,	PUNCT
dpc-4503	17	18	janssen	janssen	PROPN
dpc-4503	17	19	,	,	PUNCT
dpc-4503	17	20	eli	eli	PROPN
dpc-4503	17	21	lilly	lilly	PROPN
dpc-4503	17	22	,	,	PUNCT
dpc-4503	17	23	novartis	novartis	NOUN
dpc-4503	17	24	,	,	PUNCT
dpc-4503	17	25	pfizer	pfizer	NOUN
dpc-4503	17	26	,	,	PUNCT
dpc-4503	17	27	sanofi	sanofi	NOUN
dpc-4503	17	28	,	,	PUNCT
dpc-4503	17	29	almirall	almirall	ADJ
dpc-4503	17	30	,	,	PUNCT
dpc-4503	17	31	and	and	CCONJ
dpc-4503	17	32	leo	leo	PROPN
dpc-4503	17	33	pharma	pharma	PROPN
dpc-4503	17	34	.	.	PUNCT
dpc-4503	18	1	a.	a.	PROPN
dpc-4503	18	2	v.	v.	ADP
dpc-4503	18	3	marzano	marzano	PROPN
dpc-4503	18	4	reports	report	NOUN
dpc-4503	18	5	consultancy	consultancy	NOUN
dpc-4503	18	6	/	/	SYM
dpc-4503	18	7	advisory	advisory	ADJ
dpc-4503	18	8	boards	board	NOUN
dpc-4503	18	9	disease	disease	NOUN
dpc-4503	18	10	-	-	PUNCT
dpc-4503	18	11	relevant	relevant	ADJ
dpc-4503	18	12	honoraria	honoraria	NOUN
dpc-4503	18	13	from	from	ADP
dpc-4503	18	14	abbvie	abbvie	PROPN
dpc-4503	18	15	,	,	PUNCT
dpc-4503	18	16	boehringer	boehringer	PROPN
dpc-4503	18	17	-	-	PUNCT
dpc-4503	18	18	ingelheim	ingelheim	PROPN
dpc-4503	18	19	,	,	PUNCT
dpc-4503	18	20	novartis	novartis	PROPN
dpc-4503	18	21	,	,	PUNCT
dpc-4503	18	22	pfizer	pfizer	NOUN
dpc-4503	18	23	,	,	PUNCT
dpc-4503	18	24	sanofi	sanofi	PROPN
dpc-4503	18	25	,	,	PUNCT
dpc-4503	18	26	and	and	CCONJ
dpc-4503	18	27	ucb	ucb	PROPN
dpc-4503	18	28	.	.	PROPN
dpc-4503	18	29	m.	m.	PROPN
dpc-4503	18	30	megna	megna	PROPN
dpc-4503	18	31	acted	act	VERB
dpc-4503	18	32	as	as	ADP
dpc-4503	18	33	a	a	DET
dpc-4503	18	34	speaker	speaker	NOUN
dpc-4503	18	35	or	or	CCONJ
dpc-4503	18	36	consultant	consultant	NOUN
dpc-4503	18	37	for	for	ADP
dpc-4503	18	38	abbvie	abbvie	PROPN
dpc-4503	18	39	,	,	PUNCT
dpc-4503	18	40	eli	eli	PROPN
dpc-4503	18	41	lilly	lilly	PROPN
dpc-4503	18	42	,	,	PUNCT
dpc-4503	18	43	janssen	janssen	PROPN
dpc-4503	18	44	,	,	PUNCT
dpc-4503	18	45	leo	leo	PROPN
dpc-4503	18	46	-	-	PUNCT
dpc-4503	18	47	pharma	pharma	PROPN
dpc-4503	18	48	,	,	PUNCT
dpc-4503	18	49	ucb	ucb	PROPN
dpc-4503	18	50	,	,	PUNCT
dpc-4503	18	51	and	and	CCONJ
dpc-4503	18	52	novartis	novartis	PROPN
dpc-4503	18	53	.	.	PUNCT
dpc-4503	19	1	a.	a.	PROPN
dpc-4503	19	2	costanzo	costanzo	PROPN
dpc-4503	19	3	has	have	AUX
dpc-4503	19	4	served	serve	VERB
dpc-4503	19	5	as	as	ADP
dpc-4503	19	6	an	an	DET
dpc-4503	19	7	advisory	advisory	ADJ
dpc-4503	19	8	board	board	NOUN
dpc-4503	19	9	member	member	NOUN
dpc-4503	19	10	,	,	PUNCT
dpc-4503	19	11	consultant	consultant	NOUN
dpc-4503	19	12	,	,	PUNCT
dpc-4503	19	13	and	and	CCONJ
dpc-4503	19	14	has	have	AUX
dpc-4503	19	15	received	receive	VERB
dpc-4503	19	16	fees	fee	NOUN
dpc-4503	19	17	and	and	CCONJ
dpc-4503	19	18	speaker	speaker	NOUN
dpc-4503	19	19	’s	’s	PART
dpc-4503	19	20	honoraria	honoraria	NOUN
dpc-4503	19	21	or	or	CCONJ
dpc-4503	19	22	has	have	AUX
dpc-4503	19	23	participated	participate	VERB
dpc-4503	19	24	in	in	ADP
dpc-4503	19	25	clinical	clinical	ADJ
dpc-4503	19	26	trials	trial	NOUN
dpc-4503	19	27	for	for	ADP
dpc-4503	19	28	abbvie	abbvie	NOUN
dpc-4503	19	29	,	,	PUNCT
dpc-4503	19	30	almirall	almirall	ADJ
dpc-4503	19	31	,	,	PUNCT
dpc-4503	19	32	biogen	biogen	PROPN
dpc-4503	19	33	,	,	PUNCT
dpc-4503	19	34	leo	leo	PROPN
dpc-4503	19	35	pharma	pharma	PROPN
dpc-4503	19	36	,	,	PUNCT
dpc-4503	19	37	lilly	lilly	PROPN
dpc-4503	19	38	,	,	PUNCT
dpc-4503	19	39	janssen	janssen	PROPN
dpc-4503	19	40	,	,	PUNCT
dpc-4503	19	41	novartis	novartis	PROPN
dpc-4503	19	42	,	,	PUNCT
dpc-4503	19	43	pfizer	pfizer	NOUN
dpc-4503	19	44	,	,	PUNCT
dpc-4503	19	45	sanofi	sanofi	PROPN
dpc-4503	19	46	genzyme	genzyme	PROPN
dpc-4503	19	47	,	,	PUNCT
dpc-4503	19	48	and	and	CCONJ
dpc-4503	19	49	ucb	ucb	PROPN
dpc-4503	19	50	-	-	PUNCT
dpc-4503	19	51	pharma	pharma	PROPN
dpc-4503	19	52	.	.	PUNCT
dpc-4503	20	1	m.	m.	PROPN
dpc-4503	20	2	valenti	valenti	PROPN
dpc-4503	20	3	has	have	AUX
dpc-4503	20	4	been	be	AUX
dpc-4503	20	5	a	a	DET
dpc-4503	20	6	consultant	consultant	NOUN
dpc-4503	20	7	and/or	and/or	CCONJ
dpc-4503	20	8	speaker	speaker	NOUN
dpc-4503	20	9	for	for	ADP
dpc-4503	20	10	sanofi	sanofi	PROPN
dpc-4503	20	11	,	,	PUNCT
dpc-4503	20	12	leo	leo	PROPN
dpc-4503	20	13	pharma	pharma	PROPN
dpc-4503	20	14	,	,	PUNCT
dpc-4503	20	15	eli	eli	PROPN
dpc-4503	20	16	lilly	lilly	PROPN
dpc-4503	20	17	,	,	PUNCT
dpc-4503	20	18	novartis	novartis	PROPN
dpc-4503	20	19	,	,	PUNCT
dpc-4503	20	20	janssen	janssen	PROPN
dpc-4503	20	21	,	,	PUNCT
dpc-4503	20	22	abbvie	abbvie	PROPN
dpc-4503	20	23	,	,	PUNCT
dpc-4503	20	24	and	and	CCONJ
dpc-4503	20	25	boehringer	boehringer	PROPN
dpc-4503	20	26	ingelheim	ingelheim	PROPN
dpc-4503	20	27	.	.	PUNCT
dpc-4503	21	1	s.	s.	PROPN
dpc-4503	21	2	giordano	giordano	PROPN
dpc-4503	21	3	,	,	PUNCT
dpc-4503	21	4	f.	f.	PROPN
dpc-4503	21	5	repetto	repetto	PROPN
dpc-4503	21	6	,	,	PUNCT
dpc-4503	21	7	c.	c.	PROPN
dpc-4503	21	8	a.	a.	PROPN
dpc-4503	21	9	maronese	maronese	PROPN
dpc-4503	21	10	,	,	PUNCT
dpc-4503	21	11	f.	f.	PROPN
dpc-4503	21	12	martora	martora	PROPN
dpc-4503	21	13	,	,	PUNCT
dpc-4503	21	14	g.	g.	PROPN
dpc-4503	21	15	paolino	paolino	PROPN
dpc-4503	21	16	,	,	PUNCT
dpc-4503	21	17	v.	v.	CCONJ
dpc-4503	21	18	dini	dini	PROPN
dpc-4503	21	19	,	,	PUNCT
dpc-4503	21	20	s.r	s.r	PROPN
dpc-4503	21	21	.	.	PROPN
dpc-4503	21	22	mercuri	mercuri	PROPN
dpc-4503	21	23	have	have	VERB
dpc-4503	21	24	nothing	nothing	PRON
dpc-4503	21	25	to	to	PART
dpc-4503	21	26	declare	declare	VERB
dpc-4503	21	27	.	.	PUNCT
dpc-4503	22	1	2	2	NUM
dpc-4503	22	2	original	original	ADJ
dpc-4503	22	3	article	article	NOUN
dpc-4503	22	4	|	|	ADV
dpc-4503	22	5	dermatol	dermatol	ADJ
dpc-4503	22	6	pract	pract	NOUN
dpc-4503	22	7	concept	concept	NOUN
dpc-4503	22	8	.	.	PUNCT
dpc-4503	23	1	2024;14(4):e2024250	2024;14(4):e2024250	NUM
dpc-4503	23	2	introduction	introduction	NOUN
dpc-4503	23	3	hidradenitis	hidradenitis	PROPN
dpc-4503	23	4	suppurativa	suppurativa	PROPN
dpc-4503	23	5	(	(	PUNCT
dpc-4503	23	6	hs	hs	X
dpc-4503	23	7	)	)	PUNCT
dpc-4503	23	8	is	be	AUX
dpc-4503	23	9	a	a	DET
dpc-4503	23	10	chronic	chronic	NOUN
dpc-4503	23	11	,	,	PUNCT
dpc-4503	23	12	debilitating	debilitate	VERB
dpc-4503	23	13	,	,	PUNCT
dpc-4503	23	14	autoinflammatory	autoinflammatory	NOUN
dpc-4503	23	15	skin	skin	NOUN
dpc-4503	23	16	disease	disease	NOUN
dpc-4503	23	17	affecting	affect	VERB
dpc-4503	23	18	approximately	approximately	ADV
dpc-4503	23	19	1	1	NUM
dpc-4503	23	20	%	%	NOUN
dpc-4503	23	21	of	of	ADP
dpc-4503	23	22	the	the	DET
dpc-4503	23	23	general	general	ADJ
dpc-4503	23	24	population	population	NOUN
dpc-4503	24	1	[	[	X
dpc-4503	24	2	1	1	NUM
dpc-4503	24	3	]	]	PUNCT
dpc-4503	24	4	.	.	PUNCT
dpc-4503	25	1	clinically	clinically	ADV
dpc-4503	25	2	,	,	PUNCT
dpc-4503	25	3	it	it	PRON
dpc-4503	25	4	is	be	AUX
dpc-4503	25	5	characterized	characterize	VERB
dpc-4503	25	6	by	by	ADP
dpc-4503	25	7	recurrent	recurrent	ADJ
dpc-4503	25	8	painful	painful	ADJ
dpc-4503	25	9	nodules	nodule	NOUN
dpc-4503	25	10	,	,	PUNCT
dpc-4503	25	11	abscesses	abscess	NOUN
dpc-4503	25	12	,	,	PUNCT
dpc-4503	25	13	draining	drain	VERB
dpc-4503	25	14	tunnels	tunnel	NOUN
dpc-4503	25	15	,	,	PUNCT
dpc-4503	25	16	and	and	CCONJ
dpc-4503	25	17	scarring	scarring	NOUN
dpc-4503	25	18	,	,	PUNCT
dpc-4503	25	19	predominantly	predominantly	ADV
dpc-4503	25	20	in	in	ADP
dpc-4503	25	21	intertriginous	intertriginous	ADJ
dpc-4503	25	22	areas	area	NOUN
dpc-4503	25	23	[	[	X
dpc-4503	25	24	1	1	NUM
dpc-4503	25	25	]	]	PUNCT
dpc-4503	25	26	.	.	PUNCT
dpc-4503	26	1	the	the	DET
dpc-4503	26	2	pathophysiology	pathophysiology	NOUN
dpc-4503	26	3	of	of	ADP
dpc-4503	26	4	hs	hs	PROPN
dpc-4503	26	5	is	be	AUX
dpc-4503	26	6	complex	complex	ADJ
dpc-4503	26	7	and	and	CCONJ
dpc-4503	26	8	not	not	PART
dpc-4503	26	9	fully	fully	ADV
dpc-4503	26	10	understood	understand	VERB
dpc-4503	26	11	,	,	PUNCT
dpc-4503	26	12	but	but	CCONJ
dpc-4503	26	13	it	it	PRON
dpc-4503	26	14	involves	involve	VERB
dpc-4503	26	15	the	the	DET
dpc-4503	26	16	dysregulation	dysregulation	NOUN
dpc-4503	26	17	of	of	ADP
dpc-4503	26	18	the	the	DET
dpc-4503	26	19	immune	immune	ADJ
dpc-4503	26	20	system	system	NOUN
dpc-4503	26	21	.	.	PUNCT
dpc-4503	27	1	in	in	ADP
dpc-4503	27	2	particular	particular	ADJ
dpc-4503	27	3	,	,	PUNCT
dpc-4503	27	4	high	high	ADJ
dpc-4503	27	5	levels	level	NOUN
dpc-4503	27	6	of	of	ADP
dpc-4503	27	7	interleukin	interleukin	NOUN
dpc-4503	27	8	(	(	PUNCT
dpc-4503	27	9	il)-1	il)-1	NOUN
dpc-4503	27	10	,	,	PUNCT
dpc-4503	27	11	il-17	il-17	ADV
dpc-4503	27	12	,	,	PUNCT
dpc-4503	27	13	il-23	il-23	NOUN
dpc-4503	27	14	,	,	PUNCT
dpc-4503	27	15	and	and	CCONJ
dpc-4503	27	16	tumor	tumor	NOUN
dpc-4503	27	17	necrosis	necrosis	NOUN
dpc-4503	27	18	factor	factor	NOUN
dpc-4503	27	19	(	(	PUNCT
dpc-4503	27	20	tnf)-alfa	tnf)-alfa	NOUN
dpc-4503	27	21	have	have	AUX
dpc-4503	27	22	been	be	AUX
dpc-4503	27	23	demonstrated	demonstrate	VERB
dpc-4503	27	24	[	[	PUNCT
dpc-4503	27	25	3	3	NUM
dpc-4503	27	26	]	]	PUNCT
dpc-4503	27	27	.	.	PUNCT
dpc-4503	28	1	traditional	traditional	ADJ
dpc-4503	28	2	therapies	therapy	NOUN
dpc-4503	28	3	for	for	ADP
dpc-4503	28	4	hs	hs	PROPN
dpc-4503	28	5	have	have	AUX
dpc-4503	28	6	had	have	VERB
dpc-4503	28	7	limited	limited	ADJ
dpc-4503	28	8	success	success	NOUN
dpc-4503	28	9	,	,	PUNCT
dpc-4503	28	10	and	and	CCONJ
dpc-4503	28	11	there	there	PRON
dpc-4503	28	12	is	be	VERB
dpc-4503	28	13	an	an	DET
dpc-4503	28	14	urgent	urgent	ADJ
dpc-4503	28	15	need	need	NOUN
dpc-4503	28	16	for	for	ADP
dpc-4503	28	17	more	more	ADV
dpc-4503	28	18	effective	effective	ADJ
dpc-4503	28	19	treatment	treatment	NOUN
dpc-4503	28	20	options	option	NOUN
dpc-4503	28	21	,	,	PUNCT
dpc-4503	28	22	as	as	ADP
dpc-4503	28	23	currently	currently	ADV
dpc-4503	28	24	only	only	ADV
dpc-4503	28	25	adalimumab	adalimumab	NOUN
dpc-4503	28	26	(	(	PUNCT
dpc-4503	28	27	an	an	DET
dpc-4503	28	28	anti	anti	ADJ
dpc-4503	28	29	-	-	ADJ
dpc-4503	28	30	tnf	tnf	ADJ
dpc-4503	28	31	-	-	PUNCT
dpc-4503	28	32	alfa	alfa	NOUN
dpc-4503	28	33	drug	drug	NOUN
dpc-4503	28	34	)	)	PUNCT
dpc-4503	28	35	and	and	CCONJ
dpc-4503	28	36	secukinumab	secukinumab	NOUN
dpc-4503	28	37	(	(	PUNCT
dpc-4503	28	38	an	an	DET
dpc-4503	28	39	anti	anti	ADJ
dpc-4503	28	40	-	-	ADJ
dpc-4503	28	41	il-17	il-17	ADV
dpc-4503	28	42	drug	drug	NOUN
dpc-4503	28	43	)	)	PUNCT
dpc-4503	28	44	are	be	AUX
dpc-4503	28	45	approved	approve	VERB
dpc-4503	28	46	for	for	ADP
dpc-4503	28	47	the	the	DET
dpc-4503	28	48	treatment	treatment	NOUN
dpc-4503	28	49	of	of	ADP
dpc-4503	28	50	severe	severe	ADJ
dpc-4503	28	51	hs	hs	PROPN
dpc-4503	29	1	[	[	X
dpc-4503	29	2	4	4	NUM
dpc-4503	29	3	,	,	PUNCT
dpc-4503	29	4	5	5	NUM
dpc-4503	29	5	]	]	PUNCT
dpc-4503	29	6	.	.	PUNCT
dpc-4503	30	1	in	in	ADP
dpc-4503	30	2	particular	particular	ADJ
dpc-4503	30	3	,	,	PUNCT
dpc-4503	30	4	secukinumab	secukinumab	NOUN
dpc-4503	30	5	was	be	AUX
dpc-4503	30	6	recently	recently	ADV
dpc-4503	30	7	approved	approve	VERB
dpc-4503	30	8	for	for	ADP
dpc-4503	30	9	the	the	DET
dpc-4503	30	10	treatment	treatment	NOUN
dpc-4503	30	11	of	of	ADP
dpc-4503	30	12	severe	severe	ADJ
dpc-4503	30	13	hs	hs	NOUN
dpc-4503	30	14	by	by	ADP
dpc-4503	30	15	the	the	DET
dpc-4503	30	16	us	us	PROPN
dpc-4503	30	17	food	food	NOUN
dpc-4503	30	18	and	and	CCONJ
dpc-4503	30	19	drug	drug	PROPN
dpc-4503	30	20	administration	administration	PROPN
dpc-4503	30	21	(	(	PUNCT
dpc-4503	30	22	fda	fda	PROPN
dpc-4503	30	23	)	)	PUNCT
dpc-4503	30	24	on	on	ADP
dpc-4503	30	25	31	31	NUM
dpc-4503	30	26	october	october	PROPN
dpc-4503	30	27	2023	2023	NUM
dpc-4503	30	28	.	.	PUNCT
dpc-4503	31	1	in	in	ADP
dpc-4503	31	2	a	a	DET
dpc-4503	31	3	large	large	ADJ
dpc-4503	31	4	-	-	PUNCT
dpc-4503	31	5	scale	scale	NOUN
dpc-4503	31	6	population	population	NOUN
dpc-4503	31	7	-	-	PUNCT
dpc-4503	31	8	based	base	VERB
dpc-4503	31	9	study	study	NOUN
dpc-4503	31	10	,	,	PUNCT
dpc-4503	31	11	the	the	DET
dpc-4503	31	12	prevalence	prevalence	NOUN
dpc-4503	31	13	of	of	ADP
dpc-4503	31	14	hs	hs	PROPN
dpc-4503	31	15	increased	increase	VERB
dpc-4503	31	16	in	in	ADP
dpc-4503	31	17	patients	patient	NOUN
dpc-4503	31	18	affected	affect	VERB
dpc-4503	31	19	by	by	ADP
dpc-4503	31	20	psoriasis	psoriasis	NOUN
dpc-4503	31	21	compared	compare	VERB
dpc-4503	31	22	with	with	ADP
dpc-4503	31	23	the	the	DET
dpc-4503	31	24	control	control	NOUN
dpc-4503	31	25	group	group	NOUN
dpc-4503	31	26	(	(	PUNCT
dpc-4503	31	27	odds	odd	NOUN
dpc-4503	31	28	ratio	ratio	VERB
dpc-4503	31	29	1.8	1.8	NUM
dpc-4503	31	30	;	;	PUNCT
dpc-4503	31	31	95	95	NUM
dpc-4503	31	32	%	%	NOUN
dpc-4503	31	33	confidence	confidence	NOUN
dpc-4503	31	34	interval	interval	NOUN
dpc-4503	31	35	(	(	PUNCT
dpc-4503	31	36	ci	ci	NOUN
dpc-4503	31	37	):	):	PUNCT
dpc-4503	31	38	1.5	1.5	NUM
dpc-4503	31	39	-	-	SYM
dpc-4503	31	40	2.3	2.3	NUM
dpc-4503	31	41	)	)	PUNCT
dpc-4503	32	1	[	[	X
dpc-4503	32	2	6	6	NUM
dpc-4503	32	3	]	]	PUNCT
dpc-4503	32	4	.	.	PUNCT
dpc-4503	33	1	the	the	DET
dpc-4503	33	2	two	two	NUM
dpc-4503	33	3	diseases	disease	NOUN
dpc-4503	33	4	share	share	VERB
dpc-4503	33	5	immune	immune	ADJ
dpc-4503	33	6	pathogenetic	pathogenetic	ADJ
dpc-4503	33	7	pathways	pathway	NOUN
dpc-4503	33	8	,	,	PUNCT
dpc-4503	33	9	including	include	VERB
dpc-4503	33	10	tnf	tnf	PROPN
dpc-4503	33	11	-	-	PUNCT
dpc-4503	33	12	alfa	alfa	PROPN
dpc-4503	33	13	,	,	PUNCT
dpc-4503	33	14	il-12/23	il-12/23	ADJ
dpc-4503	33	15	and	and	CCONJ
dpc-4503	33	16	other	other	ADJ
dpc-4503	33	17	cytokines	cytokine	NOUN
dpc-4503	33	18	produced	produce	VERB
dpc-4503	33	19	by	by	ADP
dpc-4503	33	20	t	t	PROPN
dpc-4503	33	21	-	-	PUNCT
dpc-4503	33	22	helper	helper	NOUN
dpc-4503	33	23	17	17	NUM
dpc-4503	33	24	cells	cell	NOUN
dpc-4503	33	25	[	[	X
dpc-4503	33	26	6	6	NUM
dpc-4503	33	27	,	,	PUNCT
dpc-4503	33	28	7	7	NUM
dpc-4503	33	29	]	]	PUNCT
dpc-4503	33	30	.	.	PUNCT
dpc-4503	34	1	the	the	DET
dpc-4503	34	2	overlapping	overlap	VERB
dpc-4503	34	3	pathogenesis	pathogenesis	NOUN
dpc-4503	34	4	of	of	ADP
dpc-4503	34	5	psoriasis	psoriasis	NOUN
dpc-4503	34	6	and	and	CCONJ
dpc-4503	34	7	hs	hs	PROPN
dpc-4503	34	8	has	have	AUX
dpc-4503	34	9	led	lead	VERB
dpc-4503	34	10	to	to	ADP
dpc-4503	34	11	the	the	DET
dpc-4503	34	12	development	development	NOUN
dpc-4503	34	13	of	of	ADP
dpc-4503	34	14	several	several	ADJ
dpc-4503	34	15	clinical	clinical	ADJ
dpc-4503	34	16	trials	trial	NOUN
dpc-4503	34	17	to	to	PART
dpc-4503	34	18	investigate	investigate	VERB
dpc-4503	34	19	the	the	DET
dpc-4503	34	20	role	role	NOUN
dpc-4503	34	21	of	of	ADP
dpc-4503	34	22	anti	anti	ADJ
dpc-4503	34	23	-	-	ADJ
dpc-4503	34	24	il-17	il-17	ADJ
dpc-4503	34	25	and	and	CCONJ
dpc-4503	34	26	anti	anti	ADJ
dpc-4503	34	27	-	-	ADJ
dpc-4503	34	28	il-23	il-23	ADJ
dpc-4503	34	29	drugs	drug	NOUN
dpc-4503	34	30	for	for	ADP
dpc-4503	34	31	the	the	DET
dpc-4503	34	32	treatment	treatment	NOUN
dpc-4503	34	33	of	of	ADP
dpc-4503	34	34	hs	hs	PROPN
dpc-4503	34	35	.	.	PROPN
dpc-4503	34	36	among	among	ADP
dpc-4503	34	37	the	the	DET
dpc-4503	34	38	anti	anti	NOUN
dpc-4503	34	39	-	-	NOUN
dpc-4503	34	40	il-23	il-23	ADJ
dpc-4503	34	41	(	(	PUNCT
dpc-4503	34	42	guselkumab	guselkumab	NOUN
dpc-4503	34	43	,	,	PUNCT
dpc-4503	34	44	tildrakizumab	tildrakizumab	NOUN
dpc-4503	34	45	and	and	CCONJ
dpc-4503	34	46	risankizumab	risankizumab	VERB
dpc-4503	34	47	)	)	PUNCT
dpc-4503	34	48	and	and	CCONJ
dpc-4503	34	49	anti	anti	NOUN
dpc-4503	34	50	-	-	ADJ
dpc-4503	34	51	il-17	il-17	ADJ
dpc-4503	34	52	(	(	PUNCT
dpc-4503	34	53	ixekizumab	ixekizumab	NOUN
dpc-4503	34	54	,	,	PUNCT
dpc-4503	34	55	bimekizumab	bimekizumab	PROPN
dpc-4503	34	56	,	,	PUNCT
dpc-4503	34	57	secukinumab	secukinumab	NOUN
dpc-4503	34	58	and	and	CCONJ
dpc-4503	34	59	brodalumab	brodalumab	NOUN
dpc-4503	34	60	)	)	PUNCT
dpc-4503	34	61	drugs	drug	NOUN
dpc-4503	34	62	,	,	PUNCT
dpc-4503	34	63	all	all	PRON
dpc-4503	34	64	approved	approve	VERB
dpc-4503	34	65	for	for	ADP
dpc-4503	34	66	the	the	DET
dpc-4503	34	67	treatment	treatment	NOUN
dpc-4503	34	68	of	of	ADP
dpc-4503	34	69	moderate	moderate	ADJ
dpc-4503	34	70	-	-	PUNCT
dpc-4503	34	71	to	to	ADP
dpc-4503	34	72	-	-	PUNCT
dpc-4503	34	73	severe	severe	ADJ
dpc-4503	34	74	psoriasis	psoriasis	NOUN
dpc-4503	34	75	,	,	PUNCT
dpc-4503	34	76	only	only	ADV
dpc-4503	34	77	secukinumab	secukinumab	NOUN
dpc-4503	34	78	has	have	AUX
dpc-4503	34	79	recently	recently	ADV
dpc-4503	34	80	been	be	AUX
dpc-4503	34	81	approved	approve	VERB
dpc-4503	34	82	for	for	ADP
dpc-4503	34	83	the	the	DET
dpc-4503	34	84	treatment	treatment	NOUN
dpc-4503	34	85	of	of	ADP
dpc-4503	34	86	severe	severe	ADJ
dpc-4503	34	87	hs	hs	PROPN
dpc-4503	34	88	after	after	ADP
dpc-4503	34	89	being	be	AUX
dpc-4503	34	90	evaluated	evaluate	VERB
dpc-4503	34	91	in	in	ADP
dpc-4503	34	92	two	two	NUM
dpc-4503	34	93	phase	phase	NOUN
dpc-4503	34	94	3	3	NUM
dpc-4503	34	95	clinical	clinical	ADJ
dpc-4503	34	96	trials	trial	NOUN
dpc-4503	34	97	–	–	PUNCT
dpc-4503	34	98	sunshine	sunshine	NOUN
dpc-4503	34	99	and	and	CCONJ
dpc-4503	34	100	sunrise	sunrise	VERB
dpc-4503	34	101	[	[	X
dpc-4503	34	102	5	5	NUM
dpc-4503	34	103	,	,	PUNCT
dpc-4503	34	104	8	8	NUM
dpc-4503	34	105	]	]	PUNCT
dpc-4503	34	106	.	.	PUNCT
dpc-4503	35	1	data	datum	NOUN
dpc-4503	35	2	from	from	ADP
dpc-4503	35	3	phase	phase	NOUN
dpc-4503	35	4	3	3	NUM
dpc-4503	35	5	clinical	clinical	ADJ
dpc-4503	35	6	trials	trial	NOUN
dpc-4503	35	7	(	(	PUNCT
dpc-4503	35	8	be	be	AUX
dpc-4503	35	9	heard	hear	VERB
dpc-4503	35	10	i	i	PRON
dpc-4503	35	11	and	and	CCONJ
dpc-4503	35	12	be	be	AUX
dpc-4503	35	13	heard	hear	VERB
dpc-4503	35	14	ii	ii	NUM
dpc-4503	35	15	)	)	PUNCT
dpc-4503	35	16	have	have	AUX
dpc-4503	35	17	recently	recently	ADV
dpc-4503	35	18	been	be	AUX
dpc-4503	35	19	published	publish	VERB
dpc-4503	35	20	regarding	regard	VERB
dpc-4503	35	21	the	the	DET
dpc-4503	35	22	efficacy	efficacy	NOUN
dpc-4503	35	23	of	of	ADP
dpc-4503	35	24	bimekizumab	bimekizumab	NOUN
dpc-4503	35	25	in	in	ADP
dpc-4503	35	26	the	the	DET
dpc-4503	35	27	treatment	treatment	NOUN
dpc-4503	35	28	of	of	ADP
dpc-4503	35	29	moderate	moderate	ADJ
dpc-4503	35	30	-	-	PUNCT
dpc-4503	35	31	to	to	ADP
dpc-4503	35	32	-	-	PUNCT
dpc-4503	35	33	severe	severe	ADJ
dpc-4503	35	34	hs	hs	PROPN
dpc-4503	36	1	[	[	X
dpc-4503	36	2	9	9	NUM
dpc-4503	36	3	]	]	PUNCT
dpc-4503	36	4	.	.	PUNCT
dpc-4503	37	1	among	among	ADP
dpc-4503	37	2	the	the	DET
dpc-4503	37	3	anti	anti	ADJ
dpc-4503	37	4	-	-	ADJ
dpc-4503	37	5	il-23	il-23	ADJ
dpc-4503	37	6	drugs	drug	NOUN
dpc-4503	37	7	,	,	PUNCT
dpc-4503	37	8	both	both	PRON
dpc-4503	37	9	risankizumab	risankizumab	VERB
dpc-4503	37	10	and	and	CCONJ
dpc-4503	37	11	guselkumab	guselkumab	NOUN
dpc-4503	37	12	have	have	AUX
dpc-4503	37	13	failed	fail	VERB
dpc-4503	37	14	to	to	PART
dpc-4503	37	15	achieve	achieve	VERB
dpc-4503	37	16	the	the	DET
dpc-4503	37	17	primary	primary	ADJ
dpc-4503	37	18	endpoints	endpoint	NOUN
dpc-4503	37	19	in	in	ADP
dpc-4503	37	20	phase	phase	NOUN
dpc-4503	37	21	2	2	NUM
dpc-4503	37	22	clinical	clinical	ADJ
dpc-4503	37	23	trials	trial	NOUN
dpc-4503	37	24	for	for	ADP
dpc-4503	37	25	hs	hs	PROPN
dpc-4503	38	1	[	[	X
dpc-4503	38	2	10	10	NUM
dpc-4503	38	3	,	,	PUNCT
dpc-4503	38	4	11	11	NUM
dpc-4503	38	5	]	]	PUNCT
dpc-4503	38	6	.	.	PUNCT
dpc-4503	39	1	our	our	PRON
dpc-4503	39	2	multicenter	multicenter	ADJ
dpc-4503	39	3	study	study	NOUN
dpc-4503	39	4	aimed	aim	VERB
dpc-4503	39	5	to	to	PART
dpc-4503	39	6	assess	assess	VERB
dpc-4503	39	7	the	the	DET
dpc-4503	39	8	effectiveness	effectiveness	NOUN
dpc-4503	39	9	and	and	CCONJ
dpc-4503	39	10	safety	safety	NOUN
dpc-4503	39	11	of	of	ADP
dpc-4503	39	12	anti	anti	ADJ
dpc-4503	39	13	-	-	ADJ
dpc-4503	39	14	il-17	il-17	ADJ
dpc-4503	39	15	and	and	CCONJ
dpc-4503	39	16	anti	anti	ADJ
dpc-4503	39	17	-	-	ADJ
dpc-4503	39	18	il-23	il-23	ADJ
dpc-4503	39	19	drugs	drug	NOUN
dpc-4503	39	20	in	in	ADP
dpc-4503	39	21	patients	patient	NOUN
dpc-4503	39	22	with	with	ADP
dpc-4503	39	23	hs	hs	PROPN
dpc-4503	39	24	and	and	CCONJ
dpc-4503	39	25	concomitant	concomitant	ADJ
dpc-4503	39	26	moderate	moderate	ADJ
dpc-4503	39	27	-	-	PUNCT
dpc-4503	39	28	to	to	ADP
dpc-4503	39	29	-	-	PUNCT
dpc-4503	39	30	severe	severe	ADJ
dpc-4503	39	31	plaque	plaque	NOUN
dpc-4503	39	32	psoriasis	psoriasis	NOUN
dpc-4503	39	33	.	.	PUNCT
dpc-4503	40	1	introduction	introduction	NOUN
dpc-4503	40	2	:	:	PUNCT
dpc-4503	40	3	psoriasis	psoriasis	NOUN
dpc-4503	40	4	and	and	CCONJ
dpc-4503	40	5	hidradenitis	hidradenitis	PROPN
dpc-4503	40	6	suppurativa	suppurativa	PROPN
dpc-4503	40	7	(	(	PUNCT
dpc-4503	40	8	hs	hs	X
dpc-4503	40	9	)	)	PUNCT
dpc-4503	40	10	are	be	AUX
dpc-4503	40	11	chronic	chronic	ADJ
dpc-4503	40	12	inflammatory	inflammatory	ADJ
dpc-4503	40	13	diseases	disease	NOUN
dpc-4503	40	14	with	with	ADP
dpc-4503	40	15	significant	significant	ADJ
dpc-4503	40	16	overlap	overlap	NOUN
dpc-4503	40	17	in	in	ADP
dpc-4503	40	18	their	their	PRON
dpc-4503	40	19	immunologic	immunologic	ADJ
dpc-4503	40	20	pathways	pathway	NOUN
dpc-4503	40	21	,	,	PUNCT
dpc-4503	40	22	which	which	PRON
dpc-4503	40	23	involve	involve	VERB
dpc-4503	40	24	cytokines	cytokine	NOUN
dpc-4503	40	25	such	such	ADJ
dpc-4503	40	26	as	as	ADP
dpc-4503	40	27	tumor	tumor	NOUN
dpc-4503	40	28	necrosis	necrosis	NOUN
dpc-4503	40	29	factor	factor	NOUN
dpc-4503	40	30	-	-	PUNCT
dpc-4503	40	31	alfa	alfa	NOUN
dpc-4503	40	32	,	,	PUNCT
dpc-4503	40	33	interleukin	interleukin	NOUN
dpc-4503	40	34	(	(	PUNCT
dpc-4503	40	35	il)-17	il)-17	PROPN
dpc-4503	40	36	,	,	PUNCT
dpc-4503	40	37	and	and	CCONJ
dpc-4503	40	38	il-23	il-23	NOUN
dpc-4503	40	39	.	.	PUNCT
dpc-4503	41	1	current	current	ADJ
dpc-4503	41	2	treatment	treatment	NOUN
dpc-4503	41	3	options	option	NOUN
dpc-4503	41	4	for	for	ADP
dpc-4503	41	5	hs	hs	PROPN
dpc-4503	41	6	are	be	AUX
dpc-4503	41	7	limited	limit	VERB
dpc-4503	41	8	,	,	PUNCT
dpc-4503	41	9	as	as	SCONJ
dpc-4503	41	10	only	only	ADV
dpc-4503	41	11	adalimumab	adalimumab	NOUN
dpc-4503	41	12	and	and	CCONJ
dpc-4503	41	13	secukinumab	secukinumab	NOUN
dpc-4503	41	14	are	be	AUX
dpc-4503	41	15	approved	approve	VERB
dpc-4503	41	16	for	for	ADP
dpc-4503	41	17	severe	severe	ADJ
dpc-4503	41	18	cases	case	NOUN
dpc-4503	41	19	.	.	PUNCT
dpc-4503	42	1	given	give	VERB
dpc-4503	42	2	the	the	DET
dpc-4503	42	3	overlapping	overlap	VERB
dpc-4503	42	4	pathogenetic	pathogenetic	ADJ
dpc-4503	42	5	features	feature	NOUN
dpc-4503	42	6	between	between	ADP
dpc-4503	42	7	hs	hs	PROPN
dpc-4503	42	8	and	and	CCONJ
dpc-4503	42	9	psoriasis	psoriasis	NOUN
dpc-4503	42	10	,	,	PUNCT
dpc-4503	42	11	anti	anti	ADJ
dpc-4503	42	12	-	-	ADJ
dpc-4503	42	13	il-17	il-17	ADJ
dpc-4503	42	14	and	and	CCONJ
dpc-4503	42	15	anti	anti	ADJ
dpc-4503	42	16	-	-	ADJ
dpc-4503	42	17	il-23	il-23	ADJ
dpc-4503	42	18	drugs	drug	NOUN
dpc-4503	42	19	could	could	AUX
dpc-4503	42	20	represent	represent	VERB
dpc-4503	42	21	valuable	valuable	ADJ
dpc-4503	42	22	treatments	treatment	NOUN
dpc-4503	42	23	for	for	ADP
dpc-4503	42	24	the	the	DET
dpc-4503	42	25	management	management	NOUN
dpc-4503	42	26	of	of	ADP
dpc-4503	42	27	hs	hs	PROPN
dpc-4503	42	28	.	.	PROPN
dpc-4503	42	29	objectives	objective	NOUN
dpc-4503	42	30	:	:	PUNCT
dpc-4503	42	31	we	we	PRON
dpc-4503	42	32	sought	seek	VERB
dpc-4503	42	33	to	to	PART
dpc-4503	42	34	evaluate	evaluate	VERB
dpc-4503	42	35	the	the	DET
dpc-4503	42	36	effectiveness	effectiveness	NOUN
dpc-4503	42	37	and	and	CCONJ
dpc-4503	42	38	safety	safety	NOUN
dpc-4503	42	39	of	of	ADP
dpc-4503	42	40	anti	anti	ADJ
dpc-4503	42	41	-	-	ADJ
dpc-4503	42	42	il-17	il-17	ADJ
dpc-4503	42	43	and	and	CCONJ
dpc-4503	42	44	anti	anti	ADJ
dpc-4503	42	45	-	-	ADJ
dpc-4503	42	46	il-23	il-23	ADJ
dpc-4503	42	47	drugs	drug	NOUN
dpc-4503	42	48	in	in	ADP
dpc-4503	42	49	patients	patient	NOUN
dpc-4503	42	50	with	with	ADP
dpc-4503	42	51	hs	hs	PROPN
dpc-4503	42	52	and	and	CCONJ
dpc-4503	42	53	concomitant	concomitant	ADJ
dpc-4503	42	54	moderate	moderate	ADJ
dpc-4503	42	55	-	-	PUNCT
dpc-4503	42	56	to	to	ADP
dpc-4503	42	57	-	-	PUNCT
dpc-4503	42	58	severe	severe	ADJ
dpc-4503	42	59	plaque	plaque	NOUN
dpc-4503	42	60	psoriasis	psoriasis	NOUN
dpc-4503	42	61	.	.	PUNCT
dpc-4503	43	1	methods	method	NOUN
dpc-4503	43	2	:	:	PUNCT
dpc-4503	43	3	we	we	PRON
dpc-4503	43	4	conducted	conduct	VERB
dpc-4503	43	5	a	a	DET
dpc-4503	43	6	multicenter	multicenter	ADJ
dpc-4503	43	7	retrospective	retrospective	ADJ
dpc-4503	43	8	study	study	NOUN
dpc-4503	43	9	in	in	ADP
dpc-4503	43	10	11	11	NUM
dpc-4503	43	11	italian	italian	ADJ
dpc-4503	43	12	dermatology	dermatology	NOUN
dpc-4503	43	13	units	unit	NOUN
dpc-4503	43	14	.	.	PUNCT
dpc-4503	44	1	the	the	DET
dpc-4503	44	2	effectiveness	effectiveness	NOUN
dpc-4503	44	3	of	of	ADP
dpc-4503	44	4	the	the	DET
dpc-4503	44	5	drugs	drug	NOUN
dpc-4503	44	6	was	be	AUX
dpc-4503	44	7	evaluated	evaluate	VERB
dpc-4503	44	8	by	by	ADP
dpc-4503	44	9	assessing	assess	VERB
dpc-4503	44	10	the	the	DET
dpc-4503	44	11	percentage	percentage	NOUN
dpc-4503	44	12	of	of	ADP
dpc-4503	44	13	patients	patient	NOUN
dpc-4503	44	14	achieving	achieve	VERB
dpc-4503	44	15	hs	hs	PROPN
dpc-4503	44	16	clinical	clinical	ADJ
dpc-4503	44	17	response	response	NOUN
dpc-4503	44	18	(	(	PUNCT
dpc-4503	44	19	hiscr	hiscr	PROPN
dpc-4503	44	20	)	)	PUNCT
dpc-4503	44	21	each	each	DET
dpc-4503	44	22	week	week	NOUN
dpc-4503	44	23	.	.	PUNCT
dpc-4503	45	1	results	result	NOUN
dpc-4503	45	2	:	:	PUNCT
dpc-4503	45	3	we	we	PRON
dpc-4503	45	4	enrolled	enrol	VERB
dpc-4503	45	5	41	41	NUM
dpc-4503	45	6	patients	patient	NOUN
dpc-4503	45	7	with	with	ADP
dpc-4503	45	8	at	at	ADV
dpc-4503	45	9	least	least	ADV
dpc-4503	45	10	16	16	NUM
dpc-4503	45	11	weeks	week	NOUN
dpc-4503	45	12	of	of	ADP
dpc-4503	45	13	follow	follow	NOUN
dpc-4503	45	14	-	-	PUNCT
dpc-4503	45	15	up	up	NOUN
dpc-4503	45	16	,	,	PUNCT
dpc-4503	45	17	with	with	ADP
dpc-4503	45	18	17	17	NUM
dpc-4503	45	19	of	of	ADP
dpc-4503	45	20	them	they	PRON
dpc-4503	45	21	completing	complete	VERB
dpc-4503	45	22	52	52	NUM
dpc-4503	45	23	 	 	SPACE
dpc-4503	45	24	weeks	week	NOUN
dpc-4503	45	25	of	of	ADP
dpc-4503	45	26	treatment	treatment	NOUN
dpc-4503	45	27	.	.	PUNCT
dpc-4503	46	1	the	the	DET
dpc-4503	46	2	most	most	ADV
dpc-4503	46	3	commonly	commonly	ADV
dpc-4503	46	4	prescribed	prescribe	VERB
dpc-4503	46	5	anti	anti	ADJ
dpc-4503	46	6	-	-	ADJ
dpc-4503	46	7	il	il	ADJ
dpc-4503	46	8	drug	drug	NOUN
dpc-4503	46	9	was	be	AUX
dpc-4503	46	10	secukinumab	secukinumab	NOUN
dpc-4503	46	11	(	(	PUNCT
dpc-4503	46	12	27	27	NUM
dpc-4503	46	13	patients	patient	NOUN
dpc-4503	46	14	)	)	PUNCT
dpc-4503	46	15	,	,	PUNCT
dpc-4503	46	16	followed	follow	VERB
dpc-4503	46	17	by	by	ADP
dpc-4503	46	18	ixekizumab	ixekizumab	NOUN
dpc-4503	46	19	(	(	PUNCT
dpc-4503	46	20	5	5	NUM
dpc-4503	46	21	)	)	PUNCT
dpc-4503	46	22	and	and	CCONJ
dpc-4503	46	23	guselkumab	guselkumab	NOUN
dpc-4503	46	24	(	(	PUNCT
dpc-4503	46	25	5	5	NUM
dpc-4503	46	26	)	)	PUNCT
dpc-4503	46	27	.	.	PUNCT
dpc-4503	47	1	the	the	DET
dpc-4503	47	2	hiscr	hiscr	NOUN
dpc-4503	47	3	was	be	AUX
dpc-4503	47	4	achieved	achieve	VERB
dpc-4503	47	5	by	by	ADP
dpc-4503	47	6	39	39	NUM
dpc-4503	47	7	%	%	NOUN
dpc-4503	47	8	,	,	PUNCT
dpc-4503	47	9	74.3	74.3	NUM
dpc-4503	47	10	%	%	NOUN
dpc-4503	47	11	,	,	PUNCT
dpc-4503	47	12	and	and	CCONJ
dpc-4503	47	13	77.8	77.8	NUM
dpc-4503	47	14	%	%	NOUN
dpc-4503	47	15	of	of	ADP
dpc-4503	47	16	patients	patient	NOUN
dpc-4503	47	17	after	after	ADP
dpc-4503	47	18	16	16	NUM
dpc-4503	47	19	,	,	PUNCT
dpc-4503	47	20	32	32	NUM
dpc-4503	47	21	,	,	PUNCT
dpc-4503	47	22	and	and	CCONJ
dpc-4503	47	23	52	52	NUM
dpc-4503	47	24	weeks	week	NOUN
dpc-4503	47	25	,	,	PUNCT
dpc-4503	47	26	respectively	respectively	ADV
dpc-4503	47	27	.	.	PUNCT
dpc-4503	48	1	no	no	DET
dpc-4503	48	2	severe	severe	ADJ
dpc-4503	48	3	adverse	adverse	ADJ
dpc-4503	48	4	events	event	NOUN
dpc-4503	48	5	(	(	PUNCT
dpc-4503	48	6	aes	aes	NOUN
dpc-4503	48	7	)	)	PUNCT
dpc-4503	48	8	or	or	CCONJ
dpc-4503	48	9	aes	aes	PROPN
dpc-4503	48	10	leading	lead	VERB
dpc-4503	48	11	to	to	ADP
dpc-4503	48	12	discontinuation	discontinuation	NOUN
dpc-4503	48	13	were	be	AUX
dpc-4503	48	14	observed	observe	VERB
dpc-4503	48	15	during	during	ADP
dpc-4503	48	16	the	the	DET
dpc-4503	48	17	study	study	NOUN
dpc-4503	48	18	.	.	PUNCT
dpc-4503	49	1	the	the	DET
dpc-4503	49	2	most	most	ADV
dpc-4503	49	3	common	common	ADJ
dpc-4503	49	4	ae	ae	PROPN
dpc-4503	49	5	was	be	AUX
dpc-4503	49	6	nasopharyngitis	nasopharyngitis	NOUN
dpc-4503	49	7	(	(	PUNCT
dpc-4503	49	8	four	four	NUM
dpc-4503	49	9	patients	patient	NOUN
dpc-4503	49	10	)	)	PUNCT
dpc-4503	49	11	.	.	PUNCT
dpc-4503	50	1	conclusion	conclusion	NOUN
dpc-4503	50	2	:	:	PUNCT
dpc-4503	50	3	in	in	ADP
dpc-4503	50	4	this	this	DET
dpc-4503	50	5	real	real	ADJ
dpc-4503	50	6	-	-	PUNCT
dpc-4503	50	7	world	world	NOUN
dpc-4503	50	8	study	study	NOUN
dpc-4503	50	9	,	,	PUNCT
dpc-4503	50	10	we	we	PRON
dpc-4503	50	11	highlight	highlight	VERB
dpc-4503	50	12	the	the	DET
dpc-4503	50	13	effectiveness	effectiveness	NOUN
dpc-4503	50	14	of	of	ADP
dpc-4503	50	15	anti	anti	ADJ
dpc-4503	50	16	-	-	NOUN
dpc-4503	50	17	il-23	il-23	ADJ
dpc-4503	50	18	and	and	CCONJ
dpc-4503	50	19	anti	anti	ADJ
dpc-4503	50	20	-	-	ADJ
dpc-4503	50	21	il-17	il-17	ADV
dpc-4503	50	22	drugs	drug	NOUN
dpc-4503	50	23	in	in	ADP
dpc-4503	50	24	the	the	DET
dpc-4503	50	25	treatment	treatment	NOUN
dpc-4503	50	26	of	of	ADP
dpc-4503	50	27	concomitant	concomitant	ADJ
dpc-4503	50	28	plaque	plaque	NOUN
dpc-4503	50	29	psoriasis	psoriasis	NOUN
dpc-4503	50	30	and	and	CCONJ
dpc-4503	50	31	severe	severe	ADJ
dpc-4503	50	32	hs	h	NOUN
dpc-4503	50	33	.	.	PROPN
dpc-4503	50	34	longer	long	ADJ
dpc-4503	50	35	and	and	CCONJ
dpc-4503	50	36	larger	large	ADJ
dpc-4503	50	37	studies	study	NOUN
dpc-4503	50	38	are	be	AUX
dpc-4503	50	39	needed	need	VERB
dpc-4503	50	40	to	to	PART
dpc-4503	50	41	further	far	ADV
dpc-4503	50	42	evaluate	evaluate	VERB
dpc-4503	50	43	the	the	DET
dpc-4503	50	44	long	long	ADJ
dpc-4503	50	45	-	-	PUNCT
dpc-4503	50	46	term	term	NOUN
dpc-4503	50	47	effectiveness	effectiveness	NOUN
dpc-4503	50	48	and	and	CCONJ
dpc-4503	50	49	safety	safety	NOUN
dpc-4503	50	50	of	of	ADP
dpc-4503	50	51	these	these	DET
dpc-4503	50	52	treatments	treatment	NOUN
dpc-4503	50	53	in	in	ADP
dpc-4503	50	54	patients	patient	NOUN
dpc-4503	50	55	affected	affect	VERB
dpc-4503	50	56	by	by	ADP
dpc-4503	50	57	hs	hs	PROPN
dpc-4503	50	58	.	.	PUNCT
dpc-4503	50	59	abstract	abstract	ADJ
dpc-4503	50	60	authorship	authorship	NOUN
dpc-4503	50	61	:	:	PUNCT
dpc-4503	50	62	all	all	DET
dpc-4503	50	63	authors	author	NOUN
dpc-4503	50	64	have	have	AUX
dpc-4503	50	65	contributed	contribute	VERB
dpc-4503	50	66	significantly	significantly	ADV
dpc-4503	50	67	to	to	ADP
dpc-4503	50	68	this	this	DET
dpc-4503	50	69	publication	publication	NOUN
dpc-4503	50	70	.	.	PUNCT
dpc-4503	51	1	gargiulo	gargiulo	PROPN
dpc-4503	51	2	l.	l.	PROPN
dpc-4503	51	3	and	and	CCONJ
dpc-4503	51	4	ibba	ibba	PROPN
dpc-4503	51	5	l.	l.	PROPN
dpc-4503	51	6	contributed	contribute	VERB
dpc-4503	51	7	equally	equally	ADV
dpc-4503	51	8	to	to	ADP
dpc-4503	51	9	the	the	DET
dpc-4503	51	10	work	work	NOUN
dpc-4503	51	11	and	and	CCONJ
dpc-4503	51	12	share	share	VERB
dpc-4503	51	13	the	the	DET
dpc-4503	51	14	first	first	ADJ
dpc-4503	51	15	authorship	authorship	NOUN
dpc-4503	51	16	.	.	PUNCT
dpc-4503	52	1	corresponding	correspond	VERB
dpc-4503	52	2	author	author	NOUN
dpc-4503	52	3	:	:	PUNCT
dpc-4503	52	4	mario	mario	PROPN
dpc-4503	52	5	valenti	valenti	PROPN
dpc-4503	52	6	,	,	PUNCT
dpc-4503	52	7	md	md	PROPN
dpc-4503	52	8	,	,	PUNCT
dpc-4503	52	9	department	department	PROPN
dpc-4503	52	10	of	of	ADP
dpc-4503	52	11	biomedical	biomedical	ADJ
dpc-4503	52	12	sciences	sciences	PROPN
dpc-4503	52	13	,	,	PUNCT
dpc-4503	52	14	humanitas	humanita	NOUN
dpc-4503	52	15	university	university	NOUN
dpc-4503	52	16	,	,	PUNCT
dpc-4503	52	17	pieve	pieve	PROPN
dpc-4503	52	18	emanuele	emanuele	PROPN
dpc-4503	52	19	(	(	PUNCT
dpc-4503	52	20	mi	mi	PROPN
dpc-4503	52	21	)	)	PUNCT
dpc-4503	52	22	,	,	PUNCT
dpc-4503	52	23	italy	italy	PROPN
dpc-4503	52	24	.	.	PUNCT
dpc-4503	53	1	email	email	NOUN
dpc-4503	53	2	:	:	PUNCT
dpc-4503	53	3	mario.valenti@hunimed.eu	mario.valenti@hunimed.eu	VERB
dpc-4503	53	4	original	original	ADJ
dpc-4503	53	5	article	article	NOUN
dpc-4503	53	6	|	|	ADV
dpc-4503	53	7	dermatol	dermatol	ADJ
dpc-4503	53	8	pract	pract	NOUN
dpc-4503	53	9	concept	concept	NOUN
dpc-4503	53	10	.	.	PUNCT
dpc-4503	54	1	2024;14(4):e2024250	2024;14(4):e2024250	NUM
dpc-4503	54	2	3	3	NUM
dpc-4503	54	3	objectives	objective	NOUN
dpc-4503	54	4	we	we	PRON
dpc-4503	54	5	performed	perform	VERB
dpc-4503	54	6	a	a	DET
dpc-4503	54	7	retrospective	retrospective	ADJ
dpc-4503	54	8	multicenter	multicenter	NOUN
dpc-4503	54	9	study	study	NOUN
dpc-4503	54	10	by	by	ADP
dpc-4503	54	11	analyzing	analyze	VERB
dpc-4503	54	12	the	the	DET
dpc-4503	54	13	database	database	NOUN
dpc-4503	54	14	records	record	NOUN
dpc-4503	54	15	of	of	ADP
dpc-4503	54	16	11	11	NUM
dpc-4503	54	17	italian	italian	ADJ
dpc-4503	54	18	dermatology	dermatology	NOUN
dpc-4503	54	19	units	unit	NOUN
dpc-4503	54	20	between	between	ADP
dpc-4503	54	21	january	january	PROPN
dpc-4503	54	22	2020	2020	NUM
dpc-4503	54	23	and	and	CCONJ
dpc-4503	54	24	december	december	PROPN
dpc-4503	54	25	2023	2023	NUM
dpc-4503	54	26	to	to	PART
dpc-4503	54	27	evaluate	evaluate	VERB
dpc-4503	54	28	the	the	DET
dpc-4503	54	29	effectiveness	effectiveness	NOUN
dpc-4503	54	30	and	and	CCONJ
dpc-4503	54	31	safety	safety	NOUN
dpc-4503	54	32	of	of	ADP
dpc-4503	54	33	anti	anti	ADJ
dpc-4503	54	34	-	-	ADJ
dpc-4503	54	35	il-17	il-17	ADJ
dpc-4503	54	36	and	and	CCONJ
dpc-4503	54	37	anti	anti	ADJ
dpc-4503	54	38	-	-	ADJ
dpc-4503	54	39	il-23	il-23	ADJ
dpc-4503	54	40	drugs	drug	NOUN
dpc-4503	54	41	in	in	ADP
dpc-4503	54	42	patients	patient	NOUN
dpc-4503	54	43	with	with	ADP
dpc-4503	54	44	hs	hs	PROPN
dpc-4503	54	45	and	and	CCONJ
dpc-4503	54	46	concomitant	concomitant	ADJ
dpc-4503	54	47	moderate	moderate	ADJ
dpc-4503	54	48	-	-	PUNCT
dpc-4503	54	49	to	to	ADP
dpc-4503	54	50	-	-	PUNCT
dpc-4503	54	51	severe	severe	ADJ
dpc-4503	54	52	plaque	plaque	NOUN
dpc-4503	54	53	psoriasis	psoriasis	NOUN
dpc-4503	54	54	.	.	PUNCT
dpc-4503	55	1	methods	method	NOUN
dpc-4503	55	2	in	in	ADP
dpc-4503	55	3	our	our	PRON
dpc-4503	55	4	multicenter	multicenter	ADJ
dpc-4503	55	5	retrospective	retrospective	ADJ
dpc-4503	55	6	study	study	NOUN
dpc-4503	55	7	,	,	PUNCT
dpc-4503	55	8	we	we	PRON
dpc-4503	55	9	enrolled	enrol	VERB
dpc-4503	55	10	41	41	NUM
dpc-4503	55	11	  	  	SPACE
dpc-4503	55	12	patients	patient	NOUN
dpc-4503	55	13	who	who	PRON
dpc-4503	55	14	had	have	VERB
dpc-4503	55	15	at	at	ADV
dpc-4503	55	16	least	least	ADV
dpc-4503	55	17	16	16	NUM
dpc-4503	55	18	weeks	week	NOUN
dpc-4503	55	19	of	of	ADP
dpc-4503	55	20	follow	follow	NOUN
dpc-4503	55	21	-	-	PUNCT
dpc-4503	55	22	up	up	NOUN
dpc-4503	55	23	.	.	PUNCT
dpc-4503	56	1	all	all	DET
dpc-4503	56	2	patients	patient	NOUN
dpc-4503	56	3	had	have	VERB
dpc-4503	56	4	a	a	DET
dpc-4503	56	5	diagnosis	diagnosis	NOUN
dpc-4503	56	6	of	of	ADP
dpc-4503	56	7	moderate	moderate	ADJ
dpc-4503	56	8	-	-	PUNCT
dpc-4503	56	9	to	to	ADP
dpc-4503	56	10	-	-	PUNCT
dpc-4503	56	11	severe	severe	ADJ
dpc-4503	56	12	hidradenitis	hidradenitis	PROPN
dpc-4503	56	13	suppurativa	suppurativa	NOUN
dpc-4503	56	14	,	,	PUNCT
dpc-4503	56	15	defined	define	VERB
dpc-4503	56	16	as	as	ADP
dpc-4503	56	17	hurley	hurley	PROPN
dpc-4503	56	18	stage	stage	PROPN
dpc-4503	56	19	ii	ii	PROPN
dpc-4503	56	20	/	/	SYM
dpc-4503	56	21	iii	iii	PROPN
dpc-4503	56	22	or	or	CCONJ
dpc-4503	56	23	international	international	ADJ
dpc-4503	56	24	hs	hs	PROPN
dpc-4503	56	25	severity	severity	NOUN
dpc-4503	56	26	scoring	scoring	NOUN
dpc-4503	56	27	system	system	NOUN
dpc-4503	56	28	4	4	NUM
dpc-4503	56	29	(	(	PUNCT
dpc-4503	56	30	ihs4	ihs4	PROPN
dpc-4503	56	31	)	)	PUNCT
dpc-4503	56	32	≥	≥	NOUN
dpc-4503	56	33	4	4	NUM
dpc-4503	56	34	.	.	PUNCT
dpc-4503	57	1	all	all	DET
dpc-4503	57	2	patients	patient	NOUN
dpc-4503	57	3	had	have	VERB
dpc-4503	57	4	concomitant	concomitant	ADJ
dpc-4503	57	5	moderate	moderate	ADJ
dpc-4503	57	6	-	-	PUNCT
dpc-4503	57	7	to	to	ADP
dpc-4503	57	8	-	-	PUNCT
dpc-4503	57	9	severe	severe	ADJ
dpc-4503	57	10	plaque	plaque	NOUN
dpc-4503	57	11	psoriasis	psoriasis	NOUN
dpc-4503	57	12	,	,	PUNCT
dpc-4503	57	13	and	and	CCONJ
dpc-4503	57	14	the	the	DET
dpc-4503	57	15	eligibility	eligibility	NOUN
dpc-4503	57	16	for	for	ADP
dpc-4503	57	17	these	these	DET
dpc-4503	57	18	treatments	treatment	NOUN
dpc-4503	57	19	was	be	AUX
dpc-4503	57	20	assessed	assess	VERB
dpc-4503	57	21	following	follow	VERB
dpc-4503	57	22	the	the	DET
dpc-4503	57	23	italian	italian	ADJ
dpc-4503	57	24	adaptation	adaptation	NOUN
dpc-4503	57	25	of	of	ADP
dpc-4503	57	26	euroguiderm	euroguiderm	NOUN
dpc-4503	57	27	guideline	guideline	NOUN
dpc-4503	57	28	on	on	ADP
dpc-4503	57	29	the	the	DET
dpc-4503	57	30	systemic	systemic	ADJ
dpc-4503	57	31	treatment	treatment	NOUN
dpc-4503	57	32	of	of	ADP
dpc-4503	57	33	chronic	chronic	ADJ
dpc-4503	57	34	plaque	plaque	NOUN
dpc-4503	57	35	psoriasis	psoriasis	NOUN
dpc-4503	57	36	in	in	ADP
dpc-4503	57	37	patients	patient	NOUN
dpc-4503	57	38	with	with	ADP
dpc-4503	57	39	inadequate	inadequate	ADJ
dpc-4503	57	40	response	response	NOUN
dpc-4503	57	41	or	or	CCONJ
dpc-4503	57	42	contraindications	contraindication	NOUN
dpc-4503	57	43	to	to	ADP
dpc-4503	57	44	systemic	systemic	ADJ
dpc-4503	57	45	therapies	therapy	NOUN
dpc-4503	57	46	[	[	X
dpc-4503	57	47	12	12	NUM
dpc-4503	57	48	]	]	PUNCT
dpc-4503	57	49	.	.	PUNCT
dpc-4503	58	1	patients	patient	NOUN
dpc-4503	58	2	who	who	PRON
dpc-4503	58	3	developed	develop	VERB
dpc-4503	58	4	paradoxical	paradoxical	ADJ
dpc-4503	58	5	psoriasis	psoriasis	NOUN
dpc-4503	58	6	during	during	ADP
dpc-4503	58	7	treatment	treatment	NOUN
dpc-4503	58	8	with	with	ADP
dpc-4503	58	9	antitnf	antitnf	PROPN
dpc-4503	58	10	-	-	PUNCT
dpc-4503	58	11	alfa	alfa	PROPN
dpc-4503	58	12	for	for	ADP
dpc-4503	58	13	hs	hs	PROPN
dpc-4503	58	14	were	be	AUX
dpc-4503	58	15	not	not	PART
dpc-4503	58	16	included	include	VERB
dpc-4503	58	17	in	in	ADP
dpc-4503	58	18	this	this	DET
dpc-4503	58	19	study	study	NOUN
dpc-4503	58	20	.	.	PUNCT
dpc-4503	59	1	given	give	VERB
dpc-4503	59	2	the	the	DET
dpc-4503	59	3	recent	recent	ADJ
dpc-4503	59	4	approval	approval	NOUN
dpc-4503	59	5	of	of	ADP
dpc-4503	59	6	secukinumab	secukinumab	NOUN
dpc-4503	59	7	and	and	CCONJ
dpc-4503	59	8	the	the	DET
dpc-4503	59	9	lack	lack	NOUN
dpc-4503	59	10	of	of	ADP
dpc-4503	59	11	approval	approval	NOUN
dpc-4503	59	12	of	of	ADP
dpc-4503	59	13	other	other	ADJ
dpc-4503	59	14	anti	anti	ADJ
dpc-4503	59	15	-	-	ADJ
dpc-4503	59	16	il-17/	il-17/	ADJ
dpc-4503	59	17	23	23	NUM
dpc-4503	59	18	biologics	biologic	NOUN
dpc-4503	59	19	for	for	ADP
dpc-4503	59	20	the	the	DET
dpc-4503	59	21	treatment	treatment	NOUN
dpc-4503	59	22	of	of	ADP
dpc-4503	59	23	hs	hs	PROPN
dpc-4503	59	24	,	,	PUNCT
dpc-4503	59	25	these	these	DET
dpc-4503	59	26	drugs	drug	NOUN
dpc-4503	59	27	have	have	AUX
dpc-4503	59	28	been	be	AUX
dpc-4503	59	29	administered	administer	VERB
dpc-4503	59	30	to	to	ADP
dpc-4503	59	31	the	the	DET
dpc-4503	59	32	summary	summary	NOUN
dpc-4503	59	33	of	of	ADP
dpc-4503	59	34	product	product	NOUN
dpc-4503	59	35	characteristics	characteristic	NOUN
dpc-4503	59	36	with	with	ADP
dpc-4503	59	37	the	the	DET
dpc-4503	59	38	posology	posology	NOUN
dpc-4503	59	39	used	use	VERB
dpc-4503	59	40	for	for	ADP
dpc-4503	59	41	the	the	DET
dpc-4503	59	42	treatment	treatment	NOUN
dpc-4503	59	43	of	of	ADP
dpc-4503	59	44	psoriasis	psoriasis	NOUN
dpc-4503	59	45	[	[	X
dpc-4503	59	46	5	5	NUM
dpc-4503	59	47	,	,	PUNCT
dpc-4503	59	48	13	13	NUM
dpc-4503	59	49	-	-	SYM
dpc-4503	59	50	16	16	NUM
dpc-4503	59	51	]	]	PUNCT
dpc-4503	59	52	.	.	PUNCT
dpc-4503	60	1	institutional	institutional	ADJ
dpc-4503	60	2	review	review	PROPN
dpc-4503	60	3	board	board	NOUN
dpc-4503	60	4	approval	approval	NOUN
dpc-4503	60	5	was	be	AUX
dpc-4503	60	6	waived	waive	VERB
dpc-4503	60	7	for	for	ADP
dpc-4503	60	8	this	this	DET
dpc-4503	60	9	study	study	NOUN
dpc-4503	60	10	,	,	PUNCT
dpc-4503	60	11	as	as	SCONJ
dpc-4503	60	12	the	the	DET
dpc-4503	60	13	procedure	procedure	NOUN
dpc-4503	60	14	did	do	AUX
dpc-4503	60	15	not	not	PART
dpc-4503	60	16	deviate	deviate	VERB
dpc-4503	60	17	from	from	ADP
dpc-4503	60	18	good	good	ADJ
dpc-4503	60	19	routine	routine	ADJ
dpc-4503	60	20	clinical	clinical	ADJ
dpc-4503	60	21	practice	practice	NOUN
dpc-4503	60	22	.	.	PUNCT
dpc-4503	61	1	all	all	DET
dpc-4503	61	2	patients	patient	NOUN
dpc-4503	61	3	gave	gave	AUX
dpc-4503	61	4	written	write	VERB
dpc-4503	61	5	informed	informed	ADJ
dpc-4503	61	6	consent	consent	NOUN
dpc-4503	61	7	for	for	ADP
dpc-4503	61	8	the	the	DET
dpc-4503	61	9	retrospective	retrospective	ADJ
dpc-4503	61	10	retrieval	retrieval	NOUN
dpc-4503	61	11	of	of	ADP
dpc-4503	61	12	anonymized	anonymize	VERB
dpc-4503	61	13	data	datum	NOUN
dpc-4503	61	14	.	.	PUNCT
dpc-4503	62	1	the	the	DET
dpc-4503	62	2	study	study	NOUN
dpc-4503	62	3	was	be	AUX
dpc-4503	62	4	conducted	conduct	VERB
dpc-4503	62	5	following	follow	VERB
dpc-4503	62	6	the	the	DET
dpc-4503	62	7	helsinki	helsinki	PROPN
dpc-4503	62	8	declaration	declaration	NOUN
dpc-4503	62	9	of	of	ADP
dpc-4503	62	10	1964	1964	NUM
dpc-4503	62	11	and	and	CCONJ
dpc-4503	62	12	its	its	PRON
dpc-4503	62	13	later	later	ADJ
dpc-4503	62	14	amendments	amendment	NOUN
dpc-4503	62	15	.	.	PUNCT
dpc-4503	63	1	demographic	demographic	ADJ
dpc-4503	63	2	characteristics	characteristic	NOUN
dpc-4503	63	3	,	,	PUNCT
dpc-4503	63	4	comorbidities	comorbiditie	NOUN
dpc-4503	63	5	,	,	PUNCT
dpc-4503	63	6	disease	disease	NOUN
dpc-4503	63	7	characteristics	characteristic	NOUN
dpc-4503	63	8	,	,	PUNCT
dpc-4503	63	9	and	and	CCONJ
dpc-4503	63	10	clinical	clinical	ADJ
dpc-4503	63	11	scores	score	NOUN
dpc-4503	63	12	were	be	AUX
dpc-4503	63	13	retrieved	retrieve	VERB
dpc-4503	63	14	from	from	ADP
dpc-4503	63	15	the	the	DET
dpc-4503	63	16	electronic	electronic	ADJ
dpc-4503	63	17	medical	medical	ADJ
dpc-4503	63	18	records	record	NOUN
dpc-4503	63	19	at	at	ADP
dpc-4503	63	20	baseline	baseline	NOUN
dpc-4503	63	21	,	,	PUNCT
dpc-4503	63	22	week	week	NOUN
dpc-4503	63	23	16	16	NUM
dpc-4503	63	24	,	,	PUNCT
dpc-4503	63	25	week	week	NOUN
dpc-4503	63	26	32	32	NUM
dpc-4503	63	27	,	,	PUNCT
dpc-4503	63	28	and	and	CCONJ
dpc-4503	63	29	week	week	NOUN
dpc-4503	63	30	52	52	NUM
dpc-4503	63	31	.	.	PUNCT
dpc-4503	64	1	due	due	ADP
dpc-4503	64	2	to	to	ADP
dpc-4503	64	3	the	the	DET
dpc-4503	64	4	retrospective	retrospective	ADJ
dpc-4503	64	5	nature	nature	NOUN
dpc-4503	64	6	of	of	ADP
dpc-4503	64	7	this	this	DET
dpc-4503	64	8	study	study	NOUN
dpc-4503	64	9	,	,	PUNCT
dpc-4503	64	10	not	not	PART
dpc-4503	64	11	all	all	DET
dpc-4503	64	12	patients	patient	NOUN
dpc-4503	64	13	completed	complete	VERB
dpc-4503	64	14	all	all	DET
dpc-4503	64	15	the	the	DET
dpc-4503	64	16	follow	follow	VERB
dpc-4503	64	17	-	-	PUNCT
dpc-4503	64	18	up	up	ADP
dpc-4503	64	19	visits	visit	NOUN
dpc-4503	64	20	.	.	PUNCT
dpc-4503	65	1	for	for	ADP
dpc-4503	65	2	patients	patient	NOUN
dpc-4503	65	3	who	who	PRON
dpc-4503	65	4	did	do	AUX
dpc-4503	65	5	not	not	PART
dpc-4503	65	6	attend	attend	VERB
dpc-4503	65	7	the	the	DET
dpc-4503	65	8	scheduled	schedule	VERB
dpc-4503	65	9	dermatology	dermatology	NOUN
dpc-4503	65	10	visits	visit	NOUN
dpc-4503	65	11	and	and	CCONJ
dpc-4503	65	12	performed	perform	VERB
dpc-4503	65	13	the	the	DET
dpc-4503	65	14	injection	injection	NOUN
dpc-4503	65	15	of	of	ADP
dpc-4503	65	16	secukinumab	secukinumab	NOUN
dpc-4503	65	17	at	at	ADP
dpc-4503	65	18	home	home	NOUN
dpc-4503	65	19	or	or	CCONJ
dpc-4503	65	20	missed	miss	VERB
dpc-4503	65	21	the	the	DET
dpc-4503	65	22	dose	dose	NOUN
dpc-4503	65	23	,	,	PUNCT
dpc-4503	65	24	data	datum	NOUN
dpc-4503	65	25	were	be	AUX
dpc-4503	65	26	considered	consider	VERB
dpc-4503	65	27	from	from	ADP
dpc-4503	65	28	the	the	DET
dpc-4503	65	29	last	last	ADJ
dpc-4503	65	30	observation	observation	NOUN
dpc-4503	65	31	carried	carry	VERB
dpc-4503	65	32	forward	forward	ADV
dpc-4503	65	33	.	.	PUNCT
dpc-4503	66	1	at	at	ADP
dpc-4503	66	2	each	each	DET
dpc-4503	66	3	time	time	NOUN
dpc-4503	66	4	point	point	NOUN
dpc-4503	66	5	,	,	PUNCT
dpc-4503	66	6	the	the	DET
dpc-4503	66	7	effectiveness	effectiveness	NOUN
dpc-4503	66	8	of	of	ADP
dpc-4503	66	9	each	each	DET
dpc-4503	66	10	drug	drug	NOUN
dpc-4503	66	11	was	be	AUX
dpc-4503	66	12	assessed	assess	VERB
dpc-4503	66	13	in	in	ADP
dpc-4503	66	14	terms	term	NOUN
dpc-4503	66	15	of	of	ADP
dpc-4503	66	16	hidradenitis	hidradenitis	PROPN
dpc-4503	66	17	suppurativa	suppurativa	ADJ
dpc-4503	66	18	clinical	clinical	ADJ
dpc-4503	66	19	response	response	NOUN
dpc-4503	66	20	(	(	PUNCT
dpc-4503	66	21	hiscr	hiscr	PROPN
dpc-4503	66	22	)	)	PUNCT
dpc-4503	66	23	,	,	PUNCT
dpc-4503	66	24	defined	define	VERB
dpc-4503	66	25	as	as	ADP
dpc-4503	66	26	the	the	DET
dpc-4503	66	27	reduction	reduction	NOUN
dpc-4503	66	28	of	of	ADP
dpc-4503	66	29	at	at	ADV
dpc-4503	66	30	least	least	ADV
dpc-4503	66	31	50	50	NUM
dpc-4503	66	32	%	%	NOUN
dpc-4503	66	33	in	in	ADP
dpc-4503	66	34	nodule	nodule	NOUN
dpc-4503	66	35	and	and	CCONJ
dpc-4503	66	36	abscess	abscess	NOUN
dpc-4503	66	37	count	count	NOUN
dpc-4503	66	38	and	and	CCONJ
dpc-4503	66	39	no	no	DET
dpc-4503	66	40	increase	increase	NOUN
dpc-4503	66	41	in	in	ADP
dpc-4503	66	42	the	the	DET
dpc-4503	66	43	number	number	NOUN
dpc-4503	66	44	of	of	ADP
dpc-4503	66	45	abscesses	abscess	NOUN
dpc-4503	66	46	and	and	CCONJ
dpc-4503	66	47	draining	drain	VERB
dpc-4503	66	48	fistulas	fistula	NOUN
dpc-4503	66	49	compared	compare	VERB
dpc-4503	66	50	to	to	PART
dpc-4503	66	51	baseline	baseline	VERB
dpc-4503	66	52	[	[	X
dpc-4503	66	53	17	17	NUM
dpc-4503	66	54	]	]	PUNCT
dpc-4503	66	55	.	.	PUNCT
dpc-4503	67	1	a	a	DET
dpc-4503	67	2	reduction	reduction	NOUN
dpc-4503	67	3	of	of	ADP
dpc-4503	67	4	at	at	ADV
dpc-4503	67	5	least	least	ADV
dpc-4503	67	6	55	55	NUM
dpc-4503	67	7	%	%	NOUN
dpc-4503	67	8	in	in	ADP
dpc-4503	67	9	ihs4	ihs4	PROPN
dpc-4503	67	10	from	from	ADP
dpc-4503	67	11	baseline	baseline	PROPN
dpc-4503	67	12	(	(	PUNCT
dpc-4503	67	13	ihs455	ihs455	PROPN
dpc-4503	67	14	)	)	PUNCT
dpc-4503	68	1	[	[	X
dpc-4503	68	2	18	18	NUM
dpc-4503	68	3	]	]	PUNCT
dpc-4503	68	4	and	and	CCONJ
dpc-4503	68	5	a	a	DET
dpc-4503	68	6	reduction	reduction	NOUN
dpc-4503	68	7	in	in	ADP
dpc-4503	68	8	mean	mean	PROPN
dpc-4503	68	9	ihs4	ihs4	PROPN
dpc-4503	68	10	and	and	CCONJ
dpc-4503	68	11	dlqi	dlqi	PROPN
dpc-4503	68	12	were	be	AUX
dpc-4503	68	13	also	also	ADV
dpc-4503	68	14	selected	select	VERB
dpc-4503	68	15	as	as	ADP
dpc-4503	68	16	effectiveness	effectiveness	NOUN
dpc-4503	68	17	outcomes	outcome	NOUN
dpc-4503	68	18	.	.	PUNCT
dpc-4503	69	1	we	we	PRON
dpc-4503	69	2	also	also	ADV
dpc-4503	69	3	recorded	record	VERB
dpc-4503	69	4	the	the	DET
dpc-4503	69	5	occurrence	occurrence	NOUN
dpc-4503	69	6	of	of	ADP
dpc-4503	69	7	any	any	DET
dpc-4503	69	8	adverse	adverse	ADJ
dpc-4503	69	9	events	event	NOUN
dpc-4503	69	10	(	(	PUNCT
dpc-4503	69	11	aes	aes	NOUN
dpc-4503	69	12	)	)	PUNCT
dpc-4503	69	13	at	at	ADP
dpc-4503	69	14	each	each	DET
dpc-4503	69	15	visit	visit	NOUN
dpc-4503	69	16	,	,	PUNCT
dpc-4503	69	17	including	include	VERB
dpc-4503	69	18	serious	serious	ADJ
dpc-4503	69	19	aes	aes	PROPN
dpc-4503	69	20	and	and	CCONJ
dpc-4503	69	21	aes	aes	PROPN
dpc-4503	69	22	leading	lead	VERB
dpc-4503	69	23	to	to	ADP
dpc-4503	69	24	discontinuation	discontinuation	NOUN
dpc-4503	69	25	.	.	PUNCT
dpc-4503	70	1	continuous	continuous	ADJ
dpc-4503	70	2	data	datum	NOUN
dpc-4503	70	3	are	be	AUX
dpc-4503	70	4	reported	report	VERB
dpc-4503	70	5	as	as	ADP
dpc-4503	70	6	mean	mean	ADJ
dpc-4503	70	7	and	and	CCONJ
dpc-4503	70	8	standard	standard	ADJ
dpc-4503	70	9	deviation	deviation	NOUN
dpc-4503	70	10	(	(	PUNCT
dpc-4503	70	11	sd	sd	NOUN
dpc-4503	70	12	)	)	PUNCT
dpc-4503	70	13	,	,	PUNCT
dpc-4503	70	14	while	while	SCONJ
dpc-4503	70	15	categorical	categorical	ADJ
dpc-4503	70	16	parameters	parameter	NOUN
dpc-4503	70	17	are	be	AUX
dpc-4503	70	18	reported	report	VERB
dpc-4503	70	19	as	as	ADP
dpc-4503	70	20	absolute	absolute	ADJ
dpc-4503	70	21	numbers	number	NOUN
dpc-4503	70	22	and	and	CCONJ
dpc-4503	70	23	percentages	percentage	NOUN
dpc-4503	70	24	.	.	PUNCT
dpc-4503	71	1	microsoft	microsoft	PROPN
dpc-4503	71	2	excel	excel	PROPN
dpc-4503	71	3	was	be	AUX
dpc-4503	71	4	used	use	VERB
dpc-4503	71	5	for	for	ADP
dpc-4503	71	6	analysis	analysis	NOUN
dpc-4503	71	7	and	and	CCONJ
dpc-4503	71	8	to	to	PART
dpc-4503	71	9	generate	generate	VERB
dpc-4503	71	10	tables	table	NOUN
dpc-4503	71	11	and	and	CCONJ
dpc-4503	71	12	figures	figure	NOUN
dpc-4503	71	13	.	.	PUNCT
dpc-4503	72	1	results	result	VERB
dpc-4503	72	2	this	this	DET
dpc-4503	72	3	real	real	ADJ
dpc-4503	72	4	-	-	PUNCT
dpc-4503	72	5	world	world	NOUN
dpc-4503	72	6	study	study	NOUN
dpc-4503	72	7	involved	involve	VERB
dpc-4503	72	8	41	41	NUM
dpc-4503	72	9	patients	patient	NOUN
dpc-4503	72	10	,	,	PUNCT
dpc-4503	72	11	all	all	PRON
dpc-4503	72	12	of	of	ADP
dpc-4503	72	13	whom	whom	PRON
dpc-4503	72	14	completed	complete	VERB
dpc-4503	72	15	at	at	ADP
dpc-4503	72	16	least	least	ADV
dpc-4503	72	17	16	16	NUM
dpc-4503	72	18	weeks	week	NOUN
dpc-4503	72	19	of	of	ADP
dpc-4503	72	20	treatment	treatment	NOUN
dpc-4503	72	21	,	,	PUNCT
dpc-4503	72	22	with	with	ADP
dpc-4503	72	23	17	17	NUM
dpc-4503	72	24	of	of	ADP
dpc-4503	72	25	them	they	PRON
dpc-4503	72	26	reaching	reach	VERB
dpc-4503	72	27	one	one	NUM
dpc-4503	72	28	year	year	NOUN
dpc-4503	72	29	of	of	ADP
dpc-4503	72	30	follow	follow	NOUN
dpc-4503	72	31	-	-	PUNCT
dpc-4503	72	32	up	up	NOUN
dpc-4503	72	33	.	.	PUNCT
dpc-4503	73	1	all	all	DET
dpc-4503	73	2	patients	patient	NOUN
dpc-4503	73	3	had	have	VERB
dpc-4503	73	4	concomitant	concomitant	ADJ
dpc-4503	73	5	moderate	moderate	ADJ
dpc-4503	73	6	-	-	PUNCT
dpc-4503	73	7	to	to	ADP
dpc-4503	73	8	-	-	PUNCT
dpc-4503	73	9	severe	severe	ADJ
dpc-4503	73	10	plaque	plaque	NOUN
dpc-4503	73	11	psoriasis	psoriasis	NOUN
dpc-4503	73	12	and	and	CCONJ
dpc-4503	73	13	previously	previously	ADV
dpc-4503	73	14	failed	fail	VERB
dpc-4503	73	15	systemic	systemic	ADJ
dpc-4503	73	16	therapy	therapy	NOUN
dpc-4503	73	17	or	or	CCONJ
dpc-4503	73	18	had	have	VERB
dpc-4503	73	19	a	a	DET
dpc-4503	73	20	contraindication	contraindication	NOUN
dpc-4503	73	21	to	to	ADP
dpc-4503	73	22	them	they	PRON
dpc-4503	73	23	.	.	PUNCT
dpc-4503	74	1	the	the	DET
dpc-4503	74	2	most	most	ADV
dpc-4503	74	3	commonly	commonly	ADV
dpc-4503	74	4	prescribed	prescribe	VERB
dpc-4503	74	5	anti	anti	ADJ
dpc-4503	74	6	-	-	ADJ
dpc-4503	74	7	il	il	ADJ
dpc-4503	74	8	agent	agent	NOUN
dpc-4503	74	9	was	be	AUX
dpc-4503	74	10	secukinumab	secukinumab	NOUN
dpc-4503	74	11	(	(	PUNCT
dpc-4503	74	12	27	27	NUM
dpc-4503	74	13	patients	patient	NOUN
dpc-4503	74	14	)	)	PUNCT
dpc-4503	74	15	,	,	PUNCT
dpc-4503	74	16	followed	follow	VERB
dpc-4503	74	17	by	by	ADP
dpc-4503	74	18	ixekizumab	ixekizumab	NOUN
dpc-4503	74	19	(	(	PUNCT
dpc-4503	74	20	5	5	NUM
dpc-4503	74	21	)	)	PUNCT
dpc-4503	74	22	,	,	PUNCT
dpc-4503	74	23	guselkumab	guselkumab	NOUN
dpc-4503	74	24	(	(	PUNCT
dpc-4503	74	25	5	5	NUM
dpc-4503	74	26	)	)	PUNCT
dpc-4503	74	27	,	,	PUNCT
dpc-4503	74	28	bimekizumab	bimekizumab	X
dpc-4503	74	29	(	(	PUNCT
dpc-4503	74	30	2	2	NUM
dpc-4503	74	31	)	)	PUNCT
dpc-4503	74	32	,	,	PUNCT
dpc-4503	74	33	brodalumab	brodalumab	NOUN
dpc-4503	74	34	(	(	PUNCT
dpc-4503	74	35	1	1	NUM
dpc-4503	74	36	)	)	PUNCT
dpc-4503	74	37	,	,	PUNCT
dpc-4503	74	38	and	and	CCONJ
dpc-4503	74	39	risankizumab	risankizumab	NOUN
dpc-4503	74	40	(	(	PUNCT
dpc-4503	74	41	1	1	NUM
dpc-4503	74	42	)	)	PUNCT
dpc-4503	74	43	.	.	PUNCT
dpc-4503	75	1	twenty	twenty	NUM
dpc-4503	75	2	-	-	PUNCT
dpc-4503	75	3	eight	eight	NUM
dpc-4503	75	4	patients	patient	NOUN
dpc-4503	75	5	were	be	AUX
dpc-4503	75	6	female	female	ADJ
dpc-4503	75	7	(	(	PUNCT
dpc-4503	75	8	68.3	68.3	NUM
dpc-4503	75	9	%	%	NOUN
dpc-4503	75	10	)	)	PUNCT
dpc-4503	75	11	,	,	PUNCT
dpc-4503	75	12	with	with	ADP
dpc-4503	75	13	a	a	DET
dpc-4503	75	14	mean	mean	ADJ
dpc-4503	75	15	age	age	NOUN
dpc-4503	75	16	of	of	ADP
dpc-4503	75	17	40.59	40.59	NUM
dpc-4503	75	18	years	year	NOUN
dpc-4503	75	19	(	(	PUNCT
dpc-4503	75	20	sd	sd	ADP
dpc-4503	75	21	15	15	NUM
dpc-4503	75	22	)	)	PUNCT
dpc-4503	75	23	.	.	PUNCT
dpc-4503	76	1	thirteen	thirteen	NUM
dpc-4503	76	2	patients	patient	NOUN
dpc-4503	76	3	(	(	PUNCT
dpc-4503	76	4	31.7	31.7	NUM
dpc-4503	76	5	%	%	NOUN
dpc-4503	76	6	)	)	PUNCT
dpc-4503	76	7	were	be	AUX
dpc-4503	76	8	obese	obese	ADJ
dpc-4503	76	9	,	,	PUNCT
dpc-4503	76	10	with	with	ADP
dpc-4503	76	11	a	a	DET
dpc-4503	76	12	mean	mean	ADJ
dpc-4503	76	13	bmi	bmi	NOUN
dpc-4503	76	14	of	of	ADP
dpc-4503	76	15	27.94	27.94	NUM
dpc-4503	76	16	(	(	PUNCT
dpc-4503	76	17	sd	sd	ADP
dpc-4503	76	18	4.65	4.65	NUM
dpc-4503	76	19	)	)	PUNCT
dpc-4503	76	20	.	.	PUNCT
dpc-4503	77	1	twenty	twenty	NUM
dpc-4503	77	2	-	-	PUNCT
dpc-4503	77	3	three	three	NUM
dpc-4503	77	4	patients	patient	NOUN
dpc-4503	77	5	(	(	PUNCT
dpc-4503	77	6	56.1	56.1	NUM
dpc-4503	77	7	%	%	NOUN
dpc-4503	77	8	)	)	PUNCT
dpc-4503	77	9	referred	refer	VERB
dpc-4503	77	10	a	a	DET
dpc-4503	77	11	medical	medical	ADJ
dpc-4503	77	12	history	history	NOUN
dpc-4503	77	13	of	of	ADP
dpc-4503	77	14	concomitant	concomitant	ADJ
dpc-4503	77	15	cardiometabolic	cardiometabolic	NOUN
dpc-4503	77	16	comorbidities	comorbiditie	NOUN
dpc-4503	77	17	(	(	PUNCT
dpc-4503	77	18	including	include	VERB
dpc-4503	77	19	arterial	arterial	ADJ
dpc-4503	77	20	hypertension	hypertension	NOUN
dpc-4503	77	21	,	,	PUNCT
dpc-4503	77	22	type	type	NOUN
dpc-4503	77	23	2	2	NUM
dpc-4503	77	24	diabetes	diabetes	NOUN
dpc-4503	77	25	mellitus	mellitus	NOUN
dpc-4503	77	26	,	,	PUNCT
dpc-4503	77	27	cardiovascular	cardiovascular	ADJ
dpc-4503	77	28	disease	disease	NOUN
dpc-4503	77	29	,	,	PUNCT
dpc-4503	77	30	hypercholesterolemia	hypercholesterolemia	NOUN
dpc-4503	77	31	,	,	PUNCT
dpc-4503	77	32	and	and	CCONJ
dpc-4503	77	33	obesity	obesity	NOUN
dpc-4503	77	34	)	)	PUNCT
dpc-4503	77	35	.	.	PUNCT
dpc-4503	78	1	slightly	slightly	ADV
dpc-4503	78	2	more	more	ADJ
dpc-4503	78	3	than	than	ADP
dpc-4503	78	4	half	half	NOUN
dpc-4503	78	5	of	of	ADP
dpc-4503	78	6	our	our	PRON
dpc-4503	78	7	patients	patient	NOUN
dpc-4503	78	8	were	be	AUX
dpc-4503	78	9	smokers	smoker	NOUN
dpc-4503	78	10	(	(	PUNCT
dpc-4503	78	11	56.1	56.1	NUM
dpc-4503	78	12	%	%	NOUN
dpc-4503	78	13	)	)	PUNCT
dpc-4503	78	14	.	.	PUNCT
dpc-4503	79	1	almost	almost	ADV
dpc-4503	79	2	all	all	DET
dpc-4503	79	3	patients	patient	NOUN
dpc-4503	79	4	(	(	PUNCT
dpc-4503	79	5	85.4	85.4	NUM
dpc-4503	79	6	%	%	NOUN
dpc-4503	79	7	)	)	PUNCT
dpc-4503	79	8	had	have	AUX
dpc-4503	79	9	previously	previously	ADV
dpc-4503	79	10	failed	fail	VERB
dpc-4503	79	11	adalimumab	adalimumab	NOUN
dpc-4503	79	12	.	.	PUNCT
dpc-4503	80	1	before	before	ADP
dpc-4503	80	2	starting	start	VERB
dpc-4503	80	3	treatment	treatment	NOUN
dpc-4503	80	4	with	with	ADP
dpc-4503	80	5	anti	anti	ADJ
dpc-4503	80	6	-	-	ADJ
dpc-4503	80	7	il-17/23	il-17/23	ADJ
dpc-4503	80	8	drugs	drug	NOUN
dpc-4503	80	9	,	,	PUNCT
dpc-4503	80	10	17	17	NUM
dpc-4503	80	11	patients	patient	NOUN
dpc-4503	80	12	(	(	PUNCT
dpc-4503	80	13	41.5	41.5	NUM
dpc-4503	80	14	%	%	NOUN
dpc-4503	80	15	)	)	PUNCT
dpc-4503	80	16	had	have	VERB
dpc-4503	80	17	a	a	DET
dpc-4503	80	18	hurley	hurley	NOUN
dpc-4503	80	19	score	score	NOUN
dpc-4503	80	20	of	of	ADP
dpc-4503	80	21	ii	ii	PROPN
dpc-4503	80	22	(	(	PUNCT
dpc-4503	80	23	moderate	moderate	PROPN
dpc-4503	80	24	hs	hs	PROPN
dpc-4503	80	25	)	)	PUNCT
dpc-4503	80	26	,	,	PUNCT
dpc-4503	80	27	while	while	SCONJ
dpc-4503	80	28	24	24	NUM
dpc-4503	80	29	(	(	PUNCT
dpc-4503	80	30	58.5	58.5	NUM
dpc-4503	80	31	%	%	NOUN
dpc-4503	80	32	)	)	PUNCT
dpc-4503	80	33	had	have	VERB
dpc-4503	80	34	hurley	hurley	PROPN
dpc-4503	80	35	score	score	PROPN
dpc-4503	80	36	iii	iii	PROPN
dpc-4503	80	37	(	(	PUNCT
dpc-4503	80	38	severe	severe	ADJ
dpc-4503	80	39	hs	h	NOUN
dpc-4503	80	40	)	)	PUNCT
dpc-4503	80	41	.	.	PUNCT
dpc-4503	81	1	complete	complete	ADJ
dpc-4503	81	2	baseline	baseline	PROPN
dpc-4503	81	3	demographic	demographic	ADJ
dpc-4503	81	4	and	and	CCONJ
dpc-4503	81	5	clinical	clinical	ADJ
dpc-4503	81	6	characteristics	characteristic	NOUN
dpc-4503	81	7	of	of	ADP
dpc-4503	81	8	our	our	PRON
dpc-4503	81	9	population	population	NOUN
dpc-4503	81	10	are	be	AUX
dpc-4503	81	11	shown	show	VERB
dpc-4503	81	12	in	in	ADP
dpc-4503	81	13	table	table	NOUN
dpc-4503	81	14	1	1	NUM
dpc-4503	81	15	.	.	PUNCT
dpc-4503	82	1	the	the	DET
dpc-4503	82	2	mean	mean	ADJ
dpc-4503	82	3	ihs4	ihs4	PROPN
dpc-4503	82	4	at	at	ADP
dpc-4503	82	5	baseline	baseline	PROPN
dpc-4503	82	6	was	be	AUX
dpc-4503	82	7	29.49	29.49	NUM
dpc-4503	82	8	(	(	PUNCT
dpc-4503	82	9	sd	sd	ADP
dpc-4503	82	10	21.93	21.93	NUM
dpc-4503	82	11	)	)	PUNCT
dpc-4503	82	12	,	,	PUNCT
dpc-4503	82	13	which	which	PRON
dpc-4503	82	14	decreased	decrease	VERB
dpc-4503	82	15	to	to	ADP
dpc-4503	82	16	21.39	21.39	NUM
dpc-4503	82	17	(	(	PUNCT
dpc-4503	82	18	17.64	17.64	NUM
dpc-4503	82	19	)	)	PUNCT
dpc-4503	82	20	after	after	ADP
dpc-4503	82	21	16	16	NUM
dpc-4503	82	22	weeks	week	NOUN
dpc-4503	82	23	,	,	PUNCT
dpc-4503	82	24	to	to	ADP
dpc-4503	82	25	15.29	15.29	NUM
dpc-4503	82	26	(	(	PUNCT
dpc-4503	82	27	11.65	11.65	NUM
dpc-4503	82	28	)	)	PUNCT
dpc-4503	82	29	after	after	ADP
dpc-4503	82	30	32	32	NUM
dpc-4503	82	31	weeks	week	NOUN
dpc-4503	82	32	,	,	PUNCT
dpc-4503	82	33	and	and	CCONJ
dpc-4503	82	34	to	to	ADP
dpc-4503	82	35	10.83	10.83	NUM
dpc-4503	82	36	(	(	PUNCT
dpc-4503	82	37	9.91	9.91	NUM
dpc-4503	82	38	)	)	PUNCT
dpc-4503	82	39	after	after	ADP
dpc-4503	82	40	one	one	NUM
dpc-4503	82	41	year	year	NOUN
dpc-4503	82	42	of	of	ADP
dpc-4503	82	43	treatment	treatment	NOUN
dpc-4503	82	44	(	(	PUNCT
dpc-4503	82	45	figure	figure	NOUN
dpc-4503	82	46	1a	1a	NOUN
dpc-4503	82	47	)	)	PUNCT
dpc-4503	82	48	.	.	PUNCT
dpc-4503	83	1	our	our	PRON
dpc-4503	83	2	cohort	cohort	NOUN
dpc-4503	83	3	of	of	ADP
dpc-4503	83	4	patients	patient	NOUN
dpc-4503	83	5	also	also	ADV
dpc-4503	83	6	showed	show	VERB
dpc-4503	83	7	a	a	DET
dpc-4503	83	8	significant	significant	ADJ
dpc-4503	83	9	impact	impact	NOUN
dpc-4503	83	10	on	on	ADP
dpc-4503	83	11	quality	quality	NOUN
dpc-4503	83	12	of	of	ADP
dpc-4503	83	13	life	life	NOUN
dpc-4503	83	14	,	,	PUNCT
dpc-4503	83	15	as	as	SCONJ
dpc-4503	83	16	evidenced	evidence	VERB
dpc-4503	83	17	by	by	ADP
dpc-4503	83	18	a	a	DET
dpc-4503	83	19	mean	mean	ADJ
dpc-4503	83	20	dlqi	dlqi	NOUN
dpc-4503	83	21	of	of	ADP
dpc-4503	83	22	20.88	20.88	NUM
dpc-4503	83	23	(	(	PUNCT
dpc-4503	83	24	sd	sd	NOUN
dpc-4503	83	25	7.08	7.08	NUM
dpc-4503	83	26	)	)	PUNCT
dpc-4503	83	27	at	at	ADP
dpc-4503	83	28	baseline	baseline	NOUN
dpc-4503	83	29	,	,	PUNCT
dpc-4503	83	30	which	which	PRON
dpc-4503	83	31	decreased	decrease	VERB
dpc-4503	83	32	consistently	consistently	ADV
dpc-4503	83	33	throughout	throughout	ADP
dpc-4503	83	34	the	the	DET
dpc-4503	83	35	study	study	NOUN
dpc-4503	83	36	period	period	NOUN
dpc-4503	83	37	(	(	PUNCT
dpc-4503	83	38	figure	figure	NOUN
dpc-4503	83	39	1b	1b	NUM
dpc-4503	83	40	)	)	PUNCT
dpc-4503	83	41	.	.	PUNCT
dpc-4503	84	1	the	the	DET
dpc-4503	84	2	mean	mean	ADJ
dpc-4503	84	3	dlqi	dlqi	NOUN
dpc-4503	84	4	(	(	PUNCT
dpc-4503	84	5	sd	sd	NOUN
dpc-4503	84	6	)	)	PUNCT
dpc-4503	84	7	at	at	ADP
dpc-4503	84	8	weeks	week	NOUN
dpc-4503	84	9	16	16	NUM
dpc-4503	84	10	,	,	PUNCT
dpc-4503	84	11	32	32	NUM
dpc-4503	84	12	,	,	PUNCT
dpc-4503	84	13	and	and	CCONJ
dpc-4503	84	14	52	52	NUM
dpc-4503	84	15	was	be	AUX
dpc-4503	84	16	15.05	15.05	NUM
dpc-4503	84	17	(	(	PUNCT
dpc-4503	84	18	6.45	6.45	NUM
dpc-4503	84	19	)	)	PUNCT
dpc-4503	84	20	,	,	PUNCT
dpc-4503	84	21	10.8	10.8	NUM
dpc-4503	84	22	(	(	PUNCT
dpc-4503	84	23	6.78	6.78	NUM
dpc-4503	84	24	)	)	PUNCT
dpc-4503	84	25	,	,	PUNCT
dpc-4503	84	26	and	and	CCONJ
dpc-4503	84	27	7	7	NUM
dpc-4503	84	28	(	(	PUNCT
dpc-4503	84	29	5.71	5.71	NUM
dpc-4503	84	30	)	)	PUNCT
dpc-4503	84	31	,	,	PUNCT
dpc-4503	84	32	respectively	respectively	ADV
dpc-4503	84	33	.	.	PUNCT
dpc-4503	85	1	the	the	DET
dpc-4503	85	2	hiscr	hiscr	NOUN
dpc-4503	85	3	was	be	AUX
dpc-4503	85	4	achieved	achieve	VERB
dpc-4503	85	5	by	by	ADP
dpc-4503	85	6	39	39	NUM
dpc-4503	85	7	%	%	NOUN
dpc-4503	85	8	,	,	PUNCT
dpc-4503	85	9	74.3	74.3	NUM
dpc-4503	85	10	%	%	NOUN
dpc-4503	85	11	,	,	PUNCT
dpc-4503	85	12	and	and	CCONJ
dpc-4503	85	13	77.8	77.8	NUM
dpc-4503	85	14	%	%	NOUN
dpc-4503	85	15	of	of	ADP
dpc-4503	85	16	patients	patient	NOUN
dpc-4503	85	17	after	after	ADP
dpc-4503	85	18	16	16	NUM
dpc-4503	85	19	,	,	PUNCT
dpc-4503	85	20	32	32	NUM
dpc-4503	85	21	,	,	PUNCT
dpc-4503	85	22	and	and	CCONJ
dpc-4503	85	23	52	52	NUM
dpc-4503	85	24	weeks	week	NOUN
dpc-4503	85	25	,	,	PUNCT
dpc-4503	85	26	respectively	respectively	ADV
dpc-4503	85	27	(	(	PUNCT
dpc-4503	85	28	figure	figure	NOUN
dpc-4503	85	29	2a	2a	NUM
dpc-4503	85	30	)	)	PUNCT
dpc-4503	85	31	.	.	PUNCT
dpc-4503	86	1	a	a	DET
dpc-4503	86	2	reduction	reduction	NOUN
dpc-4503	86	3	of	of	ADP
dpc-4503	86	4	at	at	ADV
dpc-4503	86	5	least	least	ADV
dpc-4503	86	6	55	55	NUM
dpc-4503	86	7	%	%	NOUN
dpc-4503	86	8	in	in	ADP
dpc-4503	86	9	ihs4	ihs4	PROPN
dpc-4503	86	10	from	from	ADP
dpc-4503	86	11	baseline	baseline	PROPN
dpc-4503	86	12	(	(	PUNCT
dpc-4503	86	13	ihs4	ihs4	PROPN
dpc-4503	86	14	-	-	PUNCT
dpc-4503	86	15	55	55	NUM
dpc-4503	86	16	)	)	PUNCT
dpc-4503	86	17	was	be	AUX
dpc-4503	86	18	observed	observe	VERB
dpc-4503	86	19	in	in	ADP
dpc-4503	86	20	14.6	14.6	NUM
dpc-4503	86	21	%	%	NOUN
dpc-4503	86	22	,	,	PUNCT
dpc-4503	86	23	45.7	45.7	NUM
dpc-4503	86	24	%	%	NOUN
dpc-4503	86	25	,	,	PUNCT
dpc-4503	86	26	and	and	CCONJ
dpc-4503	86	27	88.9	88.9	NUM
dpc-4503	86	28	%	%	NOUN
dpc-4503	86	29	of	of	ADP
dpc-4503	86	30	patients	patient	NOUN
dpc-4503	86	31	at	at	ADP
dpc-4503	86	32	weeks	week	NOUN
dpc-4503	86	33	16	16	NUM
dpc-4503	86	34	,	,	PUNCT
dpc-4503	86	35	32	32	NUM
dpc-4503	86	36	,	,	PUNCT
dpc-4503	86	37	and	and	CCONJ
dpc-4503	86	38	52	52	NUM
dpc-4503	86	39	,	,	PUNCT
dpc-4503	86	40	respectively	respectively	ADV
dpc-4503	86	41	(	(	PUNCT
dpc-4503	86	42	figure	figure	NOUN
dpc-4503	86	43	2b	2b	NOUN
dpc-4503	86	44	)	)	PUNCT
dpc-4503	86	45	.	.	PUNCT
dpc-4503	87	1	regarding	regard	VERB
dpc-4503	87	2	the	the	DET
dpc-4503	87	3	tolerability	tolerability	NOUN
dpc-4503	87	4	of	of	ADP
dpc-4503	87	5	these	these	DET
dpc-4503	87	6	molecules	molecule	NOUN
dpc-4503	87	7	,	,	PUNCT
dpc-4503	87	8	no	no	DET
dpc-4503	87	9	new	new	ADJ
dpc-4503	87	10	safety	safety	NOUN
dpc-4503	87	11	findings	finding	NOUN
dpc-4503	87	12	emerged	emerge	VERB
dpc-4503	87	13	during	during	ADP
dpc-4503	87	14	the	the	DET
dpc-4503	87	15	study	study	NOUN
dpc-4503	87	16	.	.	PUNCT
dpc-4503	88	1	ten	ten	NUM
dpc-4503	88	2	patients	patient	NOUN
dpc-4503	88	3	experienced	experience	VERB
dpc-4503	88	4	at	at	ADV
dpc-4503	88	5	least	least	ADV
dpc-4503	88	6	one	one	NUM
dpc-4503	88	7	ae	ae	PROPN
dpc-4503	88	8	(	(	PUNCT
dpc-4503	88	9	24.4	24.4	NUM
dpc-4503	88	10	%	%	NOUN
dpc-4503	88	11	)	)	PUNCT
dpc-4503	88	12	.	.	PUNCT
dpc-4503	89	1	the	the	DET
dpc-4503	89	2	most	most	ADV
dpc-4503	89	3	common	common	ADJ
dpc-4503	89	4	aes	aes	PROPN
dpc-4503	89	5	were	be	AUX
dpc-4503	89	6	nasopharyngitis	nasopharyngitis	ADJ
dpc-4503	89	7	(	(	PUNCT
dpc-4503	89	8	four	four	NUM
dpc-4503	89	9	patients	patient	NOUN
dpc-4503	89	10	)	)	PUNCT
dpc-4503	89	11	and	and	CCONJ
dpc-4503	89	12	injection	injection	NOUN
dpc-4503	89	13	-	-	PUNCT
dpc-4503	89	14	site	site	NOUN
dpc-4503	89	15	reactions	reaction	NOUN
dpc-4503	89	16	(	(	PUNCT
dpc-4503	89	17	three	three	NUM
dpc-4503	89	18	patients	patient	NOUN
dpc-4503	89	19	)	)	PUNCT
dpc-4503	89	20	.	.	PUNCT
dpc-4503	90	1	no	no	DET
dpc-4503	90	2	severe	severe	ADJ
dpc-4503	90	3	aes	aes	PROPN
dpc-4503	90	4	or	or	CCONJ
dpc-4503	90	5	aes	aes	PROPN
dpc-4503	90	6	leading	lead	VERB
dpc-4503	90	7	to	to	ADP
dpc-4503	90	8	discontinuation	discontinuation	NOUN
dpc-4503	90	9	were	be	AUX
dpc-4503	90	10	reported	report	VERB
dpc-4503	90	11	.	.	PUNCT
dpc-4503	91	1	4	4	NUM
dpc-4503	91	2	original	original	ADJ
dpc-4503	91	3	article	article	NOUN
dpc-4503	91	4	|	|	ADV
dpc-4503	91	5	dermatol	dermatol	ADJ
dpc-4503	91	6	pract	pract	NOUN
dpc-4503	91	7	concept	concept	NOUN
dpc-4503	91	8	.	.	PUNCT
dpc-4503	92	1	2024;14(4):e2024250	2024;14(4):e2024250	NUM
dpc-4503	92	2	anti	anti	ADJ
dpc-4503	92	3	-	-	ADJ
dpc-4503	92	4	il17a	il17a	ADJ
dpc-4503	92	5	inhibitor	inhibitor	NOUN
dpc-4503	92	6	for	for	ADP
dpc-4503	92	7	moderate	moderate	ADJ
dpc-4503	92	8	-	-	PUNCT
dpc-4503	92	9	to	to	ADP
dpc-4503	92	10	-	-	PUNCT
dpc-4503	92	11	severe	severe	ADJ
dpc-4503	92	12	hidradenitis	hidradenitis	NOUN
dpc-4503	92	13	suppurativa	suppurativa	NOUN
dpc-4503	92	14	[	[	X
dpc-4503	92	15	22	22	NUM
dpc-4503	92	16	]	]	PUNCT
dpc-4503	92	17	.	.	PUNCT
dpc-4503	93	1	data	datum	NOUN
dpc-4503	93	2	for	for	ADP
dpc-4503	93	3	ixekizumab	ixekizumab	NOUN
dpc-4503	93	4	in	in	ADP
dpc-4503	93	5	hs	hs	PROPN
dpc-4503	93	6	are	be	AUX
dpc-4503	93	7	limited	limit	VERB
dpc-4503	93	8	to	to	ADP
dpc-4503	93	9	a	a	DET
dpc-4503	93	10	case	case	NOUN
dpc-4503	93	11	series	series	NOUN
dpc-4503	93	12	and	and	CCONJ
dpc-4503	93	13	a	a	DET
dpc-4503	93	14	few	few	ADJ
dpc-4503	93	15	case	case	NOUN
dpc-4503	93	16	reports	report	VERB
dpc-4503	93	17	.	.	PUNCT
dpc-4503	94	1	esme	esme	PROPN
dpc-4503	94	2	et	et	PROPN
dpc-4503	94	3	al	al	PROPN
dpc-4503	94	4	.	.	PUNCT
dpc-4503	95	1	[	[	X
dpc-4503	95	2	23	23	NUM
dpc-4503	95	3	]	]	PUNCT
dpc-4503	95	4	described	describe	VERB
dpc-4503	95	5	a	a	DET
dpc-4503	95	6	case	case	NOUN
dpc-4503	95	7	series	series	NOUN
dpc-4503	95	8	of	of	ADP
dpc-4503	95	9	five	five	NUM
dpc-4503	95	10	patients	patient	NOUN
dpc-4503	95	11	treated	treat	VERB
dpc-4503	95	12	with	with	ADP
dpc-4503	95	13	ixekizumab	ixekizumab	NOUN
dpc-4503	95	14	after	after	ADP
dpc-4503	95	15	failing	fail	VERB
dpc-4503	95	16	adalimumab	adalimumab	NOUN
dpc-4503	95	17	.	.	PUNCT
dpc-4503	96	1	in	in	ADP
dpc-4503	96	2	this	this	DET
dpc-4503	96	3	study	study	NOUN
dpc-4503	96	4	,	,	PUNCT
dpc-4503	96	5	four	four	NUM
dpc-4503	96	6	out	out	ADP
dpc-4503	96	7	of	of	ADP
dpc-4503	96	8	five	five	NUM
dpc-4503	96	9	patients	patient	NOUN
dpc-4503	96	10	achieved	achieve	VERB
dpc-4503	96	11	hiscr	hiscr	NOUN
dpc-4503	96	12	at	at	ADP
dpc-4503	96	13	week	week	NOUN
dpc-4503	96	14	12	12	NUM
dpc-4503	96	15	after	after	ADP
dpc-4503	96	16	being	be	AUX
dpc-4503	96	17	treated	treat	VERB
dpc-4503	96	18	with	with	ADP
dpc-4503	96	19	ixekizumab	ixekizumab	NOUN
dpc-4503	96	20	according	accord	VERB
dpc-4503	96	21	to	to	ADP
dpc-4503	96	22	the	the	DET
dpc-4503	96	23	same	same	ADJ
dpc-4503	96	24	posology	posology	NOUN
dpc-4503	96	25	for	for	ADP
dpc-4503	96	26	the	the	DET
dpc-4503	96	27	treatment	treatment	NOUN
dpc-4503	96	28	of	of	ADP
dpc-4503	96	29	moderate	moderate	ADJ
dpc-4503	96	30	-	-	PUNCT
dpc-4503	96	31	to	to	ADP
dpc-4503	96	32	-	-	PUNCT
dpc-4503	96	33	severe	severe	ADJ
dpc-4503	96	34	plaque	plaque	NOUN
dpc-4503	96	35	psoriasis	psoriasis	NOUN
dpc-4503	96	36	[	[	X
dpc-4503	96	37	23	23	NUM
dpc-4503	96	38	]	]	PUNCT
dpc-4503	96	39	.	.	PUNCT
dpc-4503	97	1	regarding	regard	VERB
dpc-4503	97	2	brodalumab	brodalumab	NOUN
dpc-4503	97	3	,	,	PUNCT
dpc-4503	97	4	data	datum	NOUN
dpc-4503	97	5	on	on	ADP
dpc-4503	97	6	its	its	PRON
dpc-4503	97	7	use	use	NOUN
dpc-4503	97	8	in	in	ADP
dpc-4503	97	9	patients	patient	NOUN
dpc-4503	97	10	with	with	ADP
dpc-4503	97	11	hs	hs	PROPN
dpc-4503	97	12	are	be	AUX
dpc-4503	97	13	extremely	extremely	ADV
dpc-4503	97	14	limited	limited	ADJ
dpc-4503	97	15	.	.	PUNCT
dpc-4503	98	1	a	a	DET
dpc-4503	98	2	recent	recent	ADJ
dpc-4503	98	3	case	case	NOUN
dpc-4503	98	4	series	series	NOUN
dpc-4503	98	5	reported	report	VERB
dpc-4503	98	6	a	a	DET
dpc-4503	98	7	slight	slight	ADJ
dpc-4503	98	8	improvement	improvement	NOUN
dpc-4503	98	9	in	in	ADP
dpc-4503	98	10	patient	patient	NOUN
dpc-4503	98	11	-	-	PUNCT
dpc-4503	98	12	reported	report	VERB
dpc-4503	98	13	outcomes	outcome	NOUN
dpc-4503	98	14	after	after	ADP
dpc-4503	98	15	16	16	NUM
dpc-4503	98	16	weeks	week	NOUN
dpc-4503	98	17	of	of	ADP
dpc-4503	98	18	treatment	treatment	NOUN
dpc-4503	98	19	[	[	X
dpc-4503	98	20	24	24	NUM
dpc-4503	98	21	]	]	PUNCT
dpc-4503	98	22	.	.	PUNCT
dpc-4503	99	1	discussion	discussion	NOUN
dpc-4503	99	2	our	our	PRON
dpc-4503	99	3	findings	finding	NOUN
dpc-4503	99	4	suggest	suggest	VERB
dpc-4503	99	5	that	that	SCONJ
dpc-4503	99	6	anti	anti	ADJ
dpc-4503	99	7	-	-	ADJ
dpc-4503	99	8	il-23	il-23	ADJ
dpc-4503	99	9	and	and	CCONJ
dpc-4503	99	10	anti	anti	ADJ
dpc-4503	99	11	-	-	ADJ
dpc-4503	99	12	il-17	il-17	ADV
dpc-4503	99	13	drugs	drug	NOUN
dpc-4503	99	14	approved	approve	VERB
dpc-4503	99	15	for	for	ADP
dpc-4503	99	16	moderate	moderate	ADJ
dpc-4503	99	17	-	-	PUNCT
dpc-4503	99	18	to	to	ADP
dpc-4503	99	19	-	-	PUNCT
dpc-4503	99	20	severe	severe	ADJ
dpc-4503	99	21	plaque	plaque	NOUN
dpc-4503	99	22	psoriasis	psoriasis	NOUN
dpc-4503	99	23	could	could	AUX
dpc-4503	99	24	represent	represent	VERB
dpc-4503	99	25	viable	viable	ADJ
dpc-4503	99	26	options	option	NOUN
dpc-4503	99	27	also	also	ADV
dpc-4503	99	28	for	for	ADP
dpc-4503	99	29	treating	treat	VERB
dpc-4503	99	30	hs	hs	PROPN
dpc-4503	99	31	.	.	PROPN
dpc-4503	99	32	il-17	il-17	PART
dpc-4503	99	33	inhibitors	inhibitor	NOUN
dpc-4503	99	34	have	have	AUX
dpc-4503	99	35	been	be	AUX
dpc-4503	99	36	used	use	VERB
dpc-4503	99	37	for	for	ADP
dpc-4503	99	38	the	the	DET
dpc-4503	99	39	treatment	treatment	NOUN
dpc-4503	99	40	of	of	ADP
dpc-4503	99	41	hs	hs	PROPN
dpc-4503	99	42	in	in	ADP
dpc-4503	99	43	both	both	CCONJ
dpc-4503	99	44	clinical	clinical	ADJ
dpc-4503	99	45	trials	trial	NOUN
dpc-4503	99	46	and	and	CCONJ
dpc-4503	99	47	real	real	ADJ
dpc-4503	99	48	-	-	PUNCT
dpc-4503	99	49	life	life	NOUN
dpc-4503	99	50	experiences	experience	NOUN
dpc-4503	99	51	.	.	PUNCT
dpc-4503	100	1	il-17a	il-17a	PROPN
dpc-4503	100	2	,	,	PUNCT
dpc-4503	100	3	produced	produce	VERB
dpc-4503	100	4	by	by	ADP
dpc-4503	100	5	neutrophils	neutrophil	NOUN
dpc-4503	100	6	,	,	PUNCT
dpc-4503	100	7	mast	mast	NOUN
dpc-4503	100	8	cells	cell	NOUN
dpc-4503	100	9	,	,	PUNCT
dpc-4503	100	10	and	and	CCONJ
dpc-4503	100	11	t	t	PROPN
dpc-4503	100	12	-	-	PUNCT
dpc-4503	100	13	helper	helper	NOUN
dpc-4503	100	14	17	17	NUM
dpc-4503	100	15	cells	cell	NOUN
dpc-4503	100	16	,	,	PUNCT
dpc-4503	100	17	plays	play	VERB
dpc-4503	100	18	a	a	DET
dpc-4503	100	19	critical	critical	ADJ
dpc-4503	100	20	role	role	NOUN
dpc-4503	100	21	by	by	ADP
dpc-4503	100	22	amplifying	amplify	VERB
dpc-4503	100	23	inflammation	inflammation	NOUN
dpc-4503	100	24	and	and	CCONJ
dpc-4503	100	25	promoting	promote	VERB
dpc-4503	100	26	a	a	DET
dpc-4503	100	27	cycle	cycle	NOUN
dpc-4503	100	28	of	of	ADP
dpc-4503	100	29	keratinocyte	keratinocyte	NOUN
dpc-4503	100	30	activation	activation	NOUN
dpc-4503	100	31	and	and	CCONJ
dpc-4503	100	32	hyperkeratosis	hyperkeratosis	NOUN
dpc-4503	100	33	that	that	PRON
dpc-4503	100	34	drives	drive	VERB
dpc-4503	100	35	hs	hs	PROPN
dpc-4503	100	36	progression	progression	NOUN
dpc-4503	100	37	[	[	X
dpc-4503	100	38	19	19	NUM
dpc-4503	100	39	]	]	PUNCT
dpc-4503	100	40	.	.	PUNCT
dpc-4503	101	1	regarding	regard	VERB
dpc-4503	101	2	secukinumab	secukinumab	NOUN
dpc-4503	101	3	,	,	PUNCT
dpc-4503	101	4	in	in	ADP
dpc-4503	101	5	the	the	DET
dpc-4503	101	6	phase	phase	NOUN
dpc-4503	101	7	3	3	NUM
dpc-4503	101	8	sunshine	sunshine	NOUN
dpc-4503	101	9	and	and	CCONJ
dpc-4503	101	10	sunrise	sunrise	VERB
dpc-4503	101	11	trials	trial	NOUN
dpc-4503	101	12	,	,	PUNCT
dpc-4503	101	13	the	the	DET
dpc-4503	101	14	primary	primary	ADJ
dpc-4503	101	15	endpoint	endpoint	NOUN
dpc-4503	101	16	of	of	ADP
dpc-4503	101	17	hiscr	hiscr	NOUN
dpc-4503	101	18	at	at	ADP
dpc-4503	101	19	week	week	NOUN
dpc-4503	101	20	16	16	NUM
dpc-4503	101	21	was	be	AUX
dpc-4503	101	22	met	meet	VERB
dpc-4503	101	23	by	by	ADP
dpc-4503	101	24	secukinumab	secukinumab	NOUN
dpc-4503	101	25	every	every	DET
dpc-4503	101	26	two	two	NUM
dpc-4503	101	27	weeks	week	NOUN
dpc-4503	101	28	in	in	ADP
dpc-4503	101	29	both	both	DET
dpc-4503	101	30	trials	trial	NOUN
dpc-4503	101	31	,	,	PUNCT
dpc-4503	101	32	while	while	SCONJ
dpc-4503	101	33	secukinumab	secukinumab	NOUN
dpc-4503	101	34	every	every	DET
dpc-4503	101	35	four	four	NUM
dpc-4503	101	36	weeks	week	NOUN
dpc-4503	101	37	reached	reach	VERB
dpc-4503	101	38	the	the	DET
dpc-4503	101	39	primary	primary	ADJ
dpc-4503	101	40	endpoint	endpoint	NOUN
dpc-4503	101	41	only	only	ADV
dpc-4503	101	42	in	in	ADP
dpc-4503	101	43	the	the	DET
dpc-4503	101	44	sunrise	sunrise	NOUN
dpc-4503	101	45	trial	trial	NOUN
dpc-4503	101	46	[	[	X
dpc-4503	101	47	8	8	NUM
dpc-4503	101	48	]	]	PUNCT
dpc-4503	101	49	.	.	PUNCT
dpc-4503	102	1	in	in	ADP
dpc-4503	102	2	both	both	DET
dpc-4503	102	3	trials	trial	NOUN
dpc-4503	102	4	,	,	PUNCT
dpc-4503	102	5	the	the	DET
dpc-4503	102	6	hiscr	hiscr	NOUN
dpc-4503	102	7	was	be	AUX
dpc-4503	102	8	maintained	maintain	VERB
dpc-4503	102	9	throughout	throughout	ADP
dpc-4503	102	10	52	52	NUM
dpc-4503	102	11	weeks	week	NOUN
dpc-4503	102	12	of	of	ADP
dpc-4503	102	13	follow	follow	VERB
dpc-4503	102	14	-	-	PUNCT
dpc-4503	102	15	up	up	NOUN
dpc-4503	102	16	[	[	X
dpc-4503	102	17	8	8	NUM
dpc-4503	102	18	]	]	PUNCT
dpc-4503	102	19	.	.	PUNCT
dpc-4503	103	1	in	in	ADP
dpc-4503	103	2	a	a	DET
dpc-4503	103	3	multicenter	multicenter	ADJ
dpc-4503	103	4	real	real	ADJ
dpc-4503	103	5	-	-	PUNCT
dpc-4503	103	6	world	world	NOUN
dpc-4503	103	7	study	study	NOUN
dpc-4503	103	8	,	,	PUNCT
dpc-4503	103	9	hiscr	hiscr	PROPN
dpc-4503	103	10	was	be	AUX
dpc-4503	103	11	obtained	obtain	VERB
dpc-4503	103	12	at	at	ADP
dpc-4503	103	13	week	week	NOUN
dpc-4503	103	14	28	28	NUM
dpc-4503	103	15	from	from	ADP
dpc-4503	103	16	41	41	NUM
dpc-4503	103	17	%	%	NOUN
dpc-4503	103	18	of	of	ADP
dpc-4503	103	19	31	31	NUM
dpc-4503	103	20	enrolled	enrol	VERB
dpc-4503	103	21	patients	patient	NOUN
dpc-4503	103	22	,	,	PUNCT
dpc-4503	103	23	all	all	PRON
dpc-4503	103	24	treated	treat	VERB
dpc-4503	103	25	with	with	ADP
dpc-4503	103	26	secukinumab	secukinumab	NOUN
dpc-4503	103	27	for	for	ADP
dpc-4503	103	28	severe	severe	ADJ
dpc-4503	103	29	hs	hs	PROPN
dpc-4503	104	1	[	[	X
dpc-4503	104	2	20	20	NUM
dpc-4503	104	3	]	]	PUNCT
dpc-4503	104	4	.	.	PUNCT
dpc-4503	105	1	in	in	ADP
dpc-4503	105	2	a	a	DET
dpc-4503	105	3	spanish	spanish	ADJ
dpc-4503	105	4	retrospective	retrospective	ADJ
dpc-4503	105	5	multicenter	multicenter	NOUN
dpc-4503	105	6	study	study	NOUN
dpc-4503	105	7	,	,	PUNCT
dpc-4503	105	8	hiscr	hiscr	PROPN
dpc-4503	105	9	was	be	AUX
dpc-4503	105	10	obtained	obtain	VERB
dpc-4503	105	11	in	in	ADP
dpc-4503	105	12	48.9	48.9	NUM
dpc-4503	105	13	%	%	NOUN
dpc-4503	105	14	of	of	ADP
dpc-4503	105	15	the	the	DET
dpc-4503	105	16	47	47	NUM
dpc-4503	105	17	enrolled	enrol	VERB
dpc-4503	105	18	hs	hs	PROPN
dpc-4503	105	19	patients	patient	NOUN
dpc-4503	105	20	treated	treat	VERB
dpc-4503	105	21	with	with	ADP
dpc-4503	105	22	secukinumab	secukinumab	NOUN
dpc-4503	105	23	[	[	X
dpc-4503	105	24	21	21	NUM
dpc-4503	105	25	]	]	PUNCT
dpc-4503	105	26	.	.	PUNCT
dpc-4503	106	1	recently	recently	ADV
dpc-4503	106	2	,	,	PUNCT
dpc-4503	106	3	secukinumab	secukinumab	NOUN
dpc-4503	106	4	has	have	AUX
dpc-4503	106	5	been	be	AUX
dpc-4503	106	6	approved	approve	VERB
dpc-4503	106	7	as	as	ADP
dpc-4503	106	8	the	the	DET
dpc-4503	106	9	first	first	ADJ
dpc-4503	106	10	table	table	NOUN
dpc-4503	106	11	1	1	NUM
dpc-4503	106	12	.	.	PUNCT
dpc-4503	106	13	demographic	demographic	ADJ
dpc-4503	106	14	characteristics	characteristic	NOUN
dpc-4503	106	15	of	of	ADP
dpc-4503	106	16	our	our	PRON
dpc-4503	106	17	patients	patient	NOUN
dpc-4503	106	18	at	at	ADP
dpc-4503	106	19	baseline	baseline	NOUN
dpc-4503	106	20	.	.	PUNCT
dpc-4503	107	1	total	total	ADJ
dpc-4503	107	2	patients	patient	NOUN
dpc-4503	107	3	41	41	NUM
dpc-4503	107	4	n	n	CCONJ
dpc-4503	107	5	(	(	PUNCT
dpc-4503	107	6	%	%	INTJ
dpc-4503	107	7	)	)	PUNCT
dpc-4503	107	8	female	female	ADJ
dpc-4503	107	9	28	28	NUM
dpc-4503	107	10	(	(	PUNCT
dpc-4503	107	11	68.3	68.3	NUM
dpc-4503	107	12	)	)	PUNCT
dpc-4503	107	13	at	at	ADP
dpc-4503	107	14	least	least	ADV
dpc-4503	107	15	one	one	NUM
dpc-4503	107	16	cardiometabolic	cardiometabolic	NOUN
dpc-4503	107	17	comorbidity	comorbidity	NOUN
dpc-4503	107	18	23	23	NUM
dpc-4503	107	19	(	(	PUNCT
dpc-4503	107	20	56.1	56.1	NUM
dpc-4503	107	21	)	)	PUNCT
dpc-4503	107	22	smokers	smoker	NOUN
dpc-4503	107	23	23	23	NUM
dpc-4503	107	24	(	(	PUNCT
dpc-4503	107	25	56.1	56.1	NUM
dpc-4503	107	26	)	)	PUNCT
dpc-4503	107	27	previously	previously	ADV
dpc-4503	107	28	treated	treat	VERB
dpc-4503	107	29	with	with	ADP
dpc-4503	107	30	adalimumab	adalimumab	NOUN
dpc-4503	107	31	35	35	NUM
dpc-4503	107	32	(	(	PUNCT
dpc-4503	107	33	85.4	85.4	NUM
dpc-4503	107	34	)	)	PUNCT
dpc-4503	107	35	hurley	hurley	PROPN
dpc-4503	107	36	ii	ii	PROPN
dpc-4503	107	37	17	17	NUM
dpc-4503	107	38	(	(	PUNCT
dpc-4503	107	39	41.5	41.5	NUM
dpc-4503	107	40	)	)	PUNCT
dpc-4503	107	41	hurley	hurley	PROPN
dpc-4503	107	42	iii	iii	PROPN
dpc-4503	107	43	24	24	NUM
dpc-4503	107	44	(	(	PUNCT
dpc-4503	107	45	58.5	58.5	NUM
dpc-4503	107	46	)	)	PUNCT
dpc-4503	107	47	obese	obese	ADV
dpc-4503	107	48	13	13	NUM
dpc-4503	107	49	(	(	PUNCT
dpc-4503	107	50	31.7	31.7	NUM
dpc-4503	107	51	)	)	PUNCT
dpc-4503	107	52	current	current	ADJ
dpc-4503	107	53	biological	biological	ADJ
dpc-4503	107	54	drug	drug	NOUN
dpc-4503	107	55	secukinumab	secukinumab	NOUN
dpc-4503	107	56	27	27	NUM
dpc-4503	107	57	(	(	PUNCT
dpc-4503	107	58	65.9	65.9	NUM
dpc-4503	107	59	)	)	PUNCT
dpc-4503	107	60	brodalumab	brodalumab	NOUN
dpc-4503	107	61	1	1	NUM
dpc-4503	107	62	(	(	PUNCT
dpc-4503	107	63	2.4	2.4	NUM
dpc-4503	107	64	)	)	PUNCT
dpc-4503	107	65	ixekizumab	ixekizumab	NOUN
dpc-4503	107	66	5	5	NUM
dpc-4503	107	67	(	(	PUNCT
dpc-4503	107	68	12.2	12.2	NUM
dpc-4503	107	69	)	)	PUNCT
dpc-4503	107	70	bimekizumab	bimekizumab	X
dpc-4503	107	71	2	2	NUM
dpc-4503	107	72	(	(	PUNCT
dpc-4503	107	73	4.9	4.9	NUM
dpc-4503	107	74	)	)	PUNCT
dpc-4503	107	75	risankizumab	risankizumab	NOUN
dpc-4503	107	76	1	1	NUM
dpc-4503	107	77	(	(	PUNCT
dpc-4503	107	78	2.4	2.4	NUM
dpc-4503	107	79	)	)	PUNCT
dpc-4503	107	80	guselkumab	guselkumab	NOUN
dpc-4503	107	81	5	5	NUM
dpc-4503	107	82	(	(	PUNCT
dpc-4503	107	83	12.2	12.2	NUM
dpc-4503	107	84	)	)	PUNCT
dpc-4503	107	85	mean	mean	NOUN
dpc-4503	107	86	(	(	PUNCT
dpc-4503	107	87	sd	sd	NOUN
dpc-4503	107	88	)	)	PUNCT
dpc-4503	107	89	age	age	NOUN
dpc-4503	107	90	,	,	PUNCT
dpc-4503	107	91	years	year	NOUN
dpc-4503	107	92	40.59	40.59	NUM
dpc-4503	107	93	(	(	PUNCT
dpc-4503	107	94	15	15	NUM
dpc-4503	107	95	)	)	PUNCT
dpc-4503	107	96	bmi	bmi	VERB
dpc-4503	107	97	27.94	27.94	NUM
dpc-4503	107	98	(	(	PUNCT
dpc-4503	107	99	4.65	4.65	NUM
dpc-4503	107	100	)	)	PUNCT
dpc-4503	107	101	ihs4	ihs4	PROPN
dpc-4503	107	102	at	at	ADP
dpc-4503	107	103	baseline	baseline	NOUN
dpc-4503	107	104	29.49	29.49	NUM
dpc-4503	107	105	(	(	PUNCT
dpc-4503	107	106	21.93	21.93	NUM
dpc-4503	107	107	)	)	PUNCT
dpc-4503	107	108	dlqi	dlqi	NOUN
dpc-4503	107	109	at	at	ADP
dpc-4503	107	110	baseline	baseline	PROPN
dpc-4503	107	111	20.88	20.88	NUM
dpc-4503	107	112	(	(	PUNCT
dpc-4503	107	113	7.08	7.08	NUM
dpc-4503	107	114	)	)	PUNCT
dpc-4503	107	115	abbreviations	abbreviation	NOUN
dpc-4503	107	116	:	:	PUNCT
dpc-4503	107	117	bmi	bmi	PROPN
dpc-4503	107	118	:	:	PUNCT
dpc-4503	107	119	body	body	NOUN
dpc-4503	107	120	mass	mass	PROPN
dpc-4503	107	121	index	index	NOUN
dpc-4503	107	122	;	;	PUNCT
dpc-4503	107	123	ihs4	ihs4	PROPN
dpc-4503	107	124	:	:	PUNCT
dpc-4503	107	125	international	international	ADJ
dpc-4503	107	126	hidradenitis	hidradenitis	PROPN
dpc-4503	107	127	suppurativa	suppurativa	PROPN
dpc-4503	107	128	severity	severity	NOUN
dpc-4503	107	129	scoring	scoring	NOUN
dpc-4503	107	130	system	system	NOUN
dpc-4503	107	131	4	4	NUM
dpc-4503	107	132	;	;	PUNCT
dpc-4503	107	133	dlqi	dlqi	ADJ
dpc-4503	107	134	:	:	PUNCT
dpc-4503	107	135	dermatology	dermatology	NOUN
dpc-4503	107	136	life	life	NOUN
dpc-4503	107	137	quality	quality	NOUN
dpc-4503	107	138	index	index	NOUN
dpc-4503	107	139	;	;	PUNCT
dpc-4503	107	140	sd	sd	NUM
dpc-4503	107	141	:	:	PUNCT
dpc-4503	107	142	standard	standard	ADJ
dpc-4503	107	143	deviation	deviation	NOUN
dpc-4503	107	144	.	.	PUNCT
dpc-4503	108	1	figure	figure	NOUN
dpc-4503	108	2	1	1	NUM
dpc-4503	108	3	.	.	PUNCT
dpc-4503	108	4	effectiveness	effectiveness	NOUN
dpc-4503	108	5	outcomes	outcome	NOUN
dpc-4503	108	6	throughout	throughout	ADP
dpc-4503	108	7	52	52	NUM
dpc-4503	108	8	weeks	week	NOUN
dpc-4503	108	9	of	of	ADP
dpc-4503	108	10	treatment	treatment	NOUN
dpc-4503	108	11	.	.	PUNCT
dpc-4503	109	1	(	(	PUNCT
dpc-4503	109	2	ihs4	ihs4	NOUN
dpc-4503	109	3	=	=	SYM
dpc-4503	109	4	international	international	ADJ
dpc-4503	109	5	hidradenitis	hidradenitis	PROPN
dpc-4503	109	6	suppurativa	suppurativa	PROPN
dpc-4503	109	7	severity	severity	NOUN
dpc-4503	109	8	scoring	scoring	NOUN
dpc-4503	109	9	system	system	NOUN
dpc-4503	109	10	4	4	NUM
dpc-4503	109	11	;	;	PUNCT
dpc-4503	109	12	hiscr	hiscr	NOUN
dpc-4503	109	13	=	=	SYM
dpc-4503	109	14	hidradenitis	hidradenitis	PROPN
dpc-4503	109	15	suppurativa	suppurativa	ADJ
dpc-4503	109	16	clinical	clinical	ADJ
dpc-4503	109	17	response	response	NOUN
dpc-4503	109	18	.	.	PUNCT
dpc-4503	109	19	)	)	PUNCT
dpc-4503	110	1	original	original	ADJ
dpc-4503	110	2	article	article	NOUN
dpc-4503	110	3	|	|	ADV
dpc-4503	110	4	dermatol	dermatol	ADJ
dpc-4503	110	5	pract	pract	NOUN
dpc-4503	110	6	concept	concept	NOUN
dpc-4503	110	7	.	.	PUNCT
dpc-4503	111	1	2024;14(4):e2024250	2024;14(4):e2024250	NUM
dpc-4503	111	2	5	5	NUM
dpc-4503	111	3	heard	hear	VERB
dpc-4503	111	4	1	1	NUM
dpc-4503	111	5	and	and	CCONJ
dpc-4503	111	6	2	2	NUM
dpc-4503	111	7	phase	phase	NOUN
dpc-4503	111	8	3	3	NUM
dpc-4503	111	9	clinical	clinical	ADJ
dpc-4503	111	10	trials	trial	NOUN
dpc-4503	111	11	[	[	X
dpc-4503	111	12	9	9	NUM
dpc-4503	111	13	]	]	PUNCT
dpc-4503	111	14	.	.	PUNCT
dpc-4503	112	1	data	datum	NOUN
dpc-4503	112	2	from	from	ADP
dpc-4503	112	3	the	the	DET
dpc-4503	112	4	phase	phase	NOUN
dpc-4503	112	5	2	2	NUM
dpc-4503	112	6	study	study	NOUN
dpc-4503	112	7	showed	show	VERB
dpc-4503	112	8	a	a	DET
dpc-4503	112	9	higher	high	ADJ
dpc-4503	112	10	hiscr	hiscr	NOUN
dpc-4503	112	11	rate	rate	NOUN
dpc-4503	112	12	at	at	ADP
dpc-4503	112	13	week	week	NOUN
dpc-4503	112	14	12	12	NUM
dpc-4503	112	15	compared	compare	VERB
dpc-4503	112	16	to	to	ADP
dpc-4503	112	17	placebo	placebo	NOUN
dpc-4503	112	18	,	,	PUNCT
dpc-4503	112	19	meeting	meet	VERB
dpc-4503	112	20	the	the	DET
dpc-4503	112	21	primary	primary	ADJ
dpc-4503	112	22	endpoint	endpoint	NOUN
dpc-4503	112	23	of	of	ADP
dpc-4503	112	24	the	the	DET
dpc-4503	112	25	trial	trial	NOUN
dpc-4503	112	26	[	[	X
dpc-4503	112	27	27	27	NUM
dpc-4503	112	28	]	]	PUNCT
dpc-4503	112	29	.	.	PUNCT
dpc-4503	113	1	the	the	DET
dpc-4503	113	2	safety	safety	NOUN
dpc-4503	113	3	profile	profile	NOUN
dpc-4503	113	4	of	of	ADP
dpc-4503	113	5	bimekizumab	bimekizumab	NOUN
dpc-4503	113	6	for	for	ADP
dpc-4503	113	7	the	the	DET
dpc-4503	113	8	treatment	treatment	NOUN
dpc-4503	113	9	of	of	ADP
dpc-4503	113	10	hs	hs	PROPN
dpc-4503	113	11	was	be	AUX
dpc-4503	113	12	comparable	comparable	ADJ
dpc-4503	113	13	to	to	ADP
dpc-4503	113	14	clinical	clinical	ADJ
dpc-4503	113	15	trials	trial	NOUN
dpc-4503	113	16	for	for	ADP
dpc-4503	113	17	the	the	DET
dpc-4503	113	18	treatment	treatment	NOUN
dpc-4503	113	19	of	of	ADP
dpc-4503	113	20	moderate	moderate	ADJ
dpc-4503	113	21	-	-	PUNCT
dpc-4503	113	22	to	to	ADP
dpc-4503	113	23	-	-	PUNCT
dpc-4503	113	24	severe	severe	ADJ
dpc-4503	113	25	psoriasis	psoriasis	NOUN
dpc-4503	113	26	[	[	X
dpc-4503	113	27	9	9	NUM
dpc-4503	113	28	,	,	PUNCT
dpc-4503	113	29	27	27	NUM
dpc-4503	113	30	]	]	PUNCT
dpc-4503	113	31	.	.	PUNCT
dpc-4503	114	1	data	datum	NOUN
dpc-4503	114	2	on	on	ADP
dpc-4503	114	3	anti	anti	ADJ
dpc-4503	114	4	-	-	ADJ
dpc-4503	114	5	il-23	il-23	ADJ
dpc-4503	114	6	drugs	drug	NOUN
dpc-4503	114	7	for	for	ADP
dpc-4503	114	8	treating	treat	VERB
dpc-4503	114	9	hs	hs	PROPN
dpc-4503	114	10	are	be	AUX
dpc-4503	114	11	still	still	ADV
dpc-4503	114	12	limited	limited	ADJ
dpc-4503	114	13	.	.	PUNCT
dpc-4503	115	1	regarding	regard	VERB
dpc-4503	115	2	tildrakizumab	tildrakizumab	NOUN
dpc-4503	115	3	,	,	PUNCT
dpc-4503	115	4	kok	kok	PROPN
dpc-4503	115	5	y	y	PROPN
dpc-4503	115	6	et	et	PROPN
dpc-4503	115	7	al	al	PROPN
dpc-4503	115	8	.	.	PUNCT
dpc-4503	116	1	[	[	X
dpc-4503	116	2	28	28	NUM
dpc-4503	116	3	]	]	PUNCT
dpc-4503	116	4	published	publish	VERB
dpc-4503	116	5	a	a	DET
dpc-4503	116	6	case	case	NOUN
dpc-4503	116	7	series	series	NOUN
dpc-4503	116	8	that	that	PRON
dpc-4503	116	9	included	include	VERB
dpc-4503	116	10	nine	nine	NUM
dpc-4503	116	11	patients	patient	NOUN
dpc-4503	116	12	treated	treat	VERB
dpc-4503	116	13	for	for	ADP
dpc-4503	116	14	15	15	NUM
dpc-4503	116	15	months	month	NOUN
dpc-4503	116	16	.	.	PUNCT
dpc-4503	117	1	they	they	PRON
dpc-4503	117	2	reported	report	VERB
dpc-4503	117	3	a	a	DET
dpc-4503	117	4	significant	significant	ADJ
dpc-4503	117	5	reduction	reduction	NOUN
dpc-4503	117	6	in	in	ADP
dpc-4503	117	7	mean	mean	ADJ
dpc-4503	117	8	abscess	abscess	NOUN
dpc-4503	117	9	and	and	CCONJ
dpc-4503	117	10	nodule	nodule	NOUN
dpc-4503	117	11	count	count	NOUN
dpc-4503	117	12	after	after	ADP
dpc-4503	117	13	15	15	NUM
dpc-4503	117	14	months	month	NOUN
dpc-4503	117	15	in	in	ADP
dpc-4503	117	16	the	the	DET
dpc-4503	117	17	absence	absence	NOUN
dpc-4503	117	18	of	of	ADP
dpc-4503	117	19	significant	significant	ADJ
dpc-4503	117	20	aes	aes	NOUN
dpc-4503	117	21	[	[	X
dpc-4503	117	22	28	28	NUM
dpc-4503	117	23	]	]	PUNCT
dpc-4503	117	24	.	.	PUNCT
dpc-4503	118	1	in	in	ADP
dpc-4503	118	2	a	a	DET
dpc-4503	118	3	recent	recent	ADJ
dpc-4503	118	4	case	case	NOUN
dpc-4503	118	5	series	series	NOUN
dpc-4503	118	6	including	include	VERB
dpc-4503	118	7	seven	seven	NUM
dpc-4503	118	8	patients	patient	NOUN
dpc-4503	118	9	who	who	PRON
dpc-4503	118	10	had	have	AUX
dpc-4503	118	11	failed	fail	VERB
dpc-4503	118	12	adalimumab	adalimumab	NOUN
dpc-4503	118	13	,	,	PUNCT
dpc-4503	118	14	tildrakizumab	tildrakizumab	VERB
dpc-4503	118	15	200	200	NUM
dpc-4503	118	16	mg	mg	NOUN
dpc-4503	118	17	demonstrated	demonstrate	VERB
dpc-4503	118	18	an	an	DET
dpc-4503	118	19	initial	initial	ADJ
dpc-4503	118	20	improvement	improvement	NOUN
dpc-4503	118	21	in	in	ADP
dpc-4503	118	22	disease	disease	NOUN
dpc-4503	118	23	activity	activity	NOUN
dpc-4503	118	24	after	after	ADP
dpc-4503	118	25	24	24	NUM
dpc-4503	118	26	weeks	week	NOUN
dpc-4503	118	27	of	of	ADP
dpc-4503	118	28	treatment	treatment	NOUN
dpc-4503	118	29	[	[	X
dpc-4503	118	30	29	29	NUM
dpc-4503	118	31	]	]	PUNCT
dpc-4503	118	32	.	.	PUNCT
dpc-4503	119	1	risankizumab	risankizumab	PROPN
dpc-4503	119	2	failed	fail	VERB
dpc-4503	119	3	to	to	PART
dpc-4503	119	4	meet	meet	VERB
dpc-4503	119	5	the	the	DET
dpc-4503	119	6	primary	primary	ADJ
dpc-4503	119	7	endpoint	endpoint	NOUN
dpc-4503	119	8	in	in	ADP
dpc-4503	119	9	a	a	DET
dpc-4503	119	10	phase	phase	NOUN
dpc-4503	119	11	2	2	NUM
dpc-4503	119	12	clinical	clinical	ADJ
dpc-4503	119	13	trial	trial	NOUN
dpc-4503	119	14	enrolling	enrol	VERB
dpc-4503	119	15	patients	patient	NOUN
dpc-4503	119	16	with	with	ADP
dpc-4503	119	17	severe	severe	ADJ
dpc-4503	119	18	hs	hs	PROPN
dpc-4503	120	1	[	[	X
dpc-4503	120	2	10	10	NUM
dpc-4503	120	3	]	]	PUNCT
dpc-4503	120	4	.	.	PUNCT
dpc-4503	121	1	concerning	concern	VERB
dpc-4503	121	2	real	real	ADJ
dpc-4503	121	3	-	-	PUNCT
dpc-4503	121	4	world	world	NOUN
dpc-4503	121	5	data	datum	NOUN
dpc-4503	121	6	,	,	PUNCT
dpc-4503	121	7	a	a	DET
dpc-4503	121	8	retrospective	retrospective	ADJ
dpc-4503	121	9	study	study	NOUN
dpc-4503	121	10	on	on	ADP
dpc-4503	121	11	six	six	NUM
dpc-4503	121	12	patients	patient	NOUN
dpc-4503	121	13	reported	report	VERB
dpc-4503	121	14	the	the	DET
dpc-4503	121	15	achievement	achievement	NOUN
dpc-4503	121	16	of	of	ADP
dpc-4503	121	17	hiscr	hiscr	NOUN
dpc-4503	121	18	for	for	ADP
dpc-4503	121	19	all	all	DET
dpc-4503	121	20	patients	patient	NOUN
dpc-4503	121	21	after	after	ADP
dpc-4503	121	22	six	six	NUM
dpc-4503	121	23	months	month	NOUN
dpc-4503	121	24	[	[	X
dpc-4503	121	25	30	30	NUM
dpc-4503	121	26	]	]	PUNCT
dpc-4503	121	27	.	.	PUNCT
dpc-4503	122	1	guselkumab	guselkumab	NOUN
dpc-4503	122	2	did	do	AUX
dpc-4503	122	3	not	not	PART
dpc-4503	122	4	achieve	achieve	VERB
dpc-4503	122	5	the	the	DET
dpc-4503	122	6	primary	primary	ADJ
dpc-4503	122	7	endpoints	endpoint	NOUN
dpc-4503	122	8	in	in	ADP
dpc-4503	122	9	phase	phase	NOUN
dpc-4503	122	10	2	2	NUM
dpc-4503	122	11	clinical	clinical	ADJ
dpc-4503	122	12	trials	trial	NOUN
dpc-4503	122	13	[	[	X
dpc-4503	122	14	31,32	31,32	NUM
dpc-4503	122	15	]	]	PUNCT
dpc-4503	122	16	.	.	PUNCT
dpc-4503	123	1	in	in	ADP
dpc-4503	123	2	particular	particular	ADJ
dpc-4503	123	3	,	,	PUNCT
dpc-4503	123	4	the	the	DET
dpc-4503	123	5	authors	author	NOUN
dpc-4503	123	6	of	of	ADP
dpc-4503	123	7	one	one	NUM
dpc-4503	123	8	of	of	ADP
dpc-4503	123	9	these	these	DET
dpc-4503	123	10	studies	study	NOUN
dpc-4503	123	11	concluded	conclude	VERB
dpc-4503	123	12	that	that	SCONJ
dpc-4503	123	13	il-23	il-23	NOUN
dpc-4503	123	14	does	do	AUX
dpc-4503	123	15	not	not	PART
dpc-4503	123	16	appear	appear	VERB
dpc-4503	123	17	to	to	PART
dpc-4503	123	18	be	be	AUX
dpc-4503	123	19	a	a	DET
dpc-4503	123	20	crucial	crucial	ADJ
dpc-4503	123	21	cytokine	cytokine	NOUN
dpc-4503	123	22	in	in	ADP
dpc-4503	123	23	hs	hs	PROPN
dpc-4503	123	24	pathogenesis	pathogenesis	NOUN
dpc-4503	123	25	,	,	PUNCT
dpc-4503	123	26	while	while	SCONJ
dpc-4503	123	27	guselkumab	guselkumab	NOUN
dpc-4503	123	28	showed	show	VERB
dpc-4503	123	29	efficacy	efficacy	NOUN
dpc-4503	123	30	only	only	ADV
dpc-4503	123	31	in	in	ADP
dpc-4503	123	32	a	a	DET
dpc-4503	123	33	limited	limited	ADJ
dpc-4503	123	34	subpopulation	subpopulation	NOUN
dpc-4503	123	35	of	of	ADP
dpc-4503	123	36	patients	patient	NOUN
dpc-4503	123	37	[	[	X
dpc-4503	123	38	32	32	NUM
dpc-4503	123	39	]	]	PUNCT
dpc-4503	123	40	.	.	PUNCT
dpc-4503	124	1	however	however	ADV
dpc-4503	124	2	,	,	PUNCT
dpc-4503	124	3	in	in	ADP
dpc-4503	124	4	a	a	DET
dpc-4503	124	5	recent	recent	ADJ
dpc-4503	124	6	real	real	ADJ
dpc-4503	124	7	-	-	PUNCT
dpc-4503	124	8	life	life	NOUN
dpc-4503	124	9	multicenter	multicenter	NOUN
dpc-4503	124	10	study	study	NOUN
dpc-4503	124	11	,	,	PUNCT
dpc-4503	124	12	a	a	DET
dpc-4503	124	13	significant	significant	ADJ
dpc-4503	124	14	decrease	decrease	NOUN
dpc-4503	124	15	in	in	ADP
dpc-4503	124	16	ihs4	ihs4	PROPN
dpc-4503	124	17	and	and	CCONJ
dpc-4503	124	18	dlqi	dlqi	PROPN
dpc-4503	124	19	was	be	AUX
dpc-4503	124	20	observed	observe	VERB
dpc-4503	124	21	after	after	ADP
dpc-4503	124	22	48	48	NUM
dpc-4503	124	23	weeks	week	NOUN
dpc-4503	124	24	of	of	ADP
dpc-4503	124	25	treatment	treatment	NOUN
dpc-4503	124	26	with	with	ADP
dpc-4503	124	27	guselkumab	guselkumab	NOUN
dpc-4503	124	28	,	,	PUNCT
dpc-4503	124	29	while	while	SCONJ
dpc-4503	124	30	more	more	ADJ
dpc-4503	124	31	than	than	ADP
dpc-4503	124	32	half	half	NOUN
dpc-4503	124	33	of	of	ADP
dpc-4503	124	34	the	the	DET
dpc-4503	124	35	patients	patient	NOUN
dpc-4503	124	36	achieved	achieve	VERB
dpc-4503	124	37	hiscr	hiscr	NOUN
dpc-4503	124	38	at	at	ADP
dpc-4503	124	39	week	week	NOUN
dpc-4503	124	40	16	16	NUM
dpc-4503	125	1	[	[	X
dpc-4503	125	2	4	4	NUM
dpc-4503	125	3	,	,	PUNCT
dpc-4503	125	4	33	33	NUM
dpc-4503	125	5	,	,	PUNCT
dpc-4503	125	6	34	34	NUM
dpc-4503	125	7	]	]	PUNCT
dpc-4503	125	8	.	.	PUNCT
dpc-4503	126	1	in	in	ADP
dpc-4503	126	2	our	our	PRON
dpc-4503	126	3	study	study	NOUN
dpc-4503	126	4	,	,	PUNCT
dpc-4503	126	5	we	we	PRON
dpc-4503	126	6	observed	observe	VERB
dpc-4503	126	7	good	good	ADJ
dpc-4503	126	8	clinical	clinical	ADJ
dpc-4503	126	9	responses	response	NOUN
dpc-4503	126	10	among	among	ADP
dpc-4503	126	11	a	a	DET
dpc-4503	126	12	cohort	cohort	NOUN
dpc-4503	126	13	of	of	ADP
dpc-4503	126	14	41	41	NUM
dpc-4503	126	15	patients	patient	NOUN
dpc-4503	126	16	treated	treat	VERB
dpc-4503	126	17	with	with	ADP
dpc-4503	126	18	inhibitors	inhibitor	NOUN
dpc-4503	126	19	of	of	ADP
dpc-4503	126	20	il-17	il-17	NUM
dpc-4503	126	21	and	and	CCONJ
dpc-4503	126	22	il-23	il-23	NOUN
dpc-4503	126	23	.	.	PUNCT
dpc-4503	127	1	we	we	PRON
dpc-4503	127	2	can	can	AUX
dpc-4503	127	3	speculate	speculate	VERB
dpc-4503	127	4	that	that	SCONJ
dpc-4503	127	5	the	the	DET
dpc-4503	127	6	effectiveness	effectiveness	NOUN
dpc-4503	127	7	that	that	PRON
dpc-4503	127	8	we	we	PRON
dpc-4503	127	9	observed	observe	VERB
dpc-4503	127	10	could	could	AUX
dpc-4503	127	11	be	be	AUX
dpc-4503	127	12	due	due	ADJ
dpc-4503	127	13	to	to	ADP
dpc-4503	127	14	the	the	DET
dpc-4503	127	15	concomitant	concomitant	ADJ
dpc-4503	127	16	presence	presence	NOUN
dpc-4503	127	17	of	of	ADP
dpc-4503	127	18	hs	hs	PROPN
dpc-4503	127	19	and	and	CCONJ
dpc-4503	127	20	plaque	plaque	NOUN
dpc-4503	127	21	psoriasis	psoriasis	NOUN
dpc-4503	127	22	with	with	ADP
dpc-4503	127	23	a	a	DET
dpc-4503	127	24	supposed	suppose	VERB
dpc-4503	127	25	overexpression	overexpression	NOUN
dpc-4503	127	26	of	of	ADP
dpc-4503	127	27	il-23	il-23	NOUN
dpc-4503	127	28	and	and	CCONJ
dpc-4503	127	29	il-17	il-17	ADV
dpc-4503	127	30	-	-	PUNCT
dpc-4503	127	31	related	relate	VERB
dpc-4503	127	32	cytokines	cytokine	NOUN
dpc-4503	127	33	.	.	PUNCT
dpc-4503	128	1	limitations	limitation	NOUN
dpc-4503	128	2	however	however	ADV
dpc-4503	128	3	,	,	PUNCT
dpc-4503	128	4	our	our	PRON
dpc-4503	128	5	experience	experience	NOUN
dpc-4503	128	6	has	have	VERB
dpc-4503	128	7	several	several	ADJ
dpc-4503	128	8	limitations	limitation	NOUN
dpc-4503	128	9	,	,	PUNCT
dpc-4503	128	10	the	the	DET
dpc-4503	128	11	first	first	ADJ
dpc-4503	128	12	being	be	AUX
dpc-4503	128	13	its	its	PRON
dpc-4503	128	14	retrospective	retrospective	ADJ
dpc-4503	128	15	nature	nature	NOUN
dpc-4503	128	16	.	.	PUNCT
dpc-4503	129	1	moreover	moreover	ADV
dpc-4503	129	2	,	,	PUNCT
dpc-4503	129	3	due	due	ADP
dpc-4503	129	4	to	to	ADP
dpc-4503	129	5	the	the	DET
dpc-4503	129	6	limited	limited	ADJ
dpc-4503	129	7	sample	sample	NOUN
dpc-4503	129	8	size	size	NOUN
dpc-4503	129	9	,	,	PUNCT
dpc-4503	129	10	it	it	PRON
dpc-4503	129	11	was	be	AUX
dpc-4503	129	12	not	not	PART
dpc-4503	129	13	possible	possible	ADJ
dpc-4503	129	14	to	to	PART
dpc-4503	129	15	investigate	investigate	VERB
dpc-4503	129	16	the	the	DET
dpc-4503	129	17	effectiveness	effectiveness	NOUN
dpc-4503	129	18	profile	profile	NOUN
dpc-4503	129	19	of	of	ADP
dpc-4503	129	20	each	each	DET
dpc-4503	129	21	molecule	molecule	NOUN
dpc-4503	129	22	.	.	PUNCT
dpc-4503	130	1	also	also	ADV
dpc-4503	130	2	,	,	PUNCT
dpc-4503	130	3	the	the	DET
dpc-4503	130	4	heterogeneity	heterogeneity	NOUN
dpc-4503	130	5	of	of	ADP
dpc-4503	130	6	clinical	clinical	ADJ
dpc-4503	130	7	evaluations	evaluation	NOUN
dpc-4503	130	8	from	from	ADP
dpc-4503	130	9	different	different	ADJ
dpc-4503	130	10	clinicians	clinician	NOUN
dpc-4503	130	11	could	could	AUX
dpc-4503	130	12	limit	limit	VERB
dpc-4503	130	13	the	the	DET
dpc-4503	130	14	generalization	generalization	NOUN
dpc-4503	130	15	of	of	ADP
dpc-4503	130	16	our	our	PRON
dpc-4503	130	17	findings	finding	NOUN
dpc-4503	130	18	.	.	PUNCT
dpc-4503	131	1	conclusions	conclusion	NOUN
dpc-4503	131	2	our	our	PRON
dpc-4503	131	3	real	real	ADJ
dpc-4503	131	4	-	-	PUNCT
dpc-4503	131	5	life	life	NOUN
dpc-4503	131	6	study	study	NOUN
dpc-4503	131	7	supports	support	VERB
dpc-4503	131	8	data	datum	NOUN
dpc-4503	131	9	from	from	ADP
dpc-4503	131	10	clinical	clinical	ADJ
dpc-4503	131	11	trials	trial	NOUN
dpc-4503	131	12	and	and	CCONJ
dpc-4503	131	13	real	real	ADJ
dpc-4503	131	14	-	-	PUNCT
dpc-4503	131	15	world	world	NOUN
dpc-4503	131	16	experiences	experience	NOUN
dpc-4503	131	17	highlighting	highlight	VERB
dpc-4503	131	18	the	the	DET
dpc-4503	131	19	effectiveness	effectiveness	NOUN
dpc-4503	131	20	of	of	ADP
dpc-4503	131	21	anti	anti	ADJ
dpc-4503	131	22	-	-	ADJ
dpc-4503	131	23	il-17	il-17	ADJ
dpc-4503	131	24	and	and	CCONJ
dpc-4503	131	25	anti	anti	ADJ
dpc-4503	131	26	-	-	NOUN
dpc-4503	131	27	il-23	il-23	NOUN
dpc-4503	131	28	in	in	ADP
dpc-4503	131	29	the	the	DET
dpc-4503	131	30	treatment	treatment	NOUN
dpc-4503	131	31	of	of	ADP
dpc-4503	131	32	hs	hs	PROPN
dpc-4503	131	33	.	.	PUNCT
dpc-4503	132	1	considering	consider	VERB
dpc-4503	132	2	the	the	DET
dpc-4503	132	3	recent	recent	ADJ
dpc-4503	132	4	and	and	CCONJ
dpc-4503	132	5	upcoming	upcoming	ADJ
dpc-4503	132	6	approval	approval	NOUN
dpc-4503	132	7	of	of	ADP
dpc-4503	132	8	anti	anti	ADJ
dpc-4503	132	9	-	-	ADJ
dpc-4503	132	10	interleukin	interleukin	ADJ
dpc-4503	132	11	navrazhina	navrazhina	NOUN
dpc-4503	132	12	et	et	PROPN
dpc-4503	132	13	al	al	PROPN
dpc-4503	132	14	.	.	PROPN
dpc-4503	132	15	conducted	conduct	VERB
dpc-4503	132	16	a	a	DET
dpc-4503	132	17	study	study	NOUN
dpc-4503	132	18	that	that	PRON
dpc-4503	132	19	demonstrates	demonstrate	VERB
dpc-4503	132	20	il-17ra	il-17ra	PROPN
dpc-4503	132	21	inhibition	inhibition	NOUN
dpc-4503	132	22	as	as	ADP
dpc-4503	132	23	a	a	DET
dpc-4503	132	24	potential	potential	ADJ
dpc-4503	132	25	therapy	therapy	NOUN
dpc-4503	132	26	for	for	ADP
dpc-4503	132	27	decreasing	decrease	VERB
dpc-4503	132	28	different	different	ADJ
dpc-4503	132	29	pathogenic	pathogenic	ADJ
dpc-4503	132	30	inflammatory	inflammatory	ADJ
dpc-4503	132	31	axes	axis	NOUN
dpc-4503	132	32	in	in	ADP
dpc-4503	132	33	hs	hs	PROPN
dpc-4503	133	1	[	[	X
dpc-4503	133	2	25	25	NUM
dpc-4503	133	3	]	]	PUNCT
dpc-4503	133	4	.	.	PUNCT
dpc-4503	134	1	in	in	ADP
dpc-4503	134	2	particular	particular	ADJ
dpc-4503	134	3	,	,	PUNCT
dpc-4503	134	4	a	a	DET
dpc-4503	134	5	significant	significant	ADJ
dpc-4503	134	6	reduction	reduction	NOUN
dpc-4503	134	7	in	in	ADP
dpc-4503	134	8	neutrophil	neutrophil	ADV
dpc-4503	134	9	-	-	PUNCT
dpc-4503	134	10	associated	associate	VERB
dpc-4503	134	11	lipocalin-2	lipocalin-2	X
dpc-4503	134	12	(	(	PUNCT
dpc-4503	134	13	lcn-2	lcn-2	X
dpc-4503	134	14	)	)	PUNCT
dpc-4503	134	15	in	in	ADP
dpc-4503	134	16	skin	skin	NOUN
dpc-4503	134	17	biopsies	biopsy	NOUN
dpc-4503	134	18	and	and	CCONJ
dpc-4503	134	19	in	in	ADP
dpc-4503	134	20	il-17a	il-17a	PROPN
dpc-4503	134	21	in	in	ADP
dpc-4503	134	22	serum	serum	NOUN
dpc-4503	134	23	was	be	AUX
dpc-4503	134	24	assessed	assess	VERB
dpc-4503	134	25	in	in	ADP
dpc-4503	134	26	10	10	NUM
dpc-4503	134	27	hs	hs	PROPN
dpc-4503	134	28	patients	patient	NOUN
dpc-4503	134	29	treated	treat	VERB
dpc-4503	134	30	with	with	ADP
dpc-4503	134	31	brodalumab	brodalumab	NOUN
dpc-4503	134	32	[	[	X
dpc-4503	134	33	26	26	NUM
dpc-4503	134	34	]	]	PUNCT
dpc-4503	134	35	.	.	PUNCT
dpc-4503	135	1	furthermore	furthermore	ADV
dpc-4503	135	2	,	,	PUNCT
dpc-4503	135	3	another	another	DET
dpc-4503	135	4	study	study	NOUN
dpc-4503	135	5	assessed	assess	VERB
dpc-4503	135	6	a	a	DET
dpc-4503	135	7	good	good	ADJ
dpc-4503	135	8	response	response	NOUN
dpc-4503	135	9	to	to	PART
dpc-4503	135	10	brodalumab	brodalumab	VERB
dpc-4503	135	11	in	in	ADP
dpc-4503	135	12	hs	hs	PROPN
dpc-4503	135	13	patients	patient	NOUN
dpc-4503	135	14	considering	consider	VERB
dpc-4503	135	15	sonographic	sonographic	ADJ
dpc-4503	135	16	biomarkers	biomarker	NOUN
dpc-4503	135	17	(	(	PUNCT
dpc-4503	135	18	epidermal	epidermal	ADJ
dpc-4503	135	19	thickness	thickness	NOUN
dpc-4503	135	20	and	and	CCONJ
dpc-4503	135	21	power	power	NOUN
dpc-4503	135	22	-	-	PUNCT
dpc-4503	135	23	doppler	doppler	NOUN
dpc-4503	135	24	)	)	PUNCT
dpc-4503	135	25	and	and	CCONJ
dpc-4503	135	26	correlating	correlate	VERB
dpc-4503	135	27	them	they	PRON
dpc-4503	135	28	with	with	ADP
dpc-4503	135	29	different	different	ADJ
dpc-4503	135	30	clinical	clinical	ADJ
dpc-4503	135	31	and	and	CCONJ
dpc-4503	135	32	patient	patient	NOUN
dpc-4503	135	33	-	-	PUNCT
dpc-4503	135	34	reported	report	VERB
dpc-4503	135	35	outcomes	outcome	NOUN
dpc-4503	135	36	[	[	X
dpc-4503	135	37	26	26	NUM
dpc-4503	135	38	]	]	PUNCT
dpc-4503	135	39	.	.	PUNCT
dpc-4503	136	1	bimekizumab	bimekizumab	PROPN
dpc-4503	136	2	administered	administer	VERB
dpc-4503	136	3	every	every	DET
dpc-4503	136	4	two	two	NUM
dpc-4503	136	5	weeks	week	NOUN
dpc-4503	136	6	has	have	AUX
dpc-4503	136	7	recently	recently	ADV
dpc-4503	136	8	been	be	AUX
dpc-4503	136	9	shown	show	VERB
dpc-4503	136	10	to	to	PART
dpc-4503	136	11	be	be	AUX
dpc-4503	136	12	superior	superior	ADJ
dpc-4503	136	13	to	to	AUX
dpc-4503	136	14	placebo	placebo	VERB
dpc-4503	136	15	in	in	ADP
dpc-4503	136	16	both	both	CCONJ
dpc-4503	136	17	the	the	DET
dpc-4503	136	18	be	be	NOUN
dpc-4503	136	19	figure	figure	NOUN
dpc-4503	136	20	2	2	NUM
dpc-4503	136	21	.	.	NOUN
dpc-4503	136	22	reduction	reduction	NOUN
dpc-4503	136	23	in	in	ADP
dpc-4503	136	24	the	the	DET
dpc-4503	136	25	mean	mean	ADJ
dpc-4503	136	26	ihs4	ihs4	PROPN
dpc-4503	136	27	and	and	CCONJ
dpc-4503	136	28	mean	mean	VERB
dpc-4503	136	29	dlqi	dlqi	NOUN
dpc-4503	136	30	of	of	ADP
dpc-4503	136	31	our	our	PRON
dpc-4503	136	32	patients	patient	NOUN
dpc-4503	136	33	during	during	ADP
dpc-4503	136	34	the	the	DET
dpc-4503	136	35	study	study	NOUN
dpc-4503	136	36	.	.	PUNCT
dpc-4503	137	1	(	(	PUNCT
dpc-4503	137	2	ihs4	ihs4	NOUN
dpc-4503	137	3	=	=	SYM
dpc-4503	137	4	international	international	ADJ
dpc-4503	137	5	hidradenitis	hidradenitis	PROPN
dpc-4503	137	6	suppurativa	suppurativa	PROPN
dpc-4503	137	7	severity	severity	NOUN
dpc-4503	137	8	scoring	scoring	NOUN
dpc-4503	137	9	system	system	NOUN
dpc-4503	137	10	4	4	NUM
dpc-4503	137	11	;	;	PUNCT
dpc-4503	137	12	dlqi	dlqi	ADJ
dpc-4503	137	13	=	=	PUNCT
dpc-4503	137	14	dermatology	dermatology	NOUN
dpc-4503	137	15	life	life	NOUN
dpc-4503	137	16	quality	quality	NOUN
dpc-4503	137	17	index	index	NOUN
dpc-4503	137	18	.	.	PUNCT
dpc-4503	137	19	)	)	PUNCT
dpc-4503	138	1	6	6	NUM
dpc-4503	138	2	original	original	ADJ
dpc-4503	138	3	article	article	NOUN
dpc-4503	138	4	|	|	ADV
dpc-4503	138	5	dermatol	dermatol	ADJ
dpc-4503	138	6	pract	pract	NOUN
dpc-4503	138	7	concept	concept	NOUN
dpc-4503	138	8	.	.	PUNCT
dpc-4503	139	1	2024;14(4):e2024250	2024;14(4):e2024250	NUM
dpc-4503	139	2	13	13	NUM
dpc-4503	139	3	.	.	PUNCT
dpc-4503	140	1	european	european	PROPN
dpc-4503	140	2	medicines	medicine	NOUN
dpc-4503	140	3	agency	agency	NOUN
dpc-4503	140	4	.	.	PUNCT
dpc-4503	141	1	tremfya	tremfya	PROPN
dpc-4503	141	2	(	(	PUNCT
dpc-4503	141	3	guselkumab	guselkumab	NOUN
dpc-4503	141	4	):	):	PUNCT
dpc-4503	141	5	summary	summary	NOUN
dpc-4503	141	6	of	of	ADP
dpc-4503	141	7	product	product	NOUN
dpc-4503	141	8	characteristics	characteristic	NOUN
dpc-4503	141	9	.	.	PUNCT
dpc-4503	142	1	2017	2017	NUM
dpc-4503	143	1	[	[	X
dpc-4503	143	2	cited	cite	VERB
dpc-4503	143	3	2023	2023	NUM
dpc-4503	143	4	december	december	PROPN
dpc-4503	143	5	28	28	NUM
dpc-4503	143	6	]	]	PUNCT
dpc-4503	143	7	.	.	PUNCT
dpc-4503	144	1	https://www.ema.europa.eu/en/medicines/human/epar/tremfya	https://www.ema.europa.eu/en/medicines/human/epar/tremfya	PROPN
dpc-4503	144	2	14	14	NUM
dpc-4503	144	3	.	.	PUNCT
dpc-4503	145	1	european	european	PROPN
dpc-4503	145	2	medicines	medicine	NOUN
dpc-4503	145	3	agency	agency	NOUN
dpc-4503	145	4	.	.	PUNCT
dpc-4503	146	1	skyrizi	skyrizi	PROPN
dpc-4503	146	2	(	(	PUNCT
dpc-4503	146	3	risankizumab	risankizumab	NOUN
dpc-4503	146	4	):	):	PUNCT
dpc-4503	146	5	summary	summary	NOUN
dpc-4503	146	6	of	of	ADP
dpc-4503	146	7	product	product	NOUN
dpc-4503	146	8	characteristics	characteristic	NOUN
dpc-4503	146	9	.	.	PUNCT
dpc-4503	147	1	2019	2019	NUM
dpc-4503	148	1	[	[	X
dpc-4503	148	2	cited	cite	VERB
dpc-4503	148	3	2023	2023	NUM
dpc-4503	148	4	december	december	PROPN
dpc-4503	148	5	28	28	NUM
dpc-4503	148	6	]	]	PUNCT
dpc-4503	148	7	.	.	PUNCT
dpc-4503	149	1	https://www.ema.europa.eu/en/medicines/human/epar/skyrizi	https://www.ema.europa.eu/en/medicines/human/epar/skyrizi	PROPN
dpc-4503	149	2	15	15	NUM
dpc-4503	149	3	.	.	PUNCT
dpc-4503	150	1	european	european	PROPN
dpc-4503	150	2	medicines	medicine	NOUN
dpc-4503	150	3	agency	agency	NOUN
dpc-4503	150	4	.	.	PUNCT
dpc-4503	151	1	kyntheum	kyntheum	NOUN
dpc-4503	151	2	(	(	PUNCT
dpc-4503	151	3	brodalumab	brodalumab	NOUN
dpc-4503	151	4	):	):	PUNCT
dpc-4503	151	5	summary	summary	NOUN
dpc-4503	151	6	of	of	ADP
dpc-4503	151	7	product	product	NOUN
dpc-4503	151	8	characteristics	characteristic	NOUN
dpc-4503	151	9	.	.	PUNCT
dpc-4503	151	10	2017	2017	NUM
dpc-4503	152	1	[	[	X
dpc-4503	152	2	cited	cite	VERB
dpc-4503	152	3	2023	2023	NUM
dpc-4503	152	4	december	december	PROPN
dpc-4503	152	5	28	28	NUM
dpc-4503	152	6	]	]	PUNCT
dpc-4503	152	7	.	.	PUNCT
dpc-4503	153	1	https://	https://	PROPN
dpc-4503	153	2	www.ema.europa.eu/en/medicines/human/epar/kyntheum	www.ema.europa.eu/en/medicines/human/epar/kyntheum	PROPN
dpc-4503	153	3	16	16	NUM
dpc-4503	153	4	.	.	PUNCT
dpc-4503	154	1	european	european	PROPN
dpc-4503	154	2	medicines	medicine	NOUN
dpc-4503	154	3	agency	agency	NOUN
dpc-4503	154	4	.	.	PUNCT
dpc-4503	155	1	bimzelx	bimzelx	PROPN
dpc-4503	155	2	(	(	PUNCT
dpc-4503	155	3	bimekizumab	bimekizumab	ADV
dpc-4503	155	4	):	):	PUNCT
dpc-4503	155	5	summary	summary	NOUN
dpc-4503	155	6	of	of	ADP
dpc-4503	155	7	product	product	NOUN
dpc-4503	155	8	characteristics	characteristic	NOUN
dpc-4503	155	9	.	.	PUNCT
dpc-4503	156	1	2021	2021	NUM
dpc-4503	157	1	[	[	X
dpc-4503	157	2	cited	cite	VERB
dpc-4503	157	3	2023	2023	NUM
dpc-4503	157	4	december	december	PROPN
dpc-4503	157	5	28	28	NUM
dpc-4503	157	6	]	]	PUNCT
dpc-4503	157	7	.	.	PUNCT
dpc-4503	158	1	https://www.ema.europa.eu/en/medicines/human/epar/	https://www.ema.europa.eu/en/medicines/human/epar/	PROPN
dpc-4503	158	2	bimzelx	bimzelx	PROPN
dpc-4503	158	3	17	17	NUM
dpc-4503	158	4	.	.	PUNCT
dpc-4503	159	1	kimball	kimball	PROPN
dpc-4503	159	2	ab	ab	PROPN
dpc-4503	159	3	,	,	PUNCT
dpc-4503	159	4	sobell	sobell	PROPN
dpc-4503	159	5	jm	jm	PROPN
dpc-4503	159	6	,	,	PUNCT
dpc-4503	159	7	zouboulis	zouboulis	PROPN
dpc-4503	159	8	cc	cc	PROPN
dpc-4503	159	9	,	,	PUNCT
dpc-4503	159	10	et	et	PROPN
dpc-4503	159	11	al	al	PROPN
dpc-4503	159	12	.	.	PUNCT
dpc-4503	160	1	hiscr	hiscr	PROPN
dpc-4503	160	2	(	(	PUNCT
dpc-4503	160	3	hidradenitis	hidradenitis	NOUN
dpc-4503	160	4	suppurativa	suppurativa	PROPN
dpc-4503	160	5	clinical	clinical	ADJ
dpc-4503	160	6	response	response	NOUN
dpc-4503	160	7	):	):	PUNCT
dpc-4503	160	8	a	a	DET
dpc-4503	160	9	novel	novel	ADJ
dpc-4503	160	10	clinical	clinical	ADJ
dpc-4503	160	11	endpoint	endpoint	NOUN
dpc-4503	160	12	to	to	PART
dpc-4503	160	13	evaluate	evaluate	VERB
dpc-4503	160	14	therapeutic	therapeutic	ADJ
dpc-4503	160	15	outcomes	outcome	NOUN
dpc-4503	160	16	in	in	ADP
dpc-4503	160	17	patients	patient	NOUN
dpc-4503	160	18	with	with	ADP
dpc-4503	160	19	hidradenitis	hidradenitis	PROPN
dpc-4503	160	20	suppurativa	suppurativa	NOUN
dpc-4503	160	21	from	from	ADP
dpc-4503	160	22	the	the	DET
dpc-4503	160	23	placebo	placebo	NOUN
dpc-4503	160	24	-	-	PUNCT
dpc-4503	160	25	controlled	control	VERB
dpc-4503	160	26	portion	portion	NOUN
dpc-4503	160	27	of	of	ADP
dpc-4503	160	28	a	a	DET
dpc-4503	160	29	phase	phase	NOUN
dpc-4503	160	30	2	2	NUM
dpc-4503	160	31	adalimumab	adalimumab	NOUN
dpc-4503	160	32	study	study	NOUN
dpc-4503	160	33	.	.	PUNCT
dpc-4503	160	34	 	 	SPACE
dpc-4503	161	1	j	j	PROPN
dpc-4503	161	2	eur	eur	PROPN
dpc-4503	161	3	acad	acad	PROPN
dpc-4503	161	4	dermatol	dermatol	NOUN
dpc-4503	161	5	venereol	venereol	NOUN
dpc-4503	161	6	.	.	PUNCT
dpc-4503	162	1	2016;30(6	2016;30(6	VERB
dpc-4503	162	2	):	):	PUNCT
dpc-4503	162	3	989	989	NUM
dpc-4503	162	4	-	-	SYM
dpc-4503	162	5	994	994	NUM
dpc-4503	162	6	.	.	PUNCT
dpc-4503	163	1	doi:10.1111	doi:10.1111	ADJ
dpc-4503	163	2	/	/	SYM
dpc-4503	163	3	jdv.13216	jdv.13216	PROPN
dpc-4503	163	4	18	18	NUM
dpc-4503	163	5	.	.	PROPN
dpc-4503	163	6	tzellos	tzellos	ADP
dpc-4503	163	7	t	t	PROPN
dpc-4503	163	8	,	,	PUNCT
dpc-4503	163	9	van	van	PROPN
dpc-4503	163	10	straalen	straalen	ADJ
dpc-4503	163	11	kr	kr	PROPN
dpc-4503	163	12	,	,	PUNCT
dpc-4503	163	13	kyrgidis	kyrgidi	VERB
dpc-4503	163	14	a	a	PRON
dpc-4503	163	15	,	,	PUNCT
dpc-4503	163	16	et	et	PROPN
dpc-4503	163	17	al	al	PROPN
dpc-4503	163	18	.	.	PROPN
dpc-4503	163	19	development	development	PROPN
dpc-4503	163	20	and	and	CCONJ
dpc-4503	163	21	validation	validation	NOUN
dpc-4503	163	22	of	of	ADP
dpc-4503	163	23	ihs4	ihs4	PROPN
dpc-4503	163	24	-	-	PUNCT
dpc-4503	163	25	55	55	NUM
dpc-4503	163	26	,	,	PUNCT
dpc-4503	163	27	an	an	DET
dpc-4503	163	28	ihs4	ihs4	PROPN
dpc-4503	163	29	dichotomous	dichotomous	ADJ
dpc-4503	163	30	outcome	outcome	NOUN
dpc-4503	163	31	to	to	PART
dpc-4503	163	32	assess	assess	VERB
dpc-4503	163	33	treatment	treatment	NOUN
dpc-4503	163	34	effect	effect	NOUN
dpc-4503	163	35	for	for	ADP
dpc-4503	163	36	hidradenitis	hidradenitis	PROPN
dpc-4503	163	37	suppurativa	suppurativa	PROPN
dpc-4503	163	38	.	.	PUNCT
dpc-4503	163	39	 	 	SPACE
dpc-4503	164	1	j	j	PROPN
dpc-4503	164	2	eur	eur	PROPN
dpc-4503	164	3	acad	acad	PROPN
dpc-4503	164	4	dermatol	dermatol	NOUN
dpc-4503	164	5	venereol	venereol	NOUN
dpc-4503	164	6	.	.	PUNCT
dpc-4503	165	1	2023;37(2):395	2023;37(2):395	PROPN
dpc-4503	165	2	-	-	SYM
dpc-4503	165	3	401	401	NUM
dpc-4503	165	4	.	.	PUNCT
dpc-4503	166	1	doi:10.1111	doi:10.1111	PROPN
dpc-4503	166	2	/	/	SYM
dpc-4503	166	3	jdv.18632	jdv.18632	PROPN
dpc-4503	166	4	19	19	NUM
dpc-4503	166	5	.	.	PUNCT
dpc-4503	167	1	malvaso	malvaso	PROPN
dpc-4503	167	2	d	d	NOUN
dpc-4503	167	3	,	,	PUNCT
dpc-4503	167	4	calabrese	calabrese	ADJ
dpc-4503	167	5	l	l	NOUN
dpc-4503	167	6	,	,	PUNCT
dpc-4503	167	7	chiricozzi	chiricozzi	NOUN
dpc-4503	167	8	a	a	NOUN
dpc-4503	167	9	,	,	PUNCT
dpc-4503	167	10	et	et	PROPN
dpc-4503	167	11	al	al	PROPN
dpc-4503	167	12	.	.	PROPN
dpc-4503	167	13	il-17	il-17	AUX
dpc-4503	167	14	inhibition	inhibition	NOUN
dpc-4503	167	15	:	:	PUNCT
dpc-4503	167	16	a	a	DET
dpc-4503	167	17	valid	valid	ADJ
dpc-4503	167	18	therapeutic	therapeutic	ADJ
dpc-4503	167	19	strategy	strategy	NOUN
dpc-4503	167	20	in	in	ADP
dpc-4503	167	21	the	the	DET
dpc-4503	167	22	management	management	NOUN
dpc-4503	167	23	of	of	ADP
dpc-4503	167	24	hidradenitis	hidradenitis	PROPN
dpc-4503	167	25	suppurativa	suppurativa	PROPN
dpc-4503	167	26	.	.	PUNCT
dpc-4503	167	27	 	 	SPACE
dpc-4503	167	28	pharmaceutics	pharmaceutic	NOUN
dpc-4503	167	29	.	.	PUNCT
dpc-4503	168	1	2023;15(10):2450	2023;15(10):2450	X
dpc-4503	168	2	.	.	PUNCT
dpc-4503	168	3	published	publish	VERB
dpc-4503	168	4	2023	2023	NUM
dpc-4503	168	5	oct	oct	NOUN
dpc-4503	168	6	11	11	NUM
dpc-4503	168	7	.	.	PUNCT
dpc-4503	169	1	doi:10.3390	doi:10.3390	NOUN
dpc-4503	169	2	/	/	SYM
dpc-4503	169	3	pharmaceutics15102450	pharmaceutics15102450	NOUN
dpc-4503	169	4	20	20	NUM
dpc-4503	169	5	.	.	PUNCT
dpc-4503	170	1	ribero	ribero	PROPN
dpc-4503	170	2	s	s	PROPN
dpc-4503	170	3	,	,	PUNCT
dpc-4503	170	4	ramondetta	ramondetta	VERB
dpc-4503	170	5	a	a	DET
dpc-4503	170	6	,	,	PUNCT
dpc-4503	170	7	fabbrocini	fabbrocini	NOUN
dpc-4503	170	8	g	g	NOUN
dpc-4503	170	9	,	,	PUNCT
dpc-4503	170	10	et	et	PROPN
dpc-4503	170	11	al	al	PROPN
dpc-4503	170	12	.	.	PROPN
dpc-4503	170	13	effectiveness	effectiveness	NOUN
dpc-4503	170	14	of	of	ADP
dpc-4503	170	15	secukinumab	secukinumab	NOUN
dpc-4503	170	16	in	in	ADP
dpc-4503	170	17	the	the	DET
dpc-4503	170	18	treatment	treatment	NOUN
dpc-4503	170	19	of	of	ADP
dpc-4503	170	20	moderate	moderate	ADJ
dpc-4503	170	21	-	-	PUNCT
dpc-4503	170	22	severe	severe	ADJ
dpc-4503	170	23	hidradenitis	hidradenitis	NOUN
dpc-4503	170	24	suppurativa	suppurativa	NOUN
dpc-4503	170	25	:	:	PUNCT
dpc-4503	170	26	results	result	VERB
dpc-4503	170	27	from	from	ADP
dpc-4503	170	28	an	an	DET
dpc-4503	170	29	italian	italian	ADJ
dpc-4503	170	30	multicentric	multicentric	ADJ
dpc-4503	170	31	retrospective	retrospective	ADJ
dpc-4503	170	32	study	study	NOUN
dpc-4503	170	33	in	in	ADP
dpc-4503	170	34	a	a	DET
dpc-4503	170	35	real	real	ADJ
dpc-4503	170	36	-	-	PUNCT
dpc-4503	170	37	life	life	NOUN
dpc-4503	170	38	setting	setting	NOUN
dpc-4503	170	39	.	.	PUNCT
dpc-4503	170	40	 	 	SPACE
dpc-4503	171	1	j	j	PROPN
dpc-4503	171	2	eur	eur	PROPN
dpc-4503	171	3	acad	acad	PROPN
dpc-4503	171	4	dermatol	dermatol	NOUN
dpc-4503	171	5	venereol	venereol	NOUN
dpc-4503	171	6	.	.	PUNCT
dpc-4503	172	1	2021;35(7):e441	2021;35(7):e441	AUX
dpc-4503	172	2	-	-	PUNCT
dpc-4503	172	3	e442	e442	PROPN
dpc-4503	172	4	.	.	PUNCT
dpc-4503	173	1	doi:10.1111	doi:10.1111	PROPN
dpc-4503	173	2	/	/	SYM
dpc-4503	173	3	jdv.17178	jdv.17178	PRON
dpc-4503	173	4	21	21	NUM
dpc-4503	173	5	.	.	PUNCT
dpc-4503	174	1	fernandez	fernandez	NOUN
dpc-4503	174	2	-	-	PUNCT
dpc-4503	174	3	crehuet	crehuet	NOUN
dpc-4503	174	4	p	p	NOUN
dpc-4503	174	5	,	,	PUNCT
dpc-4503	174	6	haselgruber	haselgruber	PROPN
dpc-4503	174	7	s	s	PROPN
dpc-4503	174	8	,	,	PUNCT
dpc-4503	174	9	padial	padial	ADJ
dpc-4503	174	10	-	-	PUNCT
dpc-4503	174	11	gomez	gomez	NOUN
dpc-4503	174	12	a	a	PROPN
dpc-4503	174	13	et	et	PROPN
dpc-4503	174	14	al	al	PROPN
dpc-4503	174	15	.	.	PUNCT
dpc-4503	175	1	short	short	ADJ
dpc-4503	175	2	-	-	PUNCT
dpc-4503	175	3	term	term	NOUN
dpc-4503	175	4	effectiveness	effectiveness	NOUN
dpc-4503	175	5	,	,	PUNCT
dpc-4503	175	6	safety	safety	NOUN
dpc-4503	175	7	,	,	PUNCT
dpc-4503	175	8	and	and	CCONJ
dpc-4503	175	9	potential	potential	ADJ
dpc-4503	175	10	predictors	predictor	NOUN
dpc-4503	175	11	of	of	ADP
dpc-4503	175	12	response	response	NOUN
dpc-4503	175	13	of	of	ADP
dpc-4503	175	14	secukinumab	secukinumab	NOUN
dpc-4503	175	15	in	in	ADP
dpc-4503	175	16	patients	patient	NOUN
dpc-4503	175	17	with	with	ADP
dpc-4503	175	18	severe	severe	ADJ
dpc-4503	175	19	hidradenitis	hidradenitis	PROPN
dpc-4503	175	20	suppurativa	suppurativa	PROPN
dpc-4503	175	21	refractory	refractory	NOUN
dpc-4503	175	22	to	to	ADP
dpc-4503	175	23	biologic	biologic	NOUN
dpc-4503	175	24	therapy	therapy	NOUN
dpc-4503	175	25	:	:	PUNCT
dpc-4503	175	26	a	a	DET
dpc-4503	175	27	multicenter	multicenter	ADJ
dpc-4503	175	28	observational	observational	ADJ
dpc-4503	175	29	retrospective	retrospective	ADJ
dpc-4503	175	30	study	study	NOUN
dpc-4503	175	31	.	.	PUNCT
dpc-4503	176	1	dermatol	dermatol	NOUN
dpc-4503	176	2	ther	ther	ADV
dpc-4503	176	3	(	(	PUNCT
dpc-4503	176	4	heidelb	heidelb	NOUN
dpc-4503	176	5	)	)	PUNCT
dpc-4503	176	6	.	.	PUNCT
dpc-4503	177	1	2023	2023	NUM
dpc-4503	177	2	apr;13(4):1029	apr;13(4):1029	PROPN
dpc-4503	177	3	-	-	PUNCT
dpc-4503	177	4	1038	1038	NUM
dpc-4503	177	5	.	.	PUNCT
dpc-4503	178	1	doi	doi	NOUN
dpc-4503	178	2	:	:	PUNCT
dpc-4503	178	3	10.1007	10.1007	NUM
dpc-4503	178	4	/	/	SYM
dpc-4503	178	5	s13555	s13555	PROPN
dpc-4503	178	6	-	-	PUNCT
dpc-4503	178	7	023	023	NUM
dpc-4503	178	8	-	-	PUNCT
dpc-4503	178	9	00906	00906	NUM
dpc-4503	178	10	-	-	SYM
dpc-4503	178	11	2	2	NUM
dpc-4503	178	12	22	22	NUM
dpc-4503	178	13	.	.	PUNCT
dpc-4503	179	1	european	european	PROPN
dpc-4503	179	2	medicines	medicine	NOUN
dpc-4503	179	3	agency	agency	NOUN
dpc-4503	179	4	.	.	PUNCT
dpc-4503	180	1	cosentyx	cosentyx	PROPN
dpc-4503	180	2	(	(	PUNCT
dpc-4503	180	3	secukinumab	secukinumab	NOUN
dpc-4503	180	4	):	):	PUNCT
dpc-4503	180	5	summary	summary	NOUN
dpc-4503	180	6	of	of	ADP
dpc-4503	180	7	product	product	NOUN
dpc-4503	180	8	characteristics	characteristic	NOUN
dpc-4503	180	9	.	.	PUNCT
dpc-4503	181	1	2014	2014	NUM
dpc-4503	182	1	[	[	X
dpc-4503	182	2	cited	cite	VERB
dpc-4503	182	3	2023	2023	NUM
dpc-4503	182	4	december	december	PROPN
dpc-4503	182	5	28	28	NUM
dpc-4503	182	6	]	]	PUNCT
dpc-4503	182	7	.	.	PUNCT
dpc-4503	183	1	https://www.ema.europa.eu/en/medicines/human/epar/cosentyx	https://www.ema.europa.eu/en/medicines/human/epar/cosentyx	NOUN
dpc-4503	183	2	23	23	NUM
dpc-4503	183	3	.	.	PUNCT
dpc-4503	184	1	esme	esme	PROPN
dpc-4503	184	2	p	p	PROPN
dpc-4503	184	3	,	,	PUNCT
dpc-4503	184	4	botsali	botsali	PROPN
dpc-4503	184	5	a	a	PRON
dpc-4503	184	6	,	,	PUNCT
dpc-4503	184	7	akoglu	akoglu	PROPN
dpc-4503	184	8	g	g	PROPN
dpc-4503	184	9	,	,	PUNCT
dpc-4503	184	10	caliskan	caliskan	PROPN
dpc-4503	184	11	e.	e.	PROPN
dpc-4503	185	1	an	an	DET
dpc-4503	185	2	antiinterleukin17a	antiinterleukin17a	PROPN
dpc-4503	185	3	monoclonal	monoclonal	NOUN
dpc-4503	185	4	antibody	antibody	NOUN
dpc-4503	185	5	,	,	PUNCT
dpc-4503	185	6	ixekizumab	ixekizumab	NOUN
dpc-4503	185	7	,	,	PUNCT
dpc-4503	185	8	in	in	ADP
dpc-4503	185	9	the	the	DET
dpc-4503	185	10	treatment	treatment	NOUN
dpc-4503	185	11	of	of	ADP
dpc-4503	185	12	resistant	resistant	ADJ
dpc-4503	185	13	hidradenitis	hidradenitis	NOUN
dpc-4503	185	14	suppurativa	suppurativa	NOUN
dpc-4503	185	15	:	:	PUNCT
dpc-4503	185	16	a	a	DET
dpc-4503	185	17	case	case	NOUN
dpc-4503	185	18	series	series	NOUN
dpc-4503	185	19	.	.	PUNCT
dpc-4503	185	20	 	 	SPACE
dpc-4503	185	21	skin	skin	NOUN
dpc-4503	185	22	appendage	appendage	NOUN
dpc-4503	185	23	disord	disord	NOUN
dpc-4503	185	24	.	.	PUNCT
dpc-4503	186	1	2022;8(4):342	2022;8(4):342	NUM
dpc-4503	186	2	-	-	SYM
dpc-4503	186	3	345	345	NUM
dpc-4503	186	4	.	.	PUNCT
dpc-4503	187	1	doi:10.1159/000521860	doi:10.1159/000521860	NOUN
dpc-4503	187	2	24	24	NUM
dpc-4503	187	3	.	.	PUNCT
dpc-4503	188	1	kearney	kearney	PROPN
dpc-4503	188	2	n	n	PROPN
dpc-4503	188	3	,	,	PUNCT
dpc-4503	188	4	hughes	hughes	PROPN
dpc-4503	188	5	r	r	PROPN
dpc-4503	188	6	,	,	PUNCT
dpc-4503	188	7	kirby	kirby	PROPN
dpc-4503	188	8	b.	b.	PROPN
dpc-4503	188	9	treatment	treatment	NOUN
dpc-4503	188	10	of	of	ADP
dpc-4503	188	11	hidradenitis	hidradenitis	PROPN
dpc-4503	188	12	suppurativa	suppurativa	NOUN
dpc-4503	188	13	with	with	ADP
dpc-4503	188	14	brodalumab	brodalumab	NOUN
dpc-4503	188	15	in	in	ADP
dpc-4503	188	16	 	 	SPACE
dpc-4503	188	17	biologic	biologic	NOUN
dpc-4503	188	18	treatment	treatment	NOUN
dpc-4503	188	19	failures	failure	NOUN
dpc-4503	188	20	:	:	PUNCT
dpc-4503	188	21	experiences	experience	NOUN
dpc-4503	188	22	from	from	ADP
dpc-4503	188	23	a	a	DET
dpc-4503	188	24	specialty	specialty	NOUN
dpc-4503	188	25	 	 	SPACE
dpc-4503	188	26	clinic	clinic	NOUN
dpc-4503	188	27	.	.	PUNCT
dpc-4503	188	28	 	 	SPACE
dpc-4503	189	1	clin	clin	PROPN
dpc-4503	189	2	exp	exp	NOUN
dpc-4503	189	3	dermatol	dermatol	NOUN
dpc-4503	189	4	.	.	PUNCT
dpc-4503	190	1	2023;48(7):790	2023;48(7):790	VERB
dpc-4503	190	2	-	-	SYM
dpc-4503	190	3	792	792	NUM
dpc-4503	190	4	.	.	PUNCT
dpc-4503	191	1	doi:10.1093	doi:10.1093	NOUN
dpc-4503	191	2	/	/	SYM
dpc-4503	191	3	ced	ced	PROPN
dpc-4503	191	4	/	/	SYM
dpc-4503	191	5	llad130	llad130	PROPN
dpc-4503	191	6	25	25	NUM
dpc-4503	191	7	.	.	PUNCT
dpc-4503	192	1	navrazhina	navrazhina	PROPN
dpc-4503	192	2	k	k	PROPN
dpc-4503	192	3	,	,	PUNCT
dpc-4503	192	4	frew	frew	PROPN
dpc-4503	192	5	jw	jw	PROPN
dpc-4503	192	6	,	,	PUNCT
dpc-4503	192	7	grand	grand	PROPN
dpc-4503	192	8	d	d	PROPN
dpc-4503	192	9	et	et	PROPN
dpc-4503	192	10	al	al	PROPN
dpc-4503	192	11	.	.	PROPN
dpc-4503	193	1	interleukin-17ra	interleukin-17ra	PROPN
dpc-4503	193	2	blockade	blockade	NOUN
dpc-4503	193	3	by	by	ADP
dpc-4503	193	4	brodalumab	brodalumab	NOUN
dpc-4503	193	5	decreases	decrease	NOUN
dpc-4503	193	6	inflammatory	inflammatory	ADJ
dpc-4503	193	7	pathways	pathway	NOUN
dpc-4503	193	8	in	in	ADP
dpc-4503	193	9	hidradenitis	hidradenitis	PROPN
dpc-4503	193	10	suppurativa	suppurativa	PROPN
dpc-4503	193	11	skin	skin	NOUN
dpc-4503	193	12	and	and	CCONJ
dpc-4503	193	13	serum	serum	NOUN
dpc-4503	193	14	.	.	PUNCT
dpc-4503	194	1	br	br	PROPN
dpc-4503	194	2	j	j	PROPN
dpc-4503	194	3	dermatol	dermatol	NOUN
dpc-4503	194	4	.	.	PUNCT
dpc-4503	195	1	2022	2022	NUM
dpc-4503	195	2	aug;187(2):223	aug;187(2):223	NOUN
dpc-4503	195	3	-	-	PUNCT
dpc-4503	195	4	233	233	NUM
dpc-4503	195	5	.	.	PUNCT
dpc-4503	196	1	doi	doi	NOUN
dpc-4503	196	2	:	:	PUNCT
dpc-4503	196	3	10.1111	10.1111	NUM
dpc-4503	196	4	/	/	SYM
dpc-4503	196	5	bjd.21060	bjd.21060	NOUN
dpc-4503	196	6	.	.	PUNCT
dpc-4503	197	1	26	26	NUM
dpc-4503	197	2	.	.	PUNCT
dpc-4503	197	3	frew	frew	PROPN
dpc-4503	197	4	jw	jw	PROPN
dpc-4503	197	5	,	,	PUNCT
dpc-4503	197	6	grand	grand	PROPN
dpc-4503	197	7	d	d	PROPN
dpc-4503	197	8	,	,	PUNCT
dpc-4503	197	9	navrazhina	navrazhina	PROPN
dpc-4503	197	10	k	k	PROPN
dpc-4503	197	11	,	,	PUNCT
dpc-4503	197	12	garcet	garcet	PROPN
dpc-4503	197	13	s	s	PROPN
dpc-4503	197	14	,	,	PUNCT
dpc-4503	197	15	krueger	krueger	PROPN
dpc-4503	197	16	jg	jg	PROPN
dpc-4503	197	17	.	.	PUNCT
dpc-4503	198	1	assessing	assess	VERB
dpc-4503	198	2	the	the	DET
dpc-4503	198	3	responsiveness	responsiveness	NOUN
dpc-4503	198	4	of	of	ADP
dpc-4503	198	5	sonographic	sonographic	ADJ
dpc-4503	198	6	biomarkers	biomarker	NOUN
dpc-4503	198	7	to	to	ADP
dpc-4503	198	8	brodalumab	brodalumab	NOUN
dpc-4503	198	9	therapy	therapy	NOUN
dpc-4503	198	10	in	in	ADP
dpc-4503	198	11	hidradenitis	hidradenitis	PROPN
dpc-4503	198	12	suppurativa	suppurativa	PROPN
dpc-4503	198	13	.	.	PUNCT
dpc-4503	199	1	j	j	PROPN
dpc-4503	199	2	eur	eur	PROPN
dpc-4503	199	3	acad	acad	PROPN
dpc-4503	199	4	dermatol	dermatol	NOUN
dpc-4503	199	5	venereol	venereol	NOUN
dpc-4503	199	6	.	.	PUNCT
dpc-4503	200	1	2021	2021	NUM
dpc-4503	200	2	dec;35(12):e884	dec;35(12):e884	NOUN
dpc-4503	200	3	-	-	PUNCT
dpc-4503	200	4	e887	e887	PROPN
dpc-4503	200	5	.	.	PROPN
dpc-4503	200	6	27	27	NUM
dpc-4503	200	7	.	.	PUNCT
dpc-4503	201	1	glatt	glatt	PROPN
dpc-4503	201	2	s	s	PROPN
dpc-4503	201	3	,	,	PUNCT
dpc-4503	201	4	  	  	SPACE
dpc-4503	201	5	jemec	jemec	PROPN
dpc-4503	201	6	gbe	gbe	PROPN
dpc-4503	201	7	,	,	PUNCT
dpc-4503	201	8	  	  	SPACE
dpc-4503	201	9	forman	forman	NOUN
dpc-4503	201	10	s	s	PROPN
dpc-4503	201	11	,	,	PUNCT
dpc-4503	201	12	et	et	PROPN
dpc-4503	201	13	al	al	PROPN
dpc-4503	201	14	.	.	PROPN
dpc-4503	201	15	efficacy	efficacy	NOUN
dpc-4503	201	16	and	and	CCONJ
dpc-4503	201	17	safety	safety	NOUN
dpc-4503	201	18	of	of	ADP
dpc-4503	201	19	bimekizumab	bimekizumab	NOUN
dpc-4503	201	20	in	in	ADP
dpc-4503	201	21	moderate	moderate	ADJ
dpc-4503	201	22	to	to	ADP
dpc-4503	201	23	severe	severe	ADJ
dpc-4503	201	24	hidradenitis	hidradenitis	NOUN
dpc-4503	201	25	suppurativa	suppurativa	NOUN
dpc-4503	201	26	:	:	PUNCT
dpc-4503	201	27	 	 	SPACE
dpc-4503	201	28	a	a	DET
dpc-4503	201	29	phase	phase	NOUN
dpc-4503	201	30	2	2	NUM
dpc-4503	201	31	,	,	PUNCT
dpc-4503	201	32	double	double	ADJ
dpc-4503	201	33	-	-	PUNCT
dpc-4503	201	34	blind	blind	ADJ
dpc-4503	201	35	,	,	PUNCT
dpc-4503	201	36	placebo	placebo	NOUN
dpc-4503	201	37	-	-	PUNCT
dpc-4503	201	38	controlled	control	VERB
dpc-4503	201	39	randomized	randomize	VERB
dpc-4503	201	40	clinical	clinical	ADJ
dpc-4503	201	41	drugs	drug	NOUN
dpc-4503	201	42	in	in	ADP
dpc-4503	201	43	hs	hs	PROPN
dpc-4503	201	44	,	,	PUNCT
dpc-4503	201	45	our	our	PRON
dpc-4503	201	46	preliminary	preliminary	ADJ
dpc-4503	201	47	report	report	NOUN
dpc-4503	201	48	might	might	AUX
dpc-4503	201	49	be	be	AUX
dpc-4503	201	50	useful	useful	ADJ
dpc-4503	201	51	for	for	SCONJ
dpc-4503	201	52	our	our	PRON
dpc-4503	201	53	colleagues	colleague	NOUN
dpc-4503	201	54	approaching	approach	VERB
dpc-4503	201	55	these	these	DET
dpc-4503	201	56	new	new	ADJ
dpc-4503	201	57	treatment	treatment	NOUN
dpc-4503	201	58	options	option	NOUN
dpc-4503	201	59	.	.	PUNCT
dpc-4503	202	1	longer	long	ADJ
dpc-4503	202	2	and	and	CCONJ
dpc-4503	202	3	larger	large	ADJ
dpc-4503	202	4	studies	study	NOUN
dpc-4503	202	5	are	be	AUX
dpc-4503	202	6	needed	need	VERB
dpc-4503	202	7	to	to	PART
dpc-4503	202	8	further	far	ADV
dpc-4503	202	9	evaluate	evaluate	VERB
dpc-4503	202	10	the	the	DET
dpc-4503	202	11	effectiveness	effectiveness	NOUN
dpc-4503	202	12	and	and	CCONJ
dpc-4503	202	13	safety	safety	NOUN
dpc-4503	202	14	profile	profile	NOUN
dpc-4503	202	15	of	of	ADP
dpc-4503	202	16	these	these	DET
dpc-4503	202	17	molecules	molecule	NOUN
dpc-4503	202	18	in	in	ADP
dpc-4503	202	19	the	the	DET
dpc-4503	202	20	treatment	treatment	NOUN
dpc-4503	202	21	of	of	ADP
dpc-4503	202	22	hs	hs	PROPN
dpc-4503	202	23	.	.	PROPN
dpc-4503	202	24	references	reference	NOUN
dpc-4503	202	25	1	1	NUM
dpc-4503	202	26	.	.	PUNCT
dpc-4503	203	1	bukvić	bukvić	PROPN
dpc-4503	203	2	mokos	mokos	PROPN
dpc-4503	203	3	z	z	PROPN
dpc-4503	203	4	,	,	PUNCT
dpc-4503	203	5	markota	markota	PROPN
dpc-4503	203	6	čagalj	čagalj	PROPN
dpc-4503	203	7	a	a	PROPN
dpc-4503	203	8	,	,	PUNCT
dpc-4503	203	9	marinović	marinović	NOUN
dpc-4503	203	10	b.	b.	PROPN
dpc-4503	203	11	epidemiology	epidemiology	PROPN
dpc-4503	203	12	of	of	ADP
dpc-4503	203	13	hidradenitis	hidradenitis	PROPN
dpc-4503	203	14	suppurativa	suppurativa	PROPN
dpc-4503	203	15	.	.	PUNCT
dpc-4503	203	16	  	  	SPACE
dpc-4503	203	17	clin	clin	PROPN
dpc-4503	203	18	dermatol	dermatol	NOUN
dpc-4503	203	19	.	.	PUNCT
dpc-4503	204	1	2023;41(5	2023;41(5	NUM
dpc-4503	204	2	):	):	PUNCT
dpc-4503	204	3	564	564	NUM
dpc-4503	204	4	-	-	SYM
dpc-4503	204	5	575	575	NUM
dpc-4503	204	6	.	.	PUNCT
dpc-4503	205	1	doi:10.1016	doi:10.1016	PROPN
dpc-4503	205	2	/	/	SYM
dpc-4503	205	3	j.clindermatol.2023.08.020	j.clindermatol.2023.08.020	PROPN
dpc-4503	205	4	2	2	NUM
dpc-4503	205	5	.	.	PUNCT
dpc-4503	205	6	canoui	canoui	ADJ
dpc-4503	205	7	-	-	PUNCT
dpc-4503	205	8	poitrine	poitrine	NOUN
dpc-4503	205	9	f	f	PROPN
dpc-4503	205	10	,	,	PUNCT
dpc-4503	205	11	le	le	X
dpc-4503	205	12	thuaut	thuaut	PROPN
dpc-4503	205	13	a	a	PRON
dpc-4503	205	14	,	,	PUNCT
dpc-4503	205	15	revuz	revuz	PROPN
dpc-4503	205	16	je	je	PROPN
dpc-4503	205	17	,	,	PUNCT
dpc-4503	205	18	et	et	PROPN
dpc-4503	205	19	al	al	PROPN
dpc-4503	205	20	.	.	PUNCT
dpc-4503	206	1	identification	identification	NOUN
dpc-4503	206	2	of	of	ADP
dpc-4503	206	3	three	three	NUM
dpc-4503	206	4	hidradenitis	hidradenitis	PROPN
dpc-4503	206	5	suppurativa	suppurativa	NOUN
dpc-4503	206	6	phenotypes	phenotype	NOUN
dpc-4503	206	7	:	:	PUNCT
dpc-4503	206	8	latent	latent	NOUN
dpc-4503	206	9	class	class	NOUN
dpc-4503	206	10	analysis	analysis	NOUN
dpc-4503	206	11	of	of	ADP
dpc-4503	206	12	a	a	DET
dpc-4503	206	13	cross	cross	ADJ
dpc-4503	206	14	-	-	ADJ
dpc-4503	206	15	sectional	sectional	ADJ
dpc-4503	206	16	study	study	NOUN
dpc-4503	206	17	.	.	PUNCT
dpc-4503	206	18	 	 	SPACE
dpc-4503	207	1	j	j	PROPN
dpc-4503	207	2	invest	invest	VERB
dpc-4503	207	3	dermatol	dermatol	NOUN
dpc-4503	207	4	.	.	PUNCT
dpc-4503	208	1	2013;133(6	2013;133(6	NUM
dpc-4503	208	2	):	):	PUNCT
dpc-4503	208	3	1506	1506	NUM
dpc-4503	208	4	-	-	SYM
dpc-4503	208	5	1511	1511	NUM
dpc-4503	208	6	.	.	PUNCT
dpc-4503	209	1	doi:10.1038	doi:10.1038	NOUN
dpc-4503	209	2	/	/	SYM
dpc-4503	209	3	jid.2012.472	jid.2012.472	PROPN
dpc-4503	209	4	3	3	NUM
dpc-4503	209	5	.	.	PUNCT
dpc-4503	209	6	navrazhina	navrazhina	PROPN
dpc-4503	209	7	k	k	PROPN
dpc-4503	209	8	,	,	PUNCT
dpc-4503	209	9	renert	renert	NOUN
dpc-4503	209	10	-	-	PUNCT
dpc-4503	209	11	yuval	yuval	PROPN
dpc-4503	209	12	y	y	PROPN
dpc-4503	209	13	,	,	PUNCT
dpc-4503	209	14	khattri	khattri	PROPN
dpc-4503	209	15	s	s	PROPN
dpc-4503	209	16	,	,	PUNCT
dpc-4503	209	17	et	et	PROPN
dpc-4503	209	18	al	al	PROPN
dpc-4503	209	19	.	.	PUNCT
dpc-4503	209	20	tape	tape	NOUN
dpc-4503	209	21	strips	strip	NOUN
dpc-4503	209	22	detect	detect	VERB
dpc-4503	209	23	molecular	molecular	ADJ
dpc-4503	209	24	alterations	alteration	NOUN
dpc-4503	209	25	and	and	CCONJ
dpc-4503	209	26	cutaneous	cutaneous	ADJ
dpc-4503	209	27	biomarkers	biomarker	NOUN
dpc-4503	209	28	in	in	ADP
dpc-4503	209	29	skin	skin	NOUN
dpc-4503	209	30	of	of	ADP
dpc-4503	209	31	patients	patient	NOUN
dpc-4503	209	32	with	with	ADP
dpc-4503	209	33	hidradenitis	hidradenitis	PROPN
dpc-4503	209	34	suppurativa	suppurativa	PROPN
dpc-4503	209	35	.	.	PUNCT
dpc-4503	209	36	 	 	SPACE
dpc-4503	210	1	j	j	PROPN
dpc-4503	210	2	am	be	AUX
dpc-4503	210	3	acad	acad	ADJ
dpc-4503	210	4	dermatol	dermatol	NOUN
dpc-4503	210	5	.	.	PUNCT
dpc-4503	211	1	published	publish	VERB
dpc-4503	211	2	online	online	ADJ
dpc-4503	211	3	december	december	PROPN
dpc-4503	211	4	3	3	NUM
dpc-4503	211	5	,	,	PUNCT
dpc-4503	211	6	2023	2023	NUM
dpc-4503	211	7	.	.	PUNCT
dpc-4503	212	1	doi:10.1016	doi:10.1016	PROPN
dpc-4503	212	2	/	/	SYM
dpc-4503	212	3	j.jaad.2023	j.jaad.2023	PROPN
dpc-4503	212	4	.11.048	.11.048	PUNCT
dpc-4503	212	5	4	4	X
dpc-4503	212	6	.	.	X
dpc-4503	213	1	maronese	maronese	PROPN
dpc-4503	213	2	ca	can	AUX
dpc-4503	213	3	,	,	PUNCT
dpc-4503	213	4	moltrasio	moltrasio	PROPN
dpc-4503	213	5	c	c	NOUN
dpc-4503	213	6	,	,	PUNCT
dpc-4503	213	7	genovese	genovese	NOUN
dpc-4503	213	8	g	g	NOUN
dpc-4503	213	9	,	,	PUNCT
dpc-4503	214	1	marzano	marzano	PROPN
dpc-4503	214	2	av	av	PROPN
dpc-4503	214	3	.	.	PUNCT
dpc-4503	214	4	biologics	biologic	NOUN
dpc-4503	214	5	for	for	ADP
dpc-4503	214	6	hidradenitis	hidradenitis	PROPN
dpc-4503	214	7	suppurativa	suppurativa	NOUN
dpc-4503	214	8	:	:	PUNCT
dpc-4503	214	9	evolution	evolution	NOUN
dpc-4503	214	10	of	of	ADP
dpc-4503	214	11	the	the	DET
dpc-4503	214	12	treatment	treatment	NOUN
dpc-4503	214	13	paradigm	paradigm	NOUN
dpc-4503	214	14	.	.	PUNCT
dpc-4503	214	15	 	 	SPACE
dpc-4503	215	1	expert	expert	NOUN
dpc-4503	215	2	rev	rev	VERB
dpc-4503	215	3	clin	clin	PROPN
dpc-4503	215	4	immunol	immunol	PROPN
dpc-4503	215	5	.	.	PUNCT
dpc-4503	216	1	published	publish	VERB
dpc-4503	216	2	online	online	ADV
dpc-4503	216	3	december	december	PROPN
dpc-4503	216	4	22	22	NUM
dpc-4503	216	5	,	,	PUNCT
dpc-4503	216	6	2023	2023	NUM
dpc-4503	216	7	.	.	PUNCT
dpc-4503	217	1	doi:10.1080/1744666x.2023.2298356	doi:10.1080/1744666x.2023.2298356	NOUN
dpc-4503	217	2	5	5	NUM
dpc-4503	217	3	.	.	PUNCT
dpc-4503	217	4	european	european	PROPN
dpc-4503	217	5	medicines	medicine	NOUN
dpc-4503	217	6	agency	agency	NOUN
dpc-4503	217	7	.	.	PUNCT
dpc-4503	218	1	cosentyx	cosentyx	PROPN
dpc-4503	218	2	(	(	PUNCT
dpc-4503	218	3	secukinumab	secukinumab	NOUN
dpc-4503	218	4	):	):	PUNCT
dpc-4503	218	5	summary	summary	NOUN
dpc-4503	218	6	of	of	ADP
dpc-4503	218	7	product	product	NOUN
dpc-4503	218	8	characteristics	characteristic	NOUN
dpc-4503	218	9	.	.	PUNCT
dpc-4503	219	1	2015	2015	NUM
dpc-4503	220	1	[	[	X
dpc-4503	220	2	cited	cite	VERB
dpc-4503	220	3	2023	2023	NUM
dpc-4503	220	4	december	december	PROPN
dpc-4503	220	5	28	28	NUM
dpc-4503	220	6	]	]	PUNCT
dpc-4503	220	7	.	.	PUNCT
dpc-4503	221	1	https://www.ema.europa.eu/en/medicines/human/epar/cosentyx	https://www.ema.europa.eu/en/medicines/human/epar/cosentyx	NOUN
dpc-4503	221	2	6	6	NUM
dpc-4503	221	3	.	.	PUNCT
dpc-4503	222	1	kridin	kridin	VERB
dpc-4503	222	2	k	k	PROPN
dpc-4503	222	3	,	,	PUNCT
dpc-4503	222	4	shani	shani	PROPN
dpc-4503	222	5	m	m	PROPN
dpc-4503	222	6	,	,	PUNCT
dpc-4503	222	7	schonmann	schonmann	PROPN
dpc-4503	222	8	y	y	PROPN
dpc-4503	222	9	,	,	PUNCT
dpc-4503	223	1	et	et	PROPN
dpc-4503	223	2	al	al	PROPN
dpc-4503	223	3	.	.	PUNCT
dpc-4503	223	4	psoriasis	psoriasis	NOUN
dpc-4503	223	5	and	and	CCONJ
dpc-4503	223	6	hidradenitis	hidradenitis	PROPN
dpc-4503	223	7	suppurativa	suppurativa	PROPN
dpc-4503	223	8	:	:	PUNCT
dpc-4503	223	9	a	a	DET
dpc-4503	223	10	large	large	ADJ
dpc-4503	223	11	-	-	PUNCT
dpc-4503	223	12	scale	scale	NOUN
dpc-4503	223	13	population	population	NOUN
dpc-4503	223	14	-	-	PUNCT
dpc-4503	223	15	based	base	VERB
dpc-4503	223	16	study	study	NOUN
dpc-4503	223	17	.	.	PUNCT
dpc-4503	223	18	 	 	SPACE
dpc-4503	224	1	j	j	PROPN
dpc-4503	224	2	am	be	AUX
dpc-4503	224	3	acad	acad	ADJ
dpc-4503	224	4	dermatol	dermatol	NOUN
dpc-4503	224	5	.	.	PUNCT
dpc-4503	225	1	2023;88(5):e231	2023;88(5):e231	NUM
dpc-4503	225	2	-	-	PUNCT
dpc-4503	225	3	e236	e236	PROPN
dpc-4503	225	4	.	.	PUNCT
dpc-4503	225	5	doi:10.1016	doi:10.1016	PROPN
dpc-4503	225	6	/	/	SYM
dpc-4503	225	7	j.jaad.2018.11.036	j.jaad.2018.11.036	PROPN
dpc-4503	225	8	7	7	NUM
dpc-4503	225	9	.	.	PUNCT
dpc-4503	225	10	macca	macca	PROPN
dpc-4503	225	11	l	l	PROPN
dpc-4503	225	12	,	,	PUNCT
dpc-4503	225	13	li	li	PROPN
dpc-4503	225	14	pomi	pomi	PROPN
dpc-4503	225	15	f	f	PROPN
dpc-4503	225	16	,	,	PUNCT
dpc-4503	225	17	ingrasciotta	ingrasciotta	VERB
dpc-4503	225	18	y	y	PROPN
dpc-4503	225	19	,	,	PUNCT
dpc-4503	225	20	morrone	morrone	NOUN
dpc-4503	225	21	p	p	NOUN
dpc-4503	225	22	,	,	PUNCT
dpc-4503	225	23	trifirò	trifirò	ADV
dpc-4503	225	24	g	g	NOUN
dpc-4503	225	25	,	,	PUNCT
dpc-4503	225	26	guarneri	guarneri	ADJ
dpc-4503	225	27	c.	c.	PROPN
dpc-4503	225	28	hidradenitis	hidradenitis	PROPN
dpc-4503	225	29	suppurativa	suppurativa	PROPN
dpc-4503	225	30	and	and	CCONJ
dpc-4503	225	31	psoriasis	psoriasis	NOUN
dpc-4503	225	32	:	:	PUNCT
dpc-4503	225	33	the	the	DET
dpc-4503	225	34	odd	odd	ADJ
dpc-4503	225	35	couple	couple	NOUN
dpc-4503	225	36	.	.	PUNCT
dpc-4503	225	37	 	 	SPACE
dpc-4503	226	1	front	front	ADJ
dpc-4503	226	2	med	med	PROPN
dpc-4503	226	3	(	(	PUNCT
dpc-4503	226	4	lausanne	lausanne	PROPN
dpc-4503	226	5	)	)	PUNCT
dpc-4503	226	6	.	.	PUNCT
dpc-4503	227	1	2023;10:1208817	2023;10:1208817	X
dpc-4503	227	2	.	.	PUNCT
dpc-4503	227	3	published	publish	VERB
dpc-4503	227	4	2023	2023	NUM
dpc-4503	227	5	jul	jul	PROPN
dpc-4503	227	6	7	7	NUM
dpc-4503	227	7	.	.	PUNCT
dpc-4503	227	8	doi:10.3389	doi:10.3389	PROPN
dpc-4503	227	9	/	/	SYM
dpc-4503	227	10	fmed.2023.1208817	fmed.2023.1208817	PROPN
dpc-4503	227	11	8	8	PROPN
dpc-4503	227	12	.	.	PUNCT
dpc-4503	228	1	kimball	kimball	PROPN
dpc-4503	228	2	ab	ab	PROPN
dpc-4503	228	3	,	,	PUNCT
dpc-4503	228	4	jemec	jemec	PROPN
dpc-4503	228	5	gbe	gbe	PROPN
dpc-4503	228	6	,	,	PUNCT
dpc-4503	228	7	alavi	alavi	VERB
dpc-4503	228	8	a	a	DET
dpc-4503	228	9	,	,	PUNCT
dpc-4503	228	10	et	et	PROPN
dpc-4503	228	11	al	al	PROPN
dpc-4503	228	12	.	.	PROPN
dpc-4503	228	13	secukinumab	secukinumab	PROPN
dpc-4503	228	14	in	in	ADP
dpc-4503	228	15	moderate	moderate	ADJ
dpc-4503	228	16	to	to	ADP
dpc-4503	228	17	-	-	PUNCT
dpc-4503	228	18	severe	severe	ADJ
dpc-4503	228	19	hidradenitis	hidradenitis	NOUN
dpc-4503	228	20	suppurativa	suppurativa	NOUN
dpc-4503	228	21	(	(	PUNCT
dpc-4503	228	22	sunshine	sunshine	NOUN
dpc-4503	228	23	and	and	CCONJ
dpc-4503	228	24	sunrise	sunrise	VERB
dpc-4503	228	25	):	):	PUNCT
dpc-4503	228	26	week	week	NOUN
dpc-4503	228	27	16	16	NUM
dpc-4503	228	28	and	and	CCONJ
dpc-4503	228	29	week	week	NOUN
dpc-4503	228	30	52	52	NUM
dpc-4503	228	31	results	result	NOUN
dpc-4503	228	32	of	of	ADP
dpc-4503	228	33	two	two	NUM
dpc-4503	228	34	identical	identical	ADJ
dpc-4503	228	35	,	,	PUNCT
dpc-4503	228	36	multicentre	multicentre	NOUN
dpc-4503	228	37	,	,	PUNCT
dpc-4503	228	38	randomised	randomise	VERB
dpc-4503	228	39	,	,	PUNCT
dpc-4503	228	40	placebo	placebo	NOUN
dpc-4503	228	41	-	-	PUNCT
dpc-4503	228	42	controlled	control	VERB
dpc-4503	228	43	,	,	PUNCT
dpc-4503	228	44	double	double	ADJ
dpc-4503	228	45	-	-	PUNCT
dpc-4503	228	46	blind	blind	ADJ
dpc-4503	228	47	phase	phase	NOUN
dpc-4503	228	48	3	3	NUM
dpc-4503	228	49	trials	trial	NOUN
dpc-4503	228	50	.	.	PUNCT
dpc-4503	228	51	 	 	SPACE
dpc-4503	229	1	lancet	lancet	NOUN
dpc-4503	229	2	.	.	PUNCT
dpc-4503	230	1	2023;401(10378):747	2023;401(10378):747	NUM
dpc-4503	230	2	-	-	SYM
dpc-4503	230	3	761	761	NUM
dpc-4503	230	4	.	.	PUNCT
dpc-4503	231	1	doi:10.1016	doi:10.1016	PROPN
dpc-4503	231	2	/	/	SYM
dpc-4503	231	3	s0140	s0140	PROPN
dpc-4503	231	4	-	-	PUNCT
dpc-4503	231	5	6736(23)00022	6736(23)00022	NOUN
dpc-4503	231	6	-	-	PUNCT
dpc-4503	231	7	3	3	NUM
dpc-4503	231	8	9	9	NUM
dpc-4503	231	9	.	.	PUNCT
dpc-4503	232	1	kimball	kimball	PROPN
dpc-4503	232	2	ab	ab	PROPN
dpc-4503	232	3	,	,	PUNCT
dpc-4503	232	4	jemec	jemec	PROPN
dpc-4503	232	5	gbe	gbe	PROPN
dpc-4503	232	6	,	,	PUNCT
dpc-4503	232	7	sayed	say	VERB
dpc-4503	232	8	cj	cj	PROPN
dpc-4503	232	9	,	,	PUNCT
dpc-4503	233	1	et	et	PROPN
dpc-4503	233	2	al	al	PROPN
dpc-4503	233	3	.	.	PROPN
dpc-4503	233	4	efficacy	efficacy	NOUN
dpc-4503	233	5	and	and	CCONJ
dpc-4503	233	6	safety	safety	NOUN
dpc-4503	233	7	of	of	ADP
dpc-4503	233	8	bimekizumab	bimekizumab	NOUN
dpc-4503	233	9	in	in	ADP
dpc-4503	233	10	patients	patient	NOUN
dpc-4503	233	11	with	with	ADP
dpc-4503	233	12	moderate	moderate	ADJ
dpc-4503	233	13	-	-	PUNCT
dpc-4503	233	14	to	to	ADP
dpc-4503	233	15	-	-	PUNCT
dpc-4503	233	16	severe	severe	ADJ
dpc-4503	233	17	hidradenitis	hidradenitis	NOUN
dpc-4503	233	18	suppurativa	suppurativa	NOUN
dpc-4503	233	19	(	(	PUNCT
dpc-4503	233	20	be	be	AUX
dpc-4503	233	21	heard	hear	VERB
dpc-4503	233	22	i	i	PRON
dpc-4503	233	23	and	and	CCONJ
dpc-4503	233	24	be	be	AUX
dpc-4503	233	25	heard	hear	VERB
dpc-4503	233	26	ii	ii	NUM
dpc-4503	233	27	):	):	PUNCT
dpc-4503	233	28	two	two	NUM
dpc-4503	233	29	48	48	NUM
dpc-4503	233	30	-	-	PUNCT
dpc-4503	233	31	week	week	NOUN
dpc-4503	233	32	,	,	PUNCT
dpc-4503	233	33	randomised	randomise	VERB
dpc-4503	233	34	,	,	PUNCT
dpc-4503	233	35	double	double	ADJ
dpc-4503	233	36	-	-	PUNCT
dpc-4503	233	37	blind	blind	ADJ
dpc-4503	233	38	,	,	PUNCT
dpc-4503	233	39	placebo	placebo	NOUN
dpc-4503	233	40	-	-	PUNCT
dpc-4503	233	41	controlled	control	VERB
dpc-4503	233	42	,	,	PUNCT
dpc-4503	233	43	multicentre	multicentre	NOUN
dpc-4503	233	44	phase	phase	NOUN
dpc-4503	233	45	3	3	NUM
dpc-4503	233	46	trials	trial	NOUN
dpc-4503	233	47	.	.	PUNCT
dpc-4503	233	48	 	 	SPACE
dpc-4503	234	1	lancet	lancet	VERB
dpc-4503	234	2	.	.	PUNCT
dpc-4503	235	1	2024;403(10443):2504	2024;403(10443):2504	NUM
dpc-4503	235	2	-	-	SYM
dpc-4503	235	3	2519	2519	NUM
dpc-4503	235	4	.	.	PUNCT
dpc-4503	236	1	doi:10.1016	doi:10.1016	PROPN
dpc-4503	236	2	/	/	SYM
dpc-4503	237	1	s0140	s0140	ADJ
dpc-4503	237	2	-6736(24)00101	-6736(24)00101	PROPN
dpc-4503	237	3	-	-	PUNCT
dpc-4503	237	4	6	6	NUM
dpc-4503	237	5	10	10	NUM
dpc-4503	237	6	.	.	PUNCT
dpc-4503	238	1	kimball	kimball	PROPN
dpc-4503	238	2	ab	ab	PROPN
dpc-4503	238	3	,	,	PUNCT
dpc-4503	238	4	prens	pren	VERB
dpc-4503	238	5	ep	ep	PROPN
dpc-4503	238	6	,	,	PUNCT
dpc-4503	238	7	passeron	passeron	PROPN
dpc-4503	238	8	t	t	PROPN
dpc-4503	238	9	,	,	PUNCT
dpc-4503	238	10	et	et	PROPN
dpc-4503	238	11	al	al	PROPN
dpc-4503	238	12	.	.	PROPN
dpc-4503	238	13	efficacy	efficacy	NOUN
dpc-4503	238	14	and	and	CCONJ
dpc-4503	238	15	safety	safety	NOUN
dpc-4503	238	16	of	of	ADP
dpc-4503	238	17	risankizumab	risankizumab	NOUN
dpc-4503	238	18	for	for	ADP
dpc-4503	238	19	the	the	DET
dpc-4503	238	20	treatment	treatment	NOUN
dpc-4503	238	21	of	of	ADP
dpc-4503	238	22	hidradenitis	hidradenitis	PROPN
dpc-4503	238	23	suppurativa	suppurativa	NOUN
dpc-4503	238	24	:	:	PUNCT
dpc-4503	238	25	a	a	DET
dpc-4503	238	26	phase	phase	NOUN
dpc-4503	238	27	2	2	NUM
dpc-4503	238	28	,	,	PUNCT
dpc-4503	238	29	randomized	randomize	VERB
dpc-4503	238	30	,	,	PUNCT
dpc-4503	238	31	placebo	placebo	NOUN
dpc-4503	238	32	-	-	PUNCT
dpc-4503	238	33	controlled	control	VERB
dpc-4503	238	34	trial	trial	NOUN
dpc-4503	238	35	.	.	PUNCT
dpc-4503	238	36	  	  	SPACE
dpc-4503	239	1	dermatol	dermatol	NOUN
dpc-4503	239	2	ther	ther	ADV
dpc-4503	239	3	(	(	PUNCT
dpc-4503	239	4	heidelb	heidelb	NOUN
dpc-4503	239	5	)	)	PUNCT
dpc-4503	239	6	.	.	PUNCT
dpc-4503	240	1	2023;13(5):1099	2023;13(5):1099	NUM
dpc-4503	240	2	-	-	SYM
dpc-4503	240	3	1111	1111	NUM
dpc-4503	240	4	.	.	PUNCT
dpc-4503	241	1	doi:10.1007	doi:10.1007	PROPN
dpc-4503	241	2	/	/	SYM
dpc-4503	241	3	s13555	s13555	PROPN
dpc-4503	241	4	-	-	PUNCT
dpc-4503	241	5	023	023	NUM
dpc-4503	241	6	-00913	-00913	NOUN
dpc-4503	241	7	-	-	PUNCT
dpc-4503	241	8	3	3	NUM
dpc-4503	241	9	11	11	NUM
dpc-4503	241	10	.	.	PUNCT
dpc-4503	242	1	kimball	kimball	PROPN
dpc-4503	242	2	ab	ab	PROPN
dpc-4503	242	3	,	,	PUNCT
dpc-4503	242	4	podda	podda	PROPN
dpc-4503	242	5	m	m	PROPN
dpc-4503	242	6	,	,	PUNCT
dpc-4503	242	7	alavi	alavi	VERB
dpc-4503	242	8	a	a	DET
dpc-4503	242	9	,	,	PUNCT
dpc-4503	242	10	et	et	PROPN
dpc-4503	242	11	al	al	PROPN
dpc-4503	242	12	.	.	PROPN
dpc-4503	242	13	guselkumab	guselkumab	NOUN
dpc-4503	242	14	for	for	ADP
dpc-4503	242	15	the	the	DET
dpc-4503	242	16	treatment	treatment	NOUN
dpc-4503	242	17	of	of	ADP
dpc-4503	242	18	patients	patient	NOUN
dpc-4503	242	19	with	with	ADP
dpc-4503	242	20	moderate	moderate	ADJ
dpc-4503	242	21	-	-	PUNCT
dpc-4503	242	22	to	to	ADP
dpc-4503	242	23	-	-	PUNCT
dpc-4503	242	24	severe	severe	ADJ
dpc-4503	242	25	hidradenitis	hidradenitis	NOUN
dpc-4503	242	26	suppurativa	suppurativa	NOUN
dpc-4503	242	27	:	:	PUNCT
dpc-4503	242	28	a	a	DET
dpc-4503	242	29	phase	phase	NOUN
dpc-4503	242	30	2	2	NUM
dpc-4503	242	31	randomized	randomized	ADJ
dpc-4503	242	32	study	study	NOUN
dpc-4503	242	33	.	.	PUNCT
dpc-4503	242	34	 	 	SPACE
dpc-4503	243	1	j	j	PROPN
dpc-4503	243	2	eur	eur	PROPN
dpc-4503	243	3	acad	acad	PROPN
dpc-4503	243	4	dermatol	dermatol	NOUN
dpc-4503	243	5	venereol	venereol	NOUN
dpc-4503	243	6	.	.	PUNCT
dpc-4503	244	1	2023;37(10):2098	2023;37(10):2098	NUM
dpc-4503	244	2	-	-	SYM
dpc-4503	244	3	2108	2108	NUM
dpc-4503	244	4	.	.	PUNCT
dpc-4503	245	1	doi:10.1111	doi:10.1111	PROPN
dpc-4503	245	2	/	/	SYM
dpc-4503	245	3	jdv.19252	jdv.19252	PROPN
dpc-4503	245	4	12	12	NUM
dpc-4503	245	5	.	.	PUNCT
dpc-4503	246	1	gisondi	gisondi	PROPN
dpc-4503	246	2	p	p	NOUN
dpc-4503	246	3	,	,	PUNCT
dpc-4503	246	4	fargnoli	fargnoli	PROPN
dpc-4503	246	5	mc	mc	PROPN
dpc-4503	246	6	,	,	PUNCT
dpc-4503	246	7	amerio	amerio	ADP
dpc-4503	246	8	p	p	X
dpc-4503	246	9	,	,	PUNCT
dpc-4503	246	10	et	et	PROPN
dpc-4503	246	11	al	al	PROPN
dpc-4503	246	12	.	.	PUNCT
dpc-4503	247	1	italian	italian	ADJ
dpc-4503	247	2	adaptation	adaptation	NOUN
dpc-4503	247	3	of	of	ADP
dpc-4503	247	4	euroguiderm	euroguiderm	NOUN
dpc-4503	247	5	guideline	guideline	NOUN
dpc-4503	247	6	on	on	ADP
dpc-4503	247	7	the	the	DET
dpc-4503	247	8	systemic	systemic	ADJ
dpc-4503	247	9	treatment	treatment	NOUN
dpc-4503	247	10	of	of	ADP
dpc-4503	247	11	chronic	chronic	ADJ
dpc-4503	247	12	plaque	plaque	NOUN
dpc-4503	247	13	psoriasis	psoriasis	NOUN
dpc-4503	247	14	.	.	PUNCT
dpc-4503	247	15	  	  	SPACE
dpc-4503	248	1	ital	ital	PROPN
dpc-4503	248	2	j	j	PROPN
dpc-4503	248	3	dermatol	dermatol	NOUN
dpc-4503	248	4	venerol	venerol	PROPN
dpc-4503	248	5	.	.	PUNCT
dpc-4503	249	1	2022;157	2022;157	NUM
dpc-4503	249	2	(	(	PUNCT
dpc-4503	249	3	suppl	suppl	ADJ
dpc-4503	249	4	.	.	PROPN
dpc-4503	249	5	1	1	NUM
dpc-4503	249	6	to	to	ADP
dpc-4503	249	7	no	no	NOUN
dpc-4503	249	8	.	.	PUNCT
dpc-4503	250	1	1):1	1):1	NUM
dpc-4503	250	2	-	-	SYM
dpc-4503	250	3	78	78	NUM
dpc-4503	250	4	.	.	PUNCT
dpc-4503	251	1	doi:10.23736	doi:10.23736	PROPN
dpc-4503	251	2	/	/	SYM
dpc-4503	251	3	s2784	s2784	PROPN
dpc-4503	251	4	-	-	PUNCT
dpc-4503	251	5	8671.21.07132	8671.21.07132	NUM
dpc-4503	251	6	-	-	PUNCT
dpc-4503	251	7	2	2	NUM
dpc-4503	251	8	original	original	ADJ
dpc-4503	251	9	article	article	NOUN
dpc-4503	251	10	|	|	ADV
dpc-4503	251	11	dermatol	dermatol	ADJ
dpc-4503	251	12	pract	pract	NOUN
dpc-4503	251	13	concept	concept	NOUN
dpc-4503	251	14	.	.	PUNCT
dpc-4503	252	1	2024;14(4):e2024250	2024;14(4):e2024250	NUM
dpc-4503	252	2	7	7	NUM
dpc-4503	252	3	suppurativa	suppurativa	NOUN
dpc-4503	252	4	:	:	PUNCT
dpc-4503	252	5	a	a	DET
dpc-4503	252	6	phase	phase	NOUN
dpc-4503	252	7	2	2	NUM
dpc-4503	252	8	randomized	randomized	ADJ
dpc-4503	252	9	study	study	NOUN
dpc-4503	252	10	.	.	PUNCT
dpc-4503	252	11	 	 	SPACE
dpc-4503	253	1	j	j	PROPN
dpc-4503	253	2	eur	eur	PROPN
dpc-4503	253	3	acad	acad	PROPN
dpc-4503	253	4	dermatol	dermatol	NOUN
dpc-4503	253	5	venereol	venereol	NOUN
dpc-4503	253	6	.	.	PUNCT
dpc-4503	254	1	2023;37(10):2098	2023;37(10):2098	NUM
dpc-4503	254	2	-	-	SYM
dpc-4503	254	3	2108	2108	NUM
dpc-4503	254	4	.	.	PUNCT
dpc-4503	255	1	doi:10.1111	doi:10.1111	PROPN
dpc-4503	255	2	/	/	SYM
dpc-4503	255	3	jdv.19252	jdv.19252	PROPN
dpc-4503	255	4	32	32	NUM
dpc-4503	255	5	.	.	PUNCT
dpc-4503	256	1	dudink	dudink	PROPN
dpc-4503	256	2	k	k	PROPN
dpc-4503	256	3	,	,	PUNCT
dpc-4503	256	4	bouwman	bouwman	NOUN
dpc-4503	256	5	k	k	PROPN
dpc-4503	256	6	,	,	PUNCT
dpc-4503	256	7	chen	chen	PROPN
dpc-4503	256	8	y	y	PROPN
dpc-4503	256	9	,	,	PUNCT
dpc-4503	256	10	et	et	PROPN
dpc-4503	256	11	al	al	PROPN
dpc-4503	256	12	.	.	PROPN
dpc-4503	256	13	guselkumab	guselkumab	NOUN
dpc-4503	256	14	for	for	ADP
dpc-4503	256	15	hidradenitis	hidradenitis	PROPN
dpc-4503	256	16	suppurativa	suppurativa	PROPN
dpc-4503	256	17	:	:	PUNCT
dpc-4503	256	18	a	a	DET
dpc-4503	256	19	phase	phase	NOUN
dpc-4503	256	20	ii	ii	NOUN
dpc-4503	256	21	,	,	PUNCT
dpc-4503	256	22	open	open	ADJ
dpc-4503	256	23	-	-	PUNCT
dpc-4503	256	24	label	label	NOUN
dpc-4503	256	25	,	,	PUNCT
dpc-4503	256	26	mode	mode	NOUN
dpc-4503	256	27	-	-	PUNCT
dpc-4503	256	28	of	of	ADP
dpc-4503	256	29	-	-	PUNCT
dpc-4503	256	30	action	action	NOUN
dpc-4503	256	31	study	study	NOUN
dpc-4503	256	32	.	.	PUNCT
dpc-4503	256	33	 	 	SPACE
dpc-4503	257	1	br	br	PROPN
dpc-4503	257	2	j	j	PROPN
dpc-4503	257	3	dermatol	dermatol	NOUN
dpc-4503	257	4	.	.	PUNCT
dpc-4503	258	1	2023;188(5):601	2023;188(5):601	NUM
dpc-4503	258	2	-	-	SYM
dpc-4503	258	3	609	609	NUM
dpc-4503	258	4	.	.	PUNCT
dpc-4503	259	1	doi:10.1093	doi:10.1093	NOUN
dpc-4503	259	2	/	/	SYM
dpc-4503	259	3	bjd	bjd	PROPN
dpc-4503	259	4	/	/	SYM
dpc-4503	259	5	ljad010	ljad010	PROPN
dpc-4503	259	6	33	33	NUM
dpc-4503	259	7	.	.	PUNCT
dpc-4503	260	1	rivera	rivera	NOUN
dpc-4503	260	2	-	-	PUNCT
dpc-4503	260	3	díaz	díaz	NOUN
dpc-4503	260	4	r	r	PROPN
dpc-4503	260	5	,	,	PUNCT
dpc-4503	260	6	pozo	pozo	PROPN
dpc-4503	260	7	t	t	PROPN
dpc-4503	260	8	,	,	PUNCT
dpc-4503	260	9	alfageme	alfageme	PROPN
dpc-4503	260	10	f	f	PROPN
dpc-4503	260	11	,	,	PUNCT
dpc-4503	260	12	et	et	PROPN
dpc-4503	260	13	al	al	PROPN
dpc-4503	260	14	.	.	PUNCT
dpc-4503	261	1	the	the	DET
dpc-4503	261	2	effectiveness	effectiveness	NOUN
dpc-4503	261	3	of	of	ADP
dpc-4503	261	4	guselkumab	guselkumab	NOUN
dpc-4503	261	5	in	in	ADP
dpc-4503	261	6	patients	patient	NOUN
dpc-4503	261	7	with	with	ADP
dpc-4503	261	8	hidradenitis	hidradenitis	PROPN
dpc-4503	261	9	suppurativa	suppurativa	PROPN
dpc-4503	261	10	under	under	ADP
dpc-4503	261	11	clinical	clinical	ADJ
dpc-4503	261	12	practice	practice	NOUN
dpc-4503	261	13	conditions	condition	NOUN
dpc-4503	261	14	:	:	PUNCT
dpc-4503	261	15	a	a	DET
dpc-4503	261	16	spanish	spanish	ADJ
dpc-4503	261	17	multicentre	multicentre	NOUN
dpc-4503	261	18	retrospective	retrospective	ADJ
dpc-4503	261	19	study	study	NOUN
dpc-4503	261	20	.	.	PUNCT
dpc-4503	262	1	[	[	AUX
dpc-4503	262	2	artículo	artículo	VERB
dpc-4503	262	3	traducido	traducido	NOUN
dpc-4503	262	4	]	]	PUNCT
dpc-4503	262	5	efectividad	efectividad	PROPN
dpc-4503	262	6	de	de	ADP
dpc-4503	262	7	guselkumab	guselkumab	NOUN
dpc-4503	262	8	en	en	ADP
dpc-4503	262	9	pacientes	pacientes	PROPN
dpc-4503	262	10	con	con	PROPN
dpc-4503	262	11	hidradenitis	hidradenitis	PROPN
dpc-4503	262	12	supurativa	supurativa	PROPN
dpc-4503	262	13	en	en	X
dpc-4503	262	14	condiciones	condiciones	PROPN
dpc-4503	262	15	de	de	PROPN
dpc-4503	262	16	práctica	práctica	PROPN
dpc-4503	262	17	clínica	clínica	PROPN
dpc-4503	262	18	:	:	PUNCT
dpc-4503	262	19	estudio	estudio	PROPN
dpc-4503	262	20	retrospectivo	retrospectivo	PROPN
dpc-4503	262	21	y	y	PROPN
dpc-4503	262	22	multicéntrico	multicéntrico	NOUN
dpc-4503	262	23	en	en	X
dpc-4503	262	24	españa	españa	X
dpc-4503	262	25	.	.	PUNCT
dpc-4503	262	26	 	 	SPACE
dpc-4503	262	27	actas	acta	NOUN
dpc-4503	262	28	dermosifiliogr	dermosifiliogr	NOUN
dpc-4503	262	29	.	.	PUNCT
dpc-4503	263	1	2023;114(9):t755	2023;114(9):t755	NUM
dpc-4503	263	2	-	-	PUNCT
dpc-4503	263	3	t762	t762	PROPN
dpc-4503	263	4	.	.	PUNCT
dpc-4503	263	5	doi:10.1016	doi:10.1016	PROPN
dpc-4503	263	6	/	/	SYM
dpc-4503	263	7	j.ad.2023.06.018	j.ad.2023.06.018	PROPN
dpc-4503	263	8	34	34	NUM
dpc-4503	263	9	.	.	PUNCT
dpc-4503	264	1	martora	martora	PROPN
dpc-4503	264	2	f	f	PROPN
dpc-4503	264	3	,	,	PUNCT
dpc-4503	264	4	scalvenzi	scalvenzi	PROPN
dpc-4503	264	5	m	m	PROPN
dpc-4503	264	6	,	,	PUNCT
dpc-4503	264	7	battista	battista	PROPN
dpc-4503	264	8	t	t	PROPN
dpc-4503	264	9	,	,	PUNCT
dpc-4503	264	10	et	et	PROPN
dpc-4503	264	11	al	al	PROPN
dpc-4503	264	12	.	.	PROPN
dpc-4503	264	13	guselkumab	guselkumab	PROPN
dpc-4503	264	14	,	,	PUNCT
dpc-4503	264	15	risankizumab	risankizumab	NOUN
dpc-4503	264	16	,	,	PUNCT
dpc-4503	264	17	and	and	CCONJ
dpc-4503	264	18	tildrakizumab	tildrakizumab	NOUN
dpc-4503	264	19	in	in	ADP
dpc-4503	264	20	the	the	DET
dpc-4503	264	21	management	management	NOUN
dpc-4503	264	22	of	of	ADP
dpc-4503	264	23	hidradenitis	hidradenitis	PROPN
dpc-4503	264	24	suppurativa	suppurativa	PROPN
dpc-4503	264	25	:	:	PUNCT
dpc-4503	264	26	a	a	DET
dpc-4503	264	27	review	review	NOUN
dpc-4503	264	28	of	of	ADP
dpc-4503	264	29	existing	exist	VERB
dpc-4503	264	30	trials	trial	NOUN
dpc-4503	264	31	and	and	CCONJ
dpc-4503	264	32	real	real	ADJ
dpc-4503	264	33	-	-	PUNCT
dpc-4503	264	34	life	life	NOUN
dpc-4503	264	35	data	datum	NOUN
dpc-4503	264	36	.	.	PUNCT
dpc-4503	264	37	  	  	SPACE
dpc-4503	265	1	clin	clin	PROPN
dpc-4503	265	2	cosmet	cosmet	PROPN
dpc-4503	265	3	investig	investig	NOUN
dpc-4503	265	4	dermatol	dermatol	NOUN
dpc-4503	265	5	.	.	PUNCT
dpc-4503	266	1	2023;16:2525	2023;16:2525	NUM
dpc-4503	266	2	-	-	SYM
dpc-4503	266	3	2536	2536	NUM
dpc-4503	266	4	.	.	PUNCT
dpc-4503	267	1	published	publish	VERB
dpc-4503	267	2	2023	2023	NUM
dpc-4503	267	3	sep	sep	PROPN
dpc-4503	267	4	18	18	NUM
dpc-4503	267	5	.	.	PUNCT
dpc-4503	267	6	doi:10.2147	doi:10.2147	NOUN
dpc-4503	267	7	/	/	SYM
dpc-4503	267	8	ccid.s418748	ccid.s418748	NOUN
dpc-4503	267	9	trial	trial	NOUN
dpc-4503	267	10	.	.	PUNCT
dpc-4503	267	11	  	  	SPACE
dpc-4503	267	12	jama	jama	PROPN
dpc-4503	267	13	dermatol.2021;157(11):1279–1288	dermatol.2021;157(11):1279–1288	PROPN
dpc-4503	267	14	.	.	PROPN
dpc-4503	267	15	doi:10.1001	doi:10.1001	PROPN
dpc-4503	268	1	/jamadermatol.2021.2905	/jamadermatol.2021.2905	PUNCT
dpc-4503	269	1	28	28	NUM
dpc-4503	269	2	.	.	PUNCT
dpc-4503	270	1	kok	kok	PROPN
dpc-4503	270	2	y	y	PROPN
dpc-4503	270	3	,	,	PUNCT
dpc-4503	270	4	nicolopoulos	nicolopoulos	PROPN
dpc-4503	270	5	j	j	PROPN
dpc-4503	270	6	,	,	PUNCT
dpc-4503	270	7	dolianitis	dolianitis	PROPN
dpc-4503	270	8	c.	c.	PROPN
dpc-4503	270	9	tildrakizumab	tildrakizumab	NOUN
dpc-4503	270	10	as	as	ADP
dpc-4503	270	11	a	a	DET
dpc-4503	270	12	potential	potential	ADJ
dpc-4503	270	13	long	long	ADJ
dpc-4503	270	14	-	-	PUNCT
dpc-4503	270	15	term	term	NOUN
dpc-4503	270	16	therapeutic	therapeutic	ADJ
dpc-4503	270	17	agent	agent	NOUN
dpc-4503	270	18	for	for	ADP
dpc-4503	270	19	severe	severe	ADJ
dpc-4503	270	20	hidradenitis	hidradenitis	PROPN
dpc-4503	270	21	suppurativa	suppurativa	NOUN
dpc-4503	270	22	:	:	PUNCT
dpc-4503	270	23	a	a	DET
dpc-4503	270	24	15	15	NUM
dpc-4503	270	25	months	month	NOUN
dpc-4503	270	26	experience	experience	NOUN
dpc-4503	270	27	of	of	ADP
dpc-4503	270	28	an	an	DET
dpc-4503	270	29	australian	australian	ADJ
dpc-4503	270	30	institution	institution	NOUN
dpc-4503	270	31	.	.	PUNCT
dpc-4503	270	32	 	 	SPACE
dpc-4503	271	1	australas	australa	VERB
dpc-4503	271	2	j	j	PROPN
dpc-4503	271	3	dermatol	dermatol	NOUN
dpc-4503	271	4	.	.	PUNCT
dpc-4503	272	1	2021;62(2):e313	2021;62(2):e313	NUM
dpc-4503	272	2	-	-	PUNCT
dpc-4503	272	3	e316	e316	PROPN
dpc-4503	272	4	.	.	PUNCT
dpc-4503	273	1	doi:10.1111	doi:10.1111	PROPN
dpc-4503	273	2	/	/	SYM
dpc-4503	273	3	ajd.13559	ajd.13559	NUM
dpc-4503	273	4	29	29	NUM
dpc-4503	273	5	.	.	PUNCT
dpc-4503	274	1	koszegi	koszegi	PROPN
dpc-4503	274	2	b	b	PROPN
dpc-4503	274	3	,	,	PUNCT
dpc-4503	274	4	wilson	wilson	PROPN
dpc-4503	274	5	a	a	NOUN
dpc-4503	274	6	,	,	PUNCT
dpc-4503	274	7	stone	stone	NOUN
dpc-4503	274	8	c	c	NOUN
dpc-4503	274	9	,	,	PUNCT
dpc-4503	274	10	satgé	satgé	NOUN
dpc-4503	274	11	f	f	PROPN
dpc-4503	274	12	,	,	PUNCT
dpc-4503	274	13	cowan	cowan	PROPN
dpc-4503	274	14	tl	tl	PROPN
dpc-4503	274	15	,	,	PUNCT
dpc-4503	274	16	murrell	murrell	PROPN
dpc-4503	274	17	df	df	PROPN
dpc-4503	274	18	.	.	PUNCT
dpc-4503	274	19	tildrakizumab	tildrakizumab	NOUN
dpc-4503	274	20	for	for	ADP
dpc-4503	274	21	the	the	DET
dpc-4503	274	22	treatment	treatment	NOUN
dpc-4503	274	23	of	of	ADP
dpc-4503	274	24	hidradenitis	hidradenitis	PROPN
dpc-4503	274	25	suppurativa	suppurativa	NOUN
dpc-4503	274	26	in	in	ADP
dpc-4503	274	27	patients	patient	NOUN
dpc-4503	274	28	previously	previously	ADV
dpc-4503	274	29	treated	treat	VERB
dpc-4503	274	30	with	with	ADP
dpc-4503	274	31	adalimumab	adalimumab	NOUN
dpc-4503	274	32	:	:	PUNCT
dpc-4503	274	33	a	a	DET
dpc-4503	274	34	 	 	SPACE
dpc-4503	274	35	30	30	NUM
dpc-4503	274	36	-	-	PUNCT
dpc-4503	274	37	month	month	NOUN
dpc-4503	274	38	experience	experience	NOUN
dpc-4503	274	39	.	.	PUNCT
dpc-4503	274	40	 	 	SPACE
dpc-4503	275	1	clin	clin	PROPN
dpc-4503	275	2	exp	exp	NOUN
dpc-4503	275	3	dermatol	dermatol	NOUN
dpc-4503	275	4	.	.	PUNCT
dpc-4503	276	1	2023;48(11):1266	2023;48(11):1266	X
dpc-4503	276	2	-	-	SYM
dpc-4503	276	3	1269	1269	NUM
dpc-4503	276	4	.	.	PUNCT
dpc-4503	277	1	doi:10.1093	doi:10.1093	NOUN
dpc-4503	277	2	/ced	/ced	PROPN
dpc-4503	277	3	/	/	SYM
dpc-4503	277	4	llad215	llad215	PROPN
dpc-4503	277	5	30	30	NUM
dpc-4503	277	6	.	.	PUNCT
dpc-4503	278	1	repetto	repetto	PROPN
dpc-4503	278	2	f	f	PROPN
dpc-4503	278	3	,	,	PUNCT
dpc-4503	278	4	burzi	burzi	PROPN
dpc-4503	278	5	l	l	PROPN
dpc-4503	278	6	,	,	PUNCT
dpc-4503	278	7	ribero	ribero	PROPN
dpc-4503	278	8	s	s	PROPN
dpc-4503	278	9	,	,	PUNCT
dpc-4503	278	10	quaglino	quaglino	NOUN
dpc-4503	278	11	p	p	X
dpc-4503	278	12	,	,	PUNCT
dpc-4503	278	13	dapavo	dapavo	ADJ
dpc-4503	278	14	p.	p.	NOUN
dpc-4503	278	15	efficacy	efficacy	NOUN
dpc-4503	278	16	and	and	CCONJ
dpc-4503	278	17	safety	safety	NOUN
dpc-4503	278	18	of	of	ADP
dpc-4503	278	19	risankizumab	risankizumab	NOUN
dpc-4503	278	20	in	in	ADP
dpc-4503	278	21	hidradenitis	hidradenitis	PROPN
dpc-4503	278	22	suppurativa	suppurativa	PROPN
dpc-4503	278	23	:	:	PUNCT
dpc-4503	278	24	a	a	DET
dpc-4503	278	25	case	case	NOUN
dpc-4503	278	26	series	series	NOUN
dpc-4503	278	27	.	.	PUNCT
dpc-4503	278	28	  	  	SPACE
dpc-4503	278	29	acta	acta	PROPN
dpc-4503	278	30	derm	derm	PROPN
dpc-4503	278	31	venereol	venereol	NOUN
dpc-4503	278	32	.	.	PUNCT
dpc-4503	279	1	2022;102	2022;102	NUM
dpc-4503	279	2	:	:	PUNCT
dpc-4503	279	3	adv00780	adv00780	ADJ
dpc-4503	279	4	.	.	PUNCT
dpc-4503	280	1	published	publish	VERB
dpc-4503	280	2	2022	2022	NUM
dpc-4503	280	3	sep	sep	PROPN
dpc-4503	280	4	28	28	NUM
dpc-4503	280	5	.	.	PUNCT
dpc-4503	281	1	doi:10.2340	doi:10.2340	NUM
dpc-4503	281	2	/	/	SYM
dpc-4503	281	3	actadv.v102.2926	actadv.v102.2926	NOUN
dpc-4503	281	4	31	31	NUM
dpc-4503	281	5	.	.	PUNCT
dpc-4503	282	1	kimball	kimball	PROPN
dpc-4503	282	2	ab	ab	PROPN
dpc-4503	282	3	,	,	PUNCT
dpc-4503	282	4	podda	podda	PROPN
dpc-4503	282	5	m	m	PROPN
dpc-4503	282	6	,	,	PUNCT
dpc-4503	282	7	alavi	alavi	VERB
dpc-4503	282	8	a	a	DET
dpc-4503	282	9	,	,	PUNCT
dpc-4503	282	10	et	et	PROPN
dpc-4503	282	11	al	al	PROPN
dpc-4503	282	12	.	.	PROPN
dpc-4503	282	13	guselkumab	guselkumab	NOUN
dpc-4503	282	14	for	for	ADP
dpc-4503	282	15	the	the	DET
dpc-4503	282	16	treatment	treatment	NOUN
dpc-4503	282	17	of	of	ADP
dpc-4503	282	18	patients	patient	NOUN
dpc-4503	282	19	with	with	ADP
dpc-4503	282	20	moderate	moderate	ADJ
dpc-4503	282	21	-	-	PUNCT
dpc-4503	282	22	to	to	ADP
dpc-4503	282	23	-	-	PUNCT
dpc-4503	282	24	severe	severe	ADJ
dpc-4503	282	25	hidradenitis	hidradenitis	NOUN